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Abstract 
A new wave of research recognizes a distinct subset of B regulatory cells 
(Breg) that maintain immune tolerance. Breg cells have been shown to exert 
immunoregulatory functions through the production of interleukin (IL)-10 and 
appear to play important roles in autoimmunity and in cancer. Despite the 
extensive body of evidence reinforcing the notion of B cells as potential 
regulatory cells, some controversy over the paucity of markers that can 
unequivocally identify Bregs still exists. To study the role of Breg in immune 
surveillance, I designed a comprehensive multi‐parameter panel of surface 
antibodies to define B-cell subsets in peripheral blood (PB) and cord blood 
(CB). The intracellular detection of IL-10 combined with flow cytometric 
phenotyping presented in my thesis demonstrate the presence of IL-10–
producing Bregs with Treg-independent immunosuppressive functions in both 
the IgM memory (CD19+IgM+CD27+) and transitional (CD19+CD24hiCD38hi) 
PB B-cell subsets in healthy donors. The regulatory function PB Bregs against 
CD4+T cells and CD56+NK cells required both cell-cell contact and IL-10 
production. Moreover, I demonstrate that Breg populations are expanded in 
the PB of AML patients and exert potent suppression of NK function mediated 
through 2B4-CD48 signaling. I further demonstrated the presence of IL-10-
producing B cells with Treg-independent immunosuppressive properties in CB 
with the ability to suppress allogeneic-CD4+T cells through IL-10, as well as 
cell-cell contact mediated mechanisms involving CTLA-4 and CD80/CD86. I 
found an early and robust recovery of IL-10+B cells post-CBT. High Breg 
frequencies in CB may attenuate T-cell responses and contribute to the lower 
rates of cGVHD.  
My findings have important clinical implications and suggest that Bregs may 
be exploited to treat immune-mediated diseases. Whereas, strategies to 
deplete Bregs for optimal anti-cancer immunotherapy may benefit antitumor 
activity in AML and other cancers, adoptive transfer of donor-derived Bregs 
post transplant may offer a potentially effective immunomodulatory therapy for 
the treatment of GVHD. 
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siRNA    Small interfering RNA 
SLE     systemic lupus erythematosus 
SHP-1 Src homology region 2 domain-containing 
phosphatase-1 
 
SSC     side scatter 
SHM     somatic Hypermutation 
STAT    signal transducer and activator of transcription 
Tr     Transitional B cells 
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TD     T cell dependent 
TGFβ     transforming growth factor beta 
Th     T helper 
TLR     Toll‐like receptor 
TNFα     tumour necrosis factor alpha 
Treg     regulatory T cells 
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Chapter I. Introduction 	  
I.1  Allogeneic Haematopoietic Stem cell Transplantation (AHSCT) 
Allogeneic haematopoietic stem cell transplantation (AHSCT) is considered 
an established curative option of effective adoptive cellular immunotherapy for 
the treatment of many haematological disorders (Barrett and Battiwala., 2010, 
Antin, 2002). In the ensuing years since the first successful allogeneic bone 
marrow transplantation in humans was performed (Gatti et al., 1968, Bach et 
al., 1968), an extensive body of evidence has highlighted AHSCT as an 
optional therapy for autoimmune conditions, metabolic disorders, severe 
immunodeficiencies and malignant and non-malignant diseases (Svenberg et 
al., 2009, Gyurkocza et al., 2011). AHSCT aims to improve heamatopoietic 
function through sustained engraftment, which is commonly monitored by 
chimerism, a valuable detection method for the most fatal causes of treatment 
failure in transplanted patients; GVHD outcome and graft failure or rejection 
(Svenberg et al., 2009). In contrast to autologous HSCT, allogeneic HSCT 
aims to implement induced tolerance through the transfer of a genetically 
different healthy immune complex (Svenberg et al., 2009). The increased use 
of modulated reduced-intensity conditioning (RIC) regimens to reduce acute 
toxicity and improve supportive care have widened the application of AHSCT 
to a broader spectrum of medical disorders and older patients who tend to 
have more aggressive disease (Barrett and Battiwala., 2010, Gyurkocza et al., 
2011). The benefits of AHSCT rely heavily on the immunological 
consequences of the graft versus tumor (GVT) effect or graft-versus-leukemia 
(GVL) effect and immunosuppressive features of the conditioning regimen on 
the recipient’s haematopoietic system (Pidala et al., 2011, Arnout et al., 
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2014). Current clinical strategies are exploiting T-lymphocyte-mediated GVT 
effects to improve the prospect of survival after AHSCT (Barrett and 
Battiwala., 2010). However, despite a reduction in non-relapse mortality rates 
following AHSCT witnessed in the last decade, acute and chronic graft-
versus-host disease (GVHD) and infections remain a major obstacle to 
success (Barrett and Battiwala., 2010, Pidala et al., 2011). These potentially 
fatal complications are a result of accompanying immunodeficiencies, 
toxicities of the preparative regimens and the organ damage induced by 
GVHD, leading to treatment-related mortality and morbidity associated with 
AHSCT (Barrett and Battiwala., 2010). Thus, the ultimate goal of AHSCT is to 
eradicate GVHD and augment GVL effect in transplant recipients. 
 
I.2  Cord Blood Transplantation  
Due to their less stringent requirement for human leukocyte antigen (HLA) 
matching, human cord blood (CB) is widely used as a source of hematopoietic 
stem cells (HSC) for many patients with haematological diseases who can be 
cured by AHSCT but lack a fully matched related or unrelated donor 
(Beaudette-Zlatanova et al., 2013, Komanduri et al., 2007, Stanevsky et al, 
2009). Approximately, 30% of patients who require an allograft through 
AHSCT will have an HLA-identical sibling donor, and despite over 20 million 
adult volunteers registered on the National Marrow Donor Program and 
affiliated registries, many in this group, especially patients of ethnic minorities, 
will lack a suitably matched unrelated donor (Barker et al., 2010, Ballen et al., 
2013). Hence, CBT has extended treatment options to patients that require 
AHSCT but are ineligible for this therapeutic approach.  
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In 1989, the first human related CBT was performed in France in a child with 
Fanconi Anemia (Gluckman et al., 1989). Almost 7 years later the first adult 
received an unrelated CBT (Laporte et al., 1996).  Since this pivotal approach, 
over 30,000 CBT have been performed in children and adults with subsequent 
international cord blood banks that have been founded with over 600,000 
units available for both related and unrelated CBT (Ballen et al., 2013). High 
rates of success have been reported with both related and unrelated CBT for 
several haematological diseases (malignant and non-malignant) in the 
pediatric setting as children require a lower cell dose than adults (Ballen et al., 
2013). Successively, with improved supportive care practices, use of double 
cord blood units with a greater focus on units with sufficient cell dose, use of 
non-myeloblative conditioning, clinical strategies aimed at augmenting 
engraftment and improved donor selection by HLA matching, CBT outcome in 
adults has progressed (Ballen et al., 2013, Komanduri et al., 2007).  Since 
cord blood has been reported to contain fewer nucleated cells/kg (by 1–2 
logs) than mobilized peripheral blood or bone marrow, most adult patients are 
given two mismatched cord blood units (matched at 4/6 HLA alleles), with the 
purpose of overcoming the limited cell dose recovered in a single cord blood 
unit, to overcome delayed engraftment (Barker and Wagner., 2003, 
Komanduri et al, 2007, Stanevsky et al., 2009, Newell et al., 2013). Further, 
the use of umbilical cord blood (UCB) in comparison to AHSCT results in a 
more rapid availability of grafts (cryopreserved CBU that have been banked), 
a broader and more extensive donor pool due to less stringent requirements 
for HLA-matching (especially for ethnic minorities) due to superior immune 
plasticity of CB grafts, low risk of infection via latent viral transmission and 
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lack of risk to donor (Ballen et al., 2013, Gluckman and Rocha, 2009). 
However, despite these advantages, studies have reported delayed 
haematopoietic immune reconstitution after CBT (Komanduri et al, 2007).   
Limited data exist on immune reconstitution in adult CBT recipients in the 
course of immune recovery during which infection is a leading cause of 
mortality (Komanduri et al., 2007). Previous evidence has reported delayed T 
cell recovery and prolonged T cell lymphopenia predominantly in adult CBT 
recipients and a compensatory expansion in B cells and natural killer (NK) 
cells (Klein et al., 2001, Komanduri et al., 2007, Beaudette-Zlatanova et al., 
2013). Additionally, late memory T cell skewing to the naïve compartment has 
been associated with thymopoietic failure in CBT patients (Komanduri et al., 
2007). Thus, development of clinical strategies to augment engraftment and 
the recovery of thymopoiesis may improve outcomes after CBT.   
Additionally, although an increased incidence of acute GVHD (aGVHD) after 
double-unit CBT (DUCBT) compared with single CBT has been described 
(Cutler et al., 2011, Ballen et al, 2007) a lower incidence and severity, of 
chronic extensive GVHD has been reported after CBT with compared with 
other stem cell sources, despite broader HLA disparity (Beaudette-Zlatanova 
et al., 2013, Komanduri et al., 2007, Stanevsky et al., 2009). Although the 
exact cause instrumental for this reduced alloreactivity is not well understood 
it has been associated with decreased numbers of the naive T cell repertoire 
in CBT recipients (Cohen and Madrigal., 1998, Komanduri et al., 2007). 
Notably, due to high numbers and exclusive properties of NK cells in cord 
blood graft the GVL effect has been described to be preserved after CBT 
(Dalle et al., 2005, Stanevsky et al., 2009). 
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Thus, a major goal in CBT would be the use of immune modulatory cells such 
as T regulatory cells and mesenchymal stromal cells in therapeutic 
approaches that have shown potential to control GVHD and preserve GVL 
effect by limiting donor T cells that possess the capacity to cause GVHD by 
reacting to alloantigens of the recipient (Tolar et al., 2009, Brunstein et al., 
2011, Parmar et al., 2014). Advances in immune suppressor cells offer high 
potential in safe and more efficacious treatment of hematological diseases 
treatable by CBT.  
 
 
I.3   Graft versus Host Disease (GVHD) 
I.3.1  The classification and manifestation of GVHD 
The limited understanding of GVHD hinders the clinical classification of the 
disease and hampers the development of therapeutic strategies to target 
GVHD (Pidala et al., 2011, Ferrara et al., 2009). 
The adoptive transfer of stem cells from the donor is governed by several 
factors that mediate donor selection including HLA-matching, ABO blood 
group, sex, age and CMV serostatus (Tay et al., 2012). Other factors such as 
killer immunoglobulin (KIR) immunogenetics and minor histocompatibility 
mismatch are being increasingly considered in donor selection and the 
outcome of AHSCT (Gratwohl, 2007, Dickinson and Charron, 2005). The 
success of stem cell transplantation is determined by engraftment and homing 
of donor stem cells to the bone marrow, combined with education of the donor 
immune cells to mediate tolerance (Blazer et al., 2012, Lynch et al., 2009). 
However, this effect can be counterbalanced by concurrent alloreactivity of 
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donor T lymphocytes against the host’s healthy tissues or organs (Blazer et 
al., 2012, Ferrara et al., 2009), giving rise to complications of GVHD.  
The development and severity of GVHD in transplant recipients is reliant on 
several factors including, age of recipient, heamatopoietic graft source, 
toxicity of the conditioning regimen and practices used for GVHD prophylaxis 
(Pidala et al., 2011). Traditionally, GVHD has been divided into 2 forms, acute 
and chronic, based on the time of its onset. Acute GVHD (aGVHD) has been 
described to occur within the first 100 days post transplant with strong 
inflammatory components, whereas chronic GVHD (cGVHD) occurs after the 
first 100 days post transplant and is associated with autoimmune and fibrotic 
mechanisms that are involved in its pathophysiology (Ferrara et al., 2009). 
However, discrepancies involved in an overlap syndrome of classification 
between the time of onset of acute and chronic GVHD have led to the 
National Institutes of Healthy consensus development project that has 
identified a classification criterion (Table I-1) for the diagnosis of GVHD 
(Filipovich et al., 2005, Shimabukuro-Vornhagen et al., 2009). The onset of 
aGVHD target regions including the liver (50% of recipients), skin (81% of 
recipients) and the gastrointestinal tract (54% of recipients) (Ferrara et al., 
2009). On the other hand, cGVHD targets specific organs including the skin, 
mouth, eyes, liver, genitalia and GI tract, which are commonly associated with 
autoimmune heamolysis and thrombocytopenia (Ferrara et al., 2009). In 
addition to risk of mortality, GVHD can further lead to organ dysfunction, 
impaired quality of life, augmented risk of infectious complications through 
prolonged periods of immunosuppressive therapy and intensified risk of 
mortality in the immunocompromised allogeneic recipient (Pidala et al., 2011, 
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Blazer et al., 2012). Despite, the harmful effects of GVHD in transplant 
recipients, beneficial effects of the alloimmune GVL effect have also been 
described. Previous studies have indicated that both GVL and GVHD can 
stem from alloimmune responses induced by discrepancies in minor 
histocompatibility antigens between HLA-matched AHSCT donors and 
recipients (Mutis et al., 2010). This implication was first deployed through DLI 
following AHSCT in the setting of relapsed leukaemia during the 1990’s (Kolb 
et al., 1995, Deol and Lum, 2010, Helg et al., 1998). Succeeding studies have 
thus demonstrated several leukaemia specific antigens considered to be 
targets for cytotoxic responses by T lymphocytes in GVL (Mutis and Goulmy, 
2002). 
 
Treatment   and prophylaxis of GVHD require the use of immunosuppressive 
agents such as corticosteroids, tacrolimus, mTOR inhibitors (rampamycin), 
calcineurin inhibitors and monoclonal antibodies targeting CD25 and TNFα, as 
a result of non-specificity (Blazer et al., 2012, Vogelsang, 2001, Abouelnasr et 
al., 2013, Rodriguez et al., 2007), all of which carry significant side-effects. 
Furthermore, studies using a number of targeted agents such as anti-CD20 
(Kim et al., 2010), bortezominb (Koreth et al., 2012) and cellular therapy 
approaches such as mesenchymal stem cells (MSC) are underway. However, 
as these strategies have not yet been approved by the FDA, the development 
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I.3.2  The pathophysiology of GVHD 
Billingham described the triad of contributors to the development of GVHD: (i) 
the presence of functional immune cells in an allograft; (ii) disparity in the 
expression of tissue antigens between the recipient and donor; (iii) the 
incapability of the recipient to reject the donor cells (Billingham et al., 1966). 
Thus, immunocompromised transplant patients are at a high risk of 
developing GVHD.  
Alloreactive reactions between donor-derived CD4+ and CD8+ T lymphocytes 
have typically been considered to be the chief effector cells arbitrating GVHD 
pathogenesis (Shimabukuro-Vornhagen et al., 2009, Rezvani et al., 2006). 
Clinical practices exemplify this paradigm by use of allografts depleted of T 
cells and T cell directed immunosuppression for the treatment of GVHD, 
which in some cases has failed to achieve success (Khaled et al., 2009). Host 
cells can also contribute to the development and pathogenesis of GVHD by 
Category Time of 
symptoms after 







Acute GVHD    




>100 Yes No 
Chronic GVHD    
Classic cGVHD No time limit No Yes 
Overlap 
syndrome 
No time limit Yes Yes 
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production of pro-inflammatory cytokines such as TNF-α and IL-1 (Blazer et 
al., 2012, Ferrara et al., 2009). Consequently, upon activation in the host, 
donor T cells can also secrete IL-2 and IFN-γ and induce direct tissue 
damage within the host through cell-mediated cytotoxicity by cytotoxic T 
lymphocytes (Weber et al., 2014).  
Further, previous evidence has described an immunomodulatory role of IL-10 
in controlling alloreactive T cell activation in HSCT and attenuating GVHD 
(Weber et al., 2014, Rowe et al., 2006, Holler et al., 2000, Zeller et al., 1999). 
However, murine studies have found that IL-10 can either suppress (Zeller et 
al., 1999) or enhance (Blazar t al., 1995) GVHD depending on the cell  
releasing it (Moore et al., 1993). There is considerable evidence that IL-10-
producing donor T regulatory cells, bone marrow cells, dendritic cells and host 
B cells (Fillatreau et al., 2002, Lampropoulou et al., 2008, Rowe et al., 2006) 
are possible candidates for immune modulation that may aid to improve 
GVHD post transplantation. Although T cells have been known as the chief 
effector cells involved in GVHD, recent data have provided evidence for the 
suppressive role of B cells in the pathogenesis of GVHD (Shimabukuro‐
Vornhagen et al., 2009). However a more profound insight into their role is 
required to tailor strategies to suppress the development of GVHD and 
improve patient outcome following transplantation. 
Acute GVHD is thought to be predominantly driven by alloreactive donor T 
cells that mediate cytotoxicity against the host’s healthy tissue through 
secreted factors that perpetuate the process (Pidala et al, 2011). Profound 
genetic disparity between HLA antigens in the donor and host has been 
described as a major contributor to the severity of aGVHD (Pidala et al., 2011, 
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Goulmy et al., 1996). The resultant tissue damage from radiation, conditioning 
regimens or chemotherapy subsequently leads to the recruitment of other 
immune effector cells, pathogen associated molecular patterns and release of 
chemokines, which direct effector cells to migrate to target organ and amplify 
tissue injury as illustrated in figure I-1 (Ferrara et al., 2009). Activated donor 
and host antigen presenting cells (APCs) also orchestrate a strong 
proinflammatory cytokine response by enhancing alloantigen presentation to 
T cells (Blazer et al, 2012, Pidala et al., 2011). Ultimately, the increased 
recruitment of proinflammatory cytokines (e.g. IFNγ, TNF, IL-2), 
macrophages, NK cells and effector T cells cause increased tissue 
destruction and severe organ damage (e.g. skin, gut, lungs and liver), which is 
clinically recognized as aGVHD (Blazer et al., 2012). Previous evidence has 
shown that T cell depletion from the allograft has almost completely abrogated 
the development of GVHD (Ferrara et al., 2009). Hence, further studies have 
focused on inhibiting T cell function to develop prevention and therapeutic 
strategies for aGVHD.  However, if untreated, the severity of GVHD pathology 
could amplify. 
Chronic GVHD (cGVHD) is the leading cause of transplants related morbidity 
and mortality that transpires in 30-65% of AHSCT recipients and signifies 30-
50% of 5-year death rates resultant from opportunistic infections and immune 
dysregulation (Blazer et al., 2012). Clinical manifestations of cGVHD 
resemble features of autoimmune diseases such as scleroderma, cirrhosis 
and can lead to debilitating consequences such as blindness, lung disease 
and joint contractures (Ferrara et al., 2009). Whilst the pathophysiology of 
aGVHD is propagated through a cascade of inflammatory events, cGVHD is 
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dependent on the recruitment of polarised CD4+ T cells (Blazer et al. 2012). 
Resultant damage to the thymus epithelium caused by conditioning regimens, 
or possibly the prior manifestation of aGVHD consequently impairs negative 
selection of alloreactive CD4+ T cells initiating a cytokine response that 
propagates the release of pro-fibrotic cytokines such as IL-10, IL-2 and 
transforming growth factor β1 that augment the activation and proliferation of 
tissue fibroblasts as illustrated in figure I-2 (Blazer et al., 2012). Clinical 
studies have provided support for an inverse relationship of TGF- β signalling 
in CD4+ and CD8+ T cell and risk of cGVHD (McCormick et al., 1999, Pidala 
et al., 2011). Recent evidence has underscored the significance of regulatory 
dysfunction mainly attributing to T regulatory cells during cGVHD 
development (Rezvani et al., 2006). However, a new wave of research has 
postulated a role for B cells in the regulation of cGVHD. (Shimabukuro‐
Vornhagen et al., 2009, Sarantopoulos et al., 2015). The potential role B cells 
in cGVHD is supported by reports of successful treatment of GVHD following 
B cell depletion (Cutler et al., 2006, Cutler et al., 2013). However, further 
insights into the mechanistic role of B cells in the pathogenesis of this 
debilitating disease is required to harness the therapeutic benefits of targeting 























Figure I-1: The sequential series of inflammatory mechanisms simplifying 
distinct events that occur in the biology of aGVHD.  
Resultant underlying damage from the HCT conditioning regimen provokes the 
release of proinflammatory cytokines and chemokines, which augment expression of 
antigens on APCs and subsequently lead to increased recruitment, differentiation 
and migration of effector immune cells leading to further tissue destruction. Figure 




















Figure I-2: The sequential series of inflammatory mechanisms simplifying 
distinct events that occur in the biology of cGVHD.  
Resultant damage to the thymus caused by conditioning regimens or prior 
manifestation of aGVHD, leads to decreased negative selection of alloreactive CD4+ 
T cells, which become polarized and produce pro-fibrotic cytokines such as IL-2, IL-
10 and TGF-β1. Macrophages that produce TGFβ1 and platelet-derived growth 
factor (PDGF) are also activated. Together the release of these molecules 
propagates fibroblast activation and proliferation causing tissue fibrosis. Low 
numbers of T regulatory cells and B cell dysregulation through production of 
autoreactive antibodies suggested to be the result of high B-cell activating factor 
(BAFF) levels, all contribute to fibroproliferative changes and antibody deposition in 
the tissue leading to cGVHD. Figure adopted from Blazer et al., 2012. 
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I.3.3  The role of B cells in GVHD 
I.3.3.1  The role of B cells in human aGVHD 
Donor effector T cell mediated destruction of host tissues and organs remains 
a common contributor to acute GVHD pathology (Pidala et al., 2011). 
However, the exact role of B cells in this disease remains controversial. 
Evidence from previous studies has suggested that B cell depletion is 
associated with prevention of aGVHD and improved outcome after AHSCT 
(Shimoni et al., 2003, Ratanatharathorn et al., 2009). Previous murine studies 
have reported a lower incidence of aGVHD with B cell depletion (Schultz et 
al., 1995). In accord with murine data, clinical studies have also associated 
the effectiveness of rituximab administered shortly before or after 
transplantation or as part of conditioning regimens with low rates of GVHD 
(Shimoni et al., 2003, Ratanatharathorn et al., 2009, Christopeit et al., 2009). 
In humans, a higher content of B cell progenitors in the donor graft was shown 
to be associated with less aGVHD (Michonneau et al., 2009). Kamble et al 
also highlighted successful response in 3 patients with refractory aGVHD 
treated with rituximab (Kamble et al., 2006). However, other studies failed to 
show a lower incidence of GVHD in patients with lymphoma after AHSCT 
after administration of rituximab post transplantation (Glass et al., 2008). 
These results suggest that early B cell depletion may play a role in the 
prevention GVHD. Further, high numbers of activated donor B cells in 
apheresis products was reported to increase the risk of aGVHD (Lori et al., 
2008). In contrast, although recipient APCs are essential contributors to 
aGVHD pathology, Rowe et al (2006) demonstrated that recipient mice that 
were unable to produce IL-10+ B cells developed a greater severity of aGVHD 
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than wild-type mice. Further, the induction of IL-10 production by host B cells 
was found to attenuate experimental aGVHD. This study underlined a 
protective role for host B cells in GVHD. In agreement with these findings, 
Weber et al (2014) has also shown a regulatory function of IL-10 produced by 
host and donor B cells to suppress aGVHD after AHSCT. The results 
designate a unique regulatory function of B cells, which could be used to 
improve outcome after AHSCT. Overall, the role of B cells in aGVHD remains 
controversial, as they have been reported to induce both a protective and 
pathogenic consequence in aGVHD. Thus, an in-depth imperative 
understanding on B cells in aGVHD may aid the development of targeted 
therapies to exploit regulatory B cells to improve patient outcome. 
 
 
I.3.3.2 The role of B cells in human chronic GVHD (cGVHD) 
Classically, donor T cells have been considered as the chief effector cells 
contributing to the biology of GVHD however, accumulating evidence has 
clearly demonstrated the fundamental role of B cells in this disease (Kharfan-
Dabaja and Cutler., 2011, Shimabukuro-Vornhagen., 2009). Delayed B-cell 
reconstitution and aberrant B-cell homeostasis after AHSCT has indicated a 
potential role for B cells through the presence of alloantibodies and high levels 
of B-cell activating factor (BAFF) in cGVHD development (Sarantopoulos et 
al., 2015).  
B cells have generally been considered to positively regulate inflammation in 
cGVHD (Socie., 2011, Shimabukuro-Vornhagen., 2009) and B-cell depletion 
therapy with rituximab has been found to prevent steroid-refractory cGVHD in 
humans (Cutler et al., 2006, Cutler et al., 2013). Other studies have shown 
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the presence of B cells in an activated state in the cGVHD environment (Allen 
et al., 2012). Indeed, evidence of typically activated B cells by increased 
signaling networks through ERK and AKT pathways have been discovered in 
B cells isolated from patients with cGVHD (Allen et al., 2012). Furthermore, 
the presence of autoantibodies has been associated with the onset and 
severity of cGVHD, postulating a role for donor B cells in this disease 
(Patriarca et al., 2006, Kier et al., 1990, Svegliati et al., 2007). After AHSCT in 
humans with gender disparity, presence of alloantibodies to H‐Y minor 
histocompatibility antigens has correlated with cGVHD development (Miklos et 
al., 2005). Whether this phenomenon is a result of antigenic disparity causing 
tissue injury or merely a marker for the presence of B cells during recovery 
post‐transplant is not fully known (Svegliati et al., 2007). Moreover, high levels 
of autoantibodies found in mice with cGVHD and sclerodermatous skin 
damage has suggested that donor B cells amplify CD4+ T cell expansion and 
thus induce autoimmune manifestations in cGVHD (Zhang et al., 2006, Young 
et al., 2012). To date, at least 35 autoantibodies have been related with 
cGVHD (Kapur et al., 2008).  
In addition to these findings, Rozendaal et al described the presence of 
autoreactive autoantibodies, usually expressed by circulating class-switched 
IgG memory B cells, during cGVHD. The development of these antibodies, 
reactive to recipient cells, was suggested to be a product of hyperstimulated B 
cells induced by alloreactive CD4+ T cells (Rozendaal et al., 1990). The 
emergence of autoreactive antibodies in cGVHD patients suggests that a 
critical breakdown in B cell tolerance occurs during cGVHD development after 
AHSCT. In contrast, other studies have found no association between 
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autoantibodies and onset or severity of cGVHD (Martin et al., 1997, 
Rouquette-Gally et al., 1988, Chan et al., 1997). Indeed, no evidence of 
autoimmune pathology was detected in healthy mice that were injected 
autoantibodies from mice with GVHD, suggesting that such antibodies are not 
themselves pathogenic per se (Rolink et al., 1988). Hence, the direct 
involvement of B cells or autoantibodies in pathogenesis of cGVHD still 
remains elusive.  
 
Further, a dysregulated B cell homeostatic environment has also been 
associated with active cGVHD (Greinix et al., 2008). BAFF, also known as 
THANK, BlyS, TALL-1 and zTNF4, belongs to the TNF family and is a critical 
survival factor in B cell proliferation and differentiation during B cell 
development and is secreted by monocytes, some T cells and dendritic cells 
at increased levels in response to reduced B cell numbers (e.g. following B 
cell depletion therapy by rituximab) (Saito et al., 2008). Elevated BAFF/B cell 
ratios have related to the onset and severity of cGVHD compared to patients 
without cGVHD (Sarantopoulos et al., 2007., Allen et al., 2012., Jacobson et 
al.,2014). The results support the role of excess BAFF and altered B cell 
homeostasis in cGVHD. Murine models have demonstrated that B cell 
survival and differentiation is dependent on a balance of BAFF and BCR 
signalling during B cell development (Sasaki et al., 2004). Increased BCR 
responsiveness has been noted in cGVHD patients (Allen et al., 2014). Lesley 
et al indicated that autoreactive B cells were capable of evading negative 
selection in the lymphoid germinal center as a result of elevated BAFF levels 
leading to development of autoimmunity (Lesley et al., 2004). These results 
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suggest that minimal levels of BAFF prevent B-cell autoreactivity. In accord, 
increased counts of circulating pre-germinal center B cells and post-GC 
plasmablasts were also associated with high BAFF levels in cGVHD patients 
(Sarantopoulos et al., 2009).  
This dysregulation in B cell tolerance involving BAFF may play an important 
role in the pathogenesis of cGVHD and it has been suggested that BCR 
pathways are candidates for the development of targeted therapeutic 
strategies (Sarantopoulos et a., 2015). 
 
Moreover, in addition to these studies, altered frequencies of B cell 
compartments have also been implicated in cGVHD. Higher frequencies of 
CD25+ B cells in GCSF mobilized graft has been related with higher risk of 
cGVHD development post-transplant (Tavebi et al., 2001). Additionally, 
variable impact on the class‐switched and nonswitched CD27+ memory B 
cells has been observed. D’Orsogna et al reported a reduced population of 
IgM+ CD27+ memory B cells in patients with a history of cGVHD (D'Orsogna 
et al., 2009). Further, subsequent evidence has reported a reduced population 
of both class-switched and IgM+ memory B cells in patients with cGVHD 
when compared to their non-GVHD counterparts (Hilgendorf et al., 2012, 
Greinix et al., 2008). On the contrary, Sarantopoulos et al observed patients 
with cGVHD displayed delayed reconstitution of naive B cells despite elevated 
BAFF levels and a sustained population of CD27+ memory B cells 
(Sarantopoulos et al., 2009). Further, decreased transitional B cell population 
(Hilgendorf et al., 2012, Storek et al.,1993), reduced CD5+ B1 like cells 
(Moins-Terssercne et al., 2013) and an abnormally expanded CD21lo B-cell 
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population (Kuzmina et al., 2011) have also been described in cGVHD. This 
observation is in line with studies of autoimmune and immune conditions that 
have also described an expanded population of CD21- B cells, which 
suggests a role for CD21- B cells in cGVHD biology as an auto-allo-condition 
(Sarantopoulos and Ritz., 2015). Furthermore, relatively reduced numbers of 
immature B cell subsets described in cGVHD suggests that a disturbed B cell 
homeostasis is a key component of this disease (Sarantopoulos et al., 2009). 
Although accumulating studies have provided compelling evidence that B 
cells play a fundamental role in human cGVHD pathology, the mechanisms 
that initiate and maintain B cell promote and sustain B-cell participation have 
not been fully elucidated. 
 
Recent research has provided compelling evidence that B cells can suppress 
or amplify immune responses through cytokine production, designating 
discrete regulatory and effector B cell sub populations (Sanz et al., 2007). 
Rowe et al., highlighted the presence of IL-10 producing B cells, which could 
inhibit alloreactive T-cell expansion, and subsequent induction of GVHD 
(Rowe et al., 2006). IL-10 producing B regulatory cells have been associated 
with prolonged allograft survival suggesting a protective role for this 
population post-transplant (Lee et al., 2012). In accord with this evidence, 
elevated GC-derived CD24hiCD27+ plasmablast-like IL-10 producing B cells 
have been described in the regulation of human cGVHD (de Masson et al., 
2015). A recent study has highlighted the importance of adoptively transferred 
donor derived regulatory B cells in attenuating the augmented manifestations 
of murine sclerodermatous cGVHD (Huu et al., 2013). Moreover Khoder et al., 
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has recently described that IL-10 producing regulatory B cells are deficient in 
recipients of HLA-matched sibling or matched unrelated donor HSCT with 
cGVHD than healthy donors and patients without cGVHD (Khoder et al., 
2014). Collectively, these findings provide compelling evidence for a 
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I.4.  B cell development 
B cell development progresses through several distinctive phases, which 
occur in the bone marrow and peripheral lymphoid tissues as depicted in 
figure I-3 (Cambier et al., 2007). Several micro-environmental constituents 
and cellular interfaces in the bone marrow niche direct the differentiation of 
irreversibly committed B cell precursors, which express PAX5 (Nagasawa et 
al., 2006). Following the rearrangement of the DH (diversity) and JH (junction) 
segments of the immunoglobulin (Ig) heavy chain gene, pro B cells 
(CD34+CD19+) undertake further rearrangement of the VH segment yielding a 
pre-B cell. Subsequently, upon coupling of the VDJ segments (also known as 
VDJ recombination), at a later phase of their differentiation, pre B-cells 
express pre B-cell receptor (pre-BCR), which is expressed within a cell and 
not on the surface (Cambier et al., 2007, Pieper et al., 2013). Pre-BCR 
signalling averts further recombination and propagates positive selection and 
proliferation of B cells (Pieper et al., 2013). Moreover, cells that fail to function 
undergo developmental arrest, apoptosis or receptor editing (Edry et al., 
2004). This stage of development is antigen independent and takes place in 
the bone marrow stromal environment (Maddalay et al., 2010). Hardy et al, 
highlighted that the sequential transition of B cells through different 
development stages is delineated by differential expression of surface 
markers (Hardy et al., 1991). Consequently, surface co-expression of IgM and 
IgD, namely the mature BCR which is capable of antigen binding is presented 
on pre-B cells as a result of preferential k light chain rearrangement during 
receptor editing (Marie-Cardline et al., 2008). The expression of BCR marks 
the first checkpoint in B-cell development (Cambier et al., 2007). Following 
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this stage, the vast majority of immature autoreactive B cells are removed 
from the B cell repertoire through negative selection to avoid any additional 
development of self-reactive B cells (Sims et al., 2005, Hartley et al., 1991, 
Duty et al., 2009). In this process, the immature B-cells that survive proceed 
to the peripheral blood as transitional B cells (Forster et al., 1990, Warderman 
et al., 2003). Depending on the strength of BCR signalling and antigen 
specificity, transitional ‘immature’ B cells populate niches and mature within 
the splenic microenvironment into follicular or marginal zone (MZ) B cells 
(Allman et al., 2008). Following an immune response, antigen-activated naïve 
B cells can obtain T-cell help to form germinal centers and undergo somatic 
hypermutation and isotype switching to produce memory B cells and plasma 
cells (antibody-secreting cells), forming the basis for adaptive humoral 
immunity (Carsetti et al., 2004). In contrast, MZ B cells produce T-cell 
independent-Ag responses and endure reduced levels of somatic 
hypermutation (Weill et al., 2009). 
The knowledge of B cell development is essential for better understanding 
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I.5  B cell subsets 
Immature B cells migrate from the bone marrow and into transitional B cells; 
the early emigrants from the bone marrow defined by their short lives that 
must generate a functional BCR in order to overcome negative selection 
pressures (Hartley et al., 1991, Sims et al., 2005). Transitional B cells 
preserve the capacity to reconstitute the B cell pool following bone marrow 
transplantation (Marie-Cardine et al., 2008) and B cell depletion therapy 
(Anolik et al., 2007). Transitional B cells represent 2.2-7% of B cells in healthy 
adult peripheral blood and approximately 50% of B cells in cord blood and are 
commonly distinguished as CD19+ CD24high CD38high (Sims et al., 2005, 
Carsetti et al., 2004, Marie-Cardine et al., 2008).  Transitional B cells have 
been extensively studied in murine spleen based on the expression of heat 
stable (HAS, CD24) and IgM receptors, transitional B cell population could be 
distinguished from immature to mature splenic B cells (Loder et al., 1999). 
Additional phenotypic profiling has further subdivided transitional B cells into 
T1 (CD19+ CD21low, CD23low, CD24high, IgMhigh, IgDlow), T2 (CD19+CD21low, 
CD23high, CD24high, IgMhigh, IgDhigh) and a T3 subset (CD19+ CD21low, 
CD23high, CD24high, IgMlow IgDhigh) (Sims et al., 2005, Allman et al., 2001, 
Marie-Cardine et al., 2008). T1 cells are known to be susceptible to apoptosis 
whereas T2 subsets undergo proliferation and differentiation into follicular 
mature B cells upon BCR ligation mainly through the B-cell activation factor 
receptor (BAFF-R) pathway (Sims et al., 2005, Mackay et al., 2010, Marie-
Cardine et al., 2008). Furthermore, Allman et al identified the expression of 
CD93 (the B cell lineage precursor marker) in all 3 transitional subsets, which 
distinguishes their classification from MZ B cells and mature splenic follicular 
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B cells (Allman et al., 2001). Additionally, transitional B cell are CD27- and 
express decreasing levels of CD10 and IgM with increasing levels of CD21, 
CD23 and CD44 in accord with their maturation as their percentage 
progressively decreases (Palanichamy et al., 2009).  
In human peripheral blood, transitional B cell subsets phenotypically resemble 
murine T1 and T2 subsets (Sims et al., 2005). Additionally, ATP-binding 
cassette transporter (ABCB1) expression has previously been found to define 
T3 transitional B cell subset following rituximab therapy in adult peripheral 
blood (Palanichamy et al., 2009). Transitional B cells are present in the bone 
marrow, predominantly (T1), spleen (T2), and peripheral blood and cord blood 
mostly (T3) and in small numbers in lymph nodes (Carsetti et al., 2004, 
Palanichamy et al., 2009). They mature in the spleen to follicular naïve B cells 
or MZ B cells depending on the strength of BCR signaling (Carsetti et al., 
2004, Weill et al., 2009). However, weak BCR signalling and reduced antigen 
affinity direct the differentiation of T2 B cells to marginal zone B cells 
(CD27+IgM+IgD+), which mediate T-cell independent responses and 
differentiate into short-lived plasma cells (Allman and Pillai., 2008, Carsetti et 
al., 2004, Weil et al., 2009, Srivastava et al., 2005). Moreover, previous 
reports have proposed that transitional B cells could mature into IgM 
producing memory cells upon TLR-9 triggering in vitro (Capolunghi et al., 
2008). Hence, transitional B cells are often termed as developmental 
intermediates for maturing B cells. 
 
Human naïve B cells constitute approximately 40-70% of circulating B cells in 
both peripheral blood and cord blood and are often characterized as 
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CD19+CD27−IgMlowIgDhigh CD24intCD38int bearing a functional BCR (Carsetti 
et al., 2004,  Sims et al., 2005). Additionally, they fail to express CD21, CD10 
and CD5 (Carsetti et al., 2004, Palanichamy et al., 2009). Their functional 
maturity is reflected by acquisition of surface IgD expression, longer life-span 
and proliferation upon BCR engagement and signalling (Allman et al., 2001). 
Having successfully passed the elimination checkpoints, naive B cells 
circulate through peripheral blood and have high affinity to specific non-self 
antigens. Additionally, naïve B cells possess the ability to home to and survive 
in the follicular niches of secondary lymphoid tissues (Allman and Pillai, 
2008).  Any naïve B cells that fail to encounter an antigen exit the lymph 
nodes through the lymphatic vessels and die within a few days (Perez-Andres 
et al., 2010). However, a fraction of auto-reactive anergic naïve B cells 
expressing IgD are detected in the periphery (Duty et al., 2009). Activation of 
the follicular naïve B cells is T-cell dependent and requires BCR engagement 
and CD40 signaling (Allman and Pillai, 2008). Mature naïve B cells are able to 
participate in T-dependent immune responses by presenting processed 
peptides on MHC complexes on their surface, which is recognized by cognate 
CD4+ T cells (Perez-Andres, 2008). Accumulating evidence has further 
suggested that cytokine production by B cells (i.e. IL-10) can also modulate T-
dependent immune responses (Mauri and Bosma., 2012). Following 
activation, antigen specific B cells migrate to the germinal center and undergo 
numerous rounds of division, somatic hyper-mutation, class-switch 
recombination, and affinity selection (Palanichamy et al., 2009). Naïve B cells 
are distinguished from germinal center B cells by increased expression of 
CD44 and bcl2 and decreased expression of CD10, CD95, CD38 and HLA-
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DR (Allen et al., 2007, Perez-Andres, 2010). Activating signals from the T cell 
propagate B cell activation resulting in proliferation, germinal center formation 
and eventual differentiation of naïve B cells into memory or antibody secreting 
plasma cells (Perez-Andres, 2008).  However, the factors governing the 
differentiation of activated naïve B cells into memory or plasma cells remain 
elusive (Good‐Jacobson and Shlomchik, 2010). 
 
Memory B cells form the basis for humoral adaptive immunity and are large 
antigen experienced cells, which persist in the absence of immunizing agents 
and possess increased responsiveness during a secondary response by 
secreting Ig upon stimulation (Weill et al., 2009, Good‐Jacobson and 
Shlomchik, 2010). Memory B cells constitute approximately 20-30% of B cells 
in peripheral blood and are almost absent in cord blood but gradually increase 
in proportion during the first year of life (Kruetzmann et al., 2003, Weller et al., 
2004). They are characterized by acquired somatic hypermutations in their 
rearranged Ig variable regions. Klein and Kuppers, classified memory B cells 
based on their CD27 surface expression, which is classed as a universal 
marker for memory B cells (Klein and Kuppers, 1998). Memory B cells are 
also noted to express CD24hi and CD38int, however the level of expression 
of these markers on the CD24/CD38 axis varies relative to the expression of 
CD27 (Sanz et al., 2008, Khoder et al., 2014). Interestingly, about a third of 
the circulating memory B cells with mutated BCRs are double negative CD27 
and IgD and account for 5% of total B cells in peripheral blood, which 
contradicts the classification of memory B cells on the basis of a single marker 
(CD27) as too simplistic (Sanz et al., 2008, Fecteau et al., 2006, Weill et al., 
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2009).  Additionally, this subgroup of B cells has a lower mutation rate than 
CD27+ memory B cells, which may be a result of incomplete germinal center 
reactions; however, the function and origin of this subgroup remains to be 
elucidated (Fecteau et al., 2006, Sanz et al., 2008).  
Furthermore, whilst the majority of naïve B cells recirculate between lymphoid 
tissues, memory B cells reside in areas of antigen drainage including the 
mucosal epithelium of the tonsils and the splenic marginal zone (Perez-
Andres., 2010). As naïve B cells differentiate into memory B cells, they attain 
a higher affinity to bind to antigens and exhibit an augmented in vitro 
response when exposed to different stimuli that mimic antigen-recognition (i.e. 
anti-BCR antibodies) or upon follicular T-helper cell interaction via CD40L 
(Perez-Andres., 2010). Upon such T-cell dependent activation that takes 
place in GCs within the spleen and lymph nodes, germinal center-derived 
memory B cells rapidly undergo further rounds of cell-cycle division and a 
proportion differentiates into antibody secreting cells (plasmablasts), which 
represent about 1–3% of all circulating healthy adult PB B-cells and are the 
main providers for Ig (Perez-Andres et al., 2008, Odendahl et al., 2005). Once 
generated, plasmablast cells migrate from secondary lymphoid tissue and 
mature within the bone marrow niche, which equips them with factors required 
for their survival and differentiation before entering the peripheral blood 
compartment (Odendahl et al., 2005, Perez-Andres., 2010). 
Peripheral blood CD27+ve memory B cells can be divided into two major 
groups, isotype switched (IgM-ve IgD-ve) and IgM memory (IgM+ve IgD+ve) 
(Perez-Andres., 2010). IgM only memory B cells have been suggested to be 
germinal center derived and the direct precursor of isotype switched cells 
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(Weill et al., 2009). Memory B cells that have undergone somatic hyper-
mutation are recognized as isotype switched memory B cells, which account 
for approximately 20% of all memory B cells in PB and are the final product of 
a successful T-cell dependent germinal center reaction (Good-Jacobson and 
Shlomchik., 2010, Klein et al., 1998). The mutations affecting components of 
class-switched B cells prevent the formation of plasma cells and memory B 
cells expressing IgA, IgG, and IgE (Perez-Andres et al., 2010).   
On the other hand, IgM memory B cells account for approximately 50% of 
memory B cells in PB (Perez-Andres et al., 2010). IgM memory B cells are 
large cells with abundant cytoplasm and have been known to express IgMhi, 
IgD+, CD1c+, CD21hi, CD5-, CD23- and CD27+ as well as chemokine 
receptors such as CXCR4, CXCR5 and CCR7 (Weller et al., 2004, Weill et al., 
2009, Tangye and Tarlinton, 2009). The high level of expression of CD21 on 
this subset is essential for the recognition of bacterial polysaccharides 
(Zandvoort et al., 2001). IgM memory B cells predominantly produce IgM and 
have a higher level of CD72 expression but lower CD80, CD86 and CD95 
expression than switched memory B cells (Shi et al., 2003). Further, in 
contrast to the pentamer structure of secreted IgM, membrane bound IgM 
(BCR receptor) on the surface of IgM memory B cells has a dimer or 
monomer configuration (Ehrenstein and Notley, 2010). IgM memory B cells 
develop in the MZ of the spleen with lower numbers of somatic mutations and 
have not undergone class switching and retain higher clonal diversity than 
switched memory B cells (Weller et al., 2004). Thus, the spleen and possibly 
other lymphoid organs have been recognized as a source for IgM memory B 
cell maintenance (Kruetzmann et al., 2003). Upon antigen activation, this pre-
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diversified subset of memory cells produce T cell independent IgM, IgG and 
IgA (Weill et al., 2009, Weller et al., 2004). IgM memory B cells are involved in 
providing rapid protection against bacterial infections such as Streptococcus 
pneumonia through their interaction with MZ macrophages (Kruetzmann et al., 
2003). Previous evidence has suggested that upon a primary response to 
bacterial antigens, IgM memory B cells are able to mature into CD20-IgM 
producing plasmablasts within 3 days that express high levels of CD38 and 
CD27 and higher rate of CD40 and BCR engagement (Shi et la,. 2003).  
Although previous studies have detected their presence in neonatal cord 
blood, bone marrow, lymph nodes and foetal liver at 14-16 weeks of 
gestation, others have found them completely absent in cord blood 
(Kruetzmann et al., 2003). However, previous studies have found that early 
post-rearrangement Ig diversification of IgM memory B cells through induction 
of somatic hyper-mutations may occur during foetal life (Scheeren et al., 
2008). In accord, evidence has highlighted that the maturation of cord blood-
derived transitional B cells into IgM memory B cells in vitro after CpG 
stimulation (Capolunghi et al., 2008). Thus the ontogeny of IgM memory B 
cells remain unclear; whether this subset is derived as a product of germinal 
center differentiation or as a derivative from precursor transitional B cells 
(Weller et al., 2005).  
Further, IgM memory B cells essentially serve as a bridge between innate and 
adaptive immunity and by virtue of their high avidity and poly-reactivity they 
are known to promote self-tolerance (Ehrenstein and Notley, 2010). It has 
been suggested that autoreactive MZ B cells or IgM B cells may be potential 
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regulators of immune function by secreting the immunomodulatory cytokine 
IL-10 (Zhou et al., 2011, Gray et al., 2007). 
 
Beyond the commonly recognized role of peripheral B cells in mediating 
humoral immune responses through antibody secretion and in antigen 
presentation, more recently they have been highlighted to secrete cytokines 
important in B cell homeostasis and pathogenesis of multiple diseases (Mauri 
and Bosma., 2012, Lund and Randall., 2010). Accumulating evidence has 
highlighted a potential role for some B cell populations with regulatory 
capacity in immune modulation. This revolutionary discovery has led to the 
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I.6  Regulatory B cells 
1.6.1 Origin of Regulatory B cells 
The hallmark of effective immune modulation in autoimmunity, infection, 
inflammation and during cancer immune surveillance is regulation by the 
release of anti-inflammatory mediators and cytokines, such as interleukin-10 
(IL-10), produced by regulatory immune cells (Rosser and Mauri., 2015). On 
one hand, B-cells arbitrate an effector immune response by producing pro-
inflammatory cytokines (i.e. IFN-γ and TNF-α), whereas on the other hand, B-
cells can contribute to the maintenance of immune tolerance through the 
expression of immune-regulatory cytokines (i.e. IL-10 and TGF-β) (Harris et 
al., 2000, Mauri and Bosma., 2012).  
The concept that suppressor B cells could orchestrate immune modulation 
was first proposed nearly 40 years ago, where unlike total splenocytes, B-cell 
depleted-splenocytes in guinea pigs were associated with an increase in the 
severity and duration of contact hypersensitivity suggesting that B-cells 
possessed the ability to inhibit T-cell activation (Katz et al., 1974, Neta and 
Salvin., 1974). In accord with these findings, B-cells were noted to suppress 
anti-tumor T-cell responses highlighting their role in modulating immune 
homeostasis (Gorczynski et al., 1974). These initial findings were later 
supported by a series of in vivo studies showing that adoptive transfer of 
activated splenic B-cells induced tolerance and differentiation of suppressor 
T-cells in recipient naïve mice (Shimamura et al., 1982, Shimamura et al., 
1984). Further, an enriched pool of splenic B-cells induced tolerance to MHC-
alloantigens in vivo, which are required for T-cell recognition and activation 
(Ryan et al., 1984). Moreover, antigen presentation by resting B-cells to 
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resting T-cells was similarly found to cause loss of T-cell function associated 
with induction of tolerance (Evans et al., 2000). Well-founded support for the 
tolerogenic role for B cells was further proposed by two independent studies 
indicating that B-cell deficient mice cultivate aggravated, chronic forms of 
colitis or autoimmune encephalitis, indicating that B cells possess regulatory 
properties (Mizoguchi et al., 1997 and Wolf et al., 1996). Although these 
seminal observations designated a role for suppressor B-cells in immune 
modulation and homeostatic balance, the term ‘regulatory B-cells’ (Breg) was 
first introduced by Mizoguchi and Bhan in 2002, nearly 30 years later after 
primary observations indicated their presence (Mizoguchi et al., 2002, 
Mizoguchi et al., 2006). Mizoguchi et al, described a gut-associated Il-10 
producing B-cell subset with upregulated CD1d expression that suppressed 
the progression of colitis-related intestinal inflammation by downregulating 
inflammatory cascades in a chronic inflammatory setting (Mizoguchi et al., 
2002). Shortly thereafter, the recovery in mice with experimental autoimmune 
encephalomyelitis was dependent on the presence of IL-10 producing splenic 
B cells (Fillatreau et al., 2002). Further support for Bregs comes from reports 
in transplant recipients that withdrawal of immunosuppressive drugs results in 
higher levels of B cell activation compared to patients who continued 
immunosuppressant therapy, suggesting a protective role for suppressor B-
cells in the transplant setting (Newell et al., 2010). Similar to T regulatory 
cells, the suppressive capacity of Bregs have been found to be mediated via 
the production of regulatory cytokines; namely, IL-10 and TGF-β and the 
expression of inhibitory molecules through cell-to-cell contact-dependent 
mechanisms that suppress pathogenic T cells (Lundy et al., 2009). 
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Furthermore, previous studies have indicated that Bregs exist as a 
heterogeneous population that can be derived from total B cells under 
appropriate stimulatory conditions (Gray and Gray., 2010). Despite the 
extensive body of evidence accumulating in the ensuing years since these 
studies were published, some controversy over the paucity of markers that 
can unequivocally identify Bregs, particularly in humans, still exists (Mauri and 
Bosma., 2012).  Hence, most current strategies to definitively identify Bregs in 
a reproducible manner rely on the detection of IL-10, which inhibits 
proinflammatory cytokine production and differentiation of effector T cells 
(Mauri and Bosma., 2012). However, it is questionable whether all 
mechanisms of suppression rely exclusively on the suppressive effect of IL-
10. Accumulating evidence has conclusively designated a pivotal role of 
Bregs that exert their suppressive functions though different mechanisms in 
divergent models of disease, including autoimmunity, infection, cancer and 
inflammation (DiLillo et al., 2010). Here, I review the recent advances made in 
our understanding of both the phenotypic and functional characterization of 
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1.6.2  Characterization and Identification of Regulatory B cells 
1.6.2.1    Identification and development of regulatory B cells (B10 cells 
in  mice 	  
In recent years, a diverse population of regulatory B cell (Breg) subsets has 
been identified in murine models of collagen induced arthritis (CIA), 
experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel 
disease (IBD) where adoptive transfer of Breg attenuated disease pathology 
(Yanaba et al., 2008, DiLillo et al., 2010, Mauri and Bosma., 2012). B10 cells 
were first highlighted in a contact hypersensitivity murine model in which 
CD19-/- mice exhibited augmented T-cell mediated inflammation whereas 
mice with hyperactive B cells overexpressing human CD19 transgene 
(hCD19Tg) presented substantially reduced inflammation regulated by an IL-
10 producing CD1dhiCD5+ B cell subset (Yanaba et al., 2008). This unique 
regulatory subset was absent in CD19 deficient mice but represented 1-2% of 
spleen B cells in wild-type mice, which expanded to approximately to 10% in 
hCD19Tg mice. CD19-/- mice presented increased levels of ear swelling 96h 
after immunization with oxazolone. The resulting inflammation normalized 
upon adoptive transfer of CD1dhiCD5+ B cells in CD19-/- mice and IL-10 
secretion was found to be a prerequisite for the suppressive capacity of this 
subset. Thus, the term B10 was introduced to represent this subset of potent 
regulatory B cells to functionally distinguish this defined B cell subset from 
other B cell types. Although this study provided evidence for BCR signaling in 
B10 cell induction, the data remains contradictory (Yanaba et al., 2009, Mauri 
and Bosma et al., 2012). Further, B cell activation in response to various 
stimuli including protein kinase C activator phorbol 12-myristate 13-acetate 
(PMA) and ionomycin allowing measurable levels of IL-10+B cells to be 
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detected by immunofluorescence staining has been reported (Yanaba et al., 
2009). Further, the addition of lipopolysaccharide (LPS) to these cultures was 
shown to augment the frequency of B10 cells and is commonly employed to 
identify IL-10+ murine B cells ex vivo. In addition, B cell activation with 
apoptotic cells or CpG (TLR ligand) has also been found to produce high 
levels of B10 cells suggesting that B10 cells are antigen-experienced cells 
(Yanaba et al., 2009, Gray et al., 2007). In accord with these findings, 
Fillatreau et al proposed that Bregs were recruited in close proximity to an 
antigen during inflammation in an antigen specific model and expanded in the 
lymph nodes via T-cell help (Fillatreau et al., 2002). In contrast, non-antigen 
specific models have shown that Bregs are induced through activated CD154-
expressing T-cell interaction regardless of antigen specificity and are 
abundant in the periphery (Wei et al., 2005). Additionally, Poe et al further 
noted that CD22-/- mice expressing CD40L presented increased numbers of 
CD1dhiCD5+ B and B10 cells (Poe et al., 2011). Further support for CD40 
engagement in inducing Breg function has been highlighted in models of CIA 
and EAE through IL-10 dependent mechanisms (Mizoguchi et al., 2006, Mauri 
et al., 2003). Furthermore, the role Toll-like receptors (TLR) in Breg function 
have also been suggested. Murine B cells lacking MyD88, TLR2, or TLR4 was 
associated with development of chronic EAE in mice (Lampropoulou et al., 
2008). Additional evidence has also shown an expanded pool of B10 cells 
following CD40 signaling in-vivo and an increase in IL-10+B cells after 
stimulation by agonistic-CD40 monoclonal antibody (Yanaba et al., 2009, Poe 
et al., 2011). The expanded B10 population has been termed B10 progenitor 
cells (B10pro) and CD40 signals have been proposed to mature B10 
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progenitor cells to B10 cells, whereas BCR cross-linking has been proposed 
to inhibit this progression (Yanaba et al., 2009). Thus, murine studies have 
demonstrated that Bregs are able to respond in both an antigen specific and 
polyclonal manner. 
The identification of B10pro cells following in vitro stimulation has suggested 
that selected B cells possess the capacity to produce IL-10 but require 
additional signals to actively secrete IL-10 (Nouel et al., 2014). Collective 
evidence has highlighted signals involved in B10 cell development (figure I-
4). B10pro cells are suggested to have already received appropriate BCR 
signals for molecular events required for IL-10 secretion but require additional 
signals such as CD40 stimulation, which induces IL-10 expression in B10pro 
cells and LPS stimulation with PMA and ionomycin, which acts as a potent 
stimulus to promote IL-10 secretion (Kalampokis et al., 2013, Candando et al., 
2014). Following IL-10 production, some B cells differentiate into memory B10 
cells or into plasma cells that are capable of secreting poly-, auto- or self-
reactive antibodies depending on their BCR specificity (Kalampokis et al., 
2013, Candando et al., 2014). Alternatively, following these events T-cell 
derived signaling is required for B10 cell expansion, active IL-10 secretion and 
immune regulation in vivo. Yoshizaki et al., supported this theory by showing 
that Bregs require cognate interactions with IL-21 producing T cells to exert 
IL-10 dependent suppressive function in autoimmunity (Yoshizaki et al., 
2012). IL-21R signaling with CD40 and MHC-II interactions was shown to 
augment Breg frequency and IL-10 secretion (Yoshizaki et al., 2012). Thus 
B10pro cells have been suggested to mature into B10 cells that require T-cell 
derived signals to secrete IL-10 and exert immuno suppression. These data 
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suggest that cellular cross-talk may play pivotal role in immune regulation 
than cytokine-dependent immune modulation. 
 
1.6.2.2   Immunophenotype of regulatory B cells identified in mouse 
models 	  
Mouse B10 cells have been identified in the spleen, lymph nodes, peripheral 
blood (PB) and gut associated lymphoid tissues including peritoneal cavity 
and mesenteric lymph nodes (Mizoguchi et al., 2002, Yanaba et al., 2009). 
B10 cells described in the peritoneal cavity have been identified within the 
CD5+CD11b+ B1a B cell subset (38%), CD5− CD11b+ B1b (18%) subset and 
the CD5−CD11b− B2 (4%) subset (Candando et al., 2014). B10 cells within 
other mucosal tissues signify approximately 4% of lamina propia, 3% of 
Peyer's patch B cells and 1% of mesenteric lymph nodes (Candando et al., 
2014). Additionally, a small proportion of B10 cells have been identified in the 
lymph nodes and PB (Yanaba et al., 2009). Although a number of B10 surface 
markers have been identified in murine models (Table I-2), a lack of 
consensual phenotype to define the B10 subset limits the study of IL-10+B 
cells (Mauri and Bosma., 2012). Hence, most current strategies to definitively 
identify Bregs in a reproducible manner rely on the detection of IL-10.  
 
Matsushita and Tedder highlighted that only 1-3% of total B cells from 
wildtype C57BL/6 mice produce IL-10 upon stimulation with PMA and 
ionomycin (Matsushita and Tedder., 2011). Subsequently, the intracellular 
detection of IL-10 combined with flow cytometric phenotyping has highlighted 
that murine splenic IL-10+B cells were predominantly enriched in CD1dhiCD5+ 
B cell subset, where they represent 15-20% of the cells in C57BL/6 mice 
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(Kalampokis et al., 2013). Further, this unique subset shares phenotypic 
features with IL-10 producing CD1dhiCD23-IgMhiCD1dhi marginal zone (MZ) B 
cells, CD1dhiCD23+IgMhiCD1dhi T2-MZ precursor, and CD1dhiCD5+B-1a B 
cells, but does not exclusively belong to these B cell sub-populations (figure 
I-5) (Evans et al., 2007, Yanaba et al., 2008, Mizoguchi and Bhan., 2006, 
Matsushita et al., 2008). Contrastingly, Ding et al highlighted that although 
Tim-1 expressing IL-10+ B cells are also enriched in the CD1dhiCD5+ subset, 
Tim-1-IL-10+B cells are found within the non-CD1dhiCD5+ subset (Ding et al., 
2011). Further, IL-10 producing plasma cells (CD19+CD138+) and 
plasmablasts have also been reported (Shen et al., 2014, Matsumoto et al., 
2014). Similarly, Maseda et al highlighted that B10 cells expressing 
IgMhiCD1dhiCD5+CD19hiCD23lowCD38hiB220hi were capable of differentiating 
into IgM and IgG secreting CD138+ plasma cells (Maseda et al., 2012). 
Despite discrepancies found in characterization of B10 cell phenotype, the 
capacity of B cells to produce IL-10 remains the gold standard to identify pure 
B10-cell populations for study (Rosser and Mauri., 2015). Nonetheless, the 
best current strategy for isolating an enriched population of B10-cells for use 
in adoptive transfer experiments in murine models is the isolation of 
CD1dhiCD5+ B cells or other well-defined B cell subsets enriched for IL-10+B 


























Figure I-4: B10 cell development in vivo in mice and human 
BCR signalling following antigen encounter induces a small proportion of B cells to 
produce IL-10. In mice B10 cells mature from a progenitor population (B10pro). 
Following CD40 stimulation, B10pro cells become competent for IL-10 expression. 
The resulting CD1dhiCD5-IL-10 competent B10 cells are induced to produce IL-10 in 
response to LPS stimulation with PMA and ionomycin, which acts as a potent 
stimulus to promote IL-10 secretion. Following transient B-cell IL-10 production, a 
small proportion of B-cells differentiate into antibody secreting plasma cells or 
memory B10 cells. Development of human IL-10+B cells is thought to follow a similar 
pathway as observed in mice as both B10 and B10pro cells have been recognized in 
neonatal and adult blood. Whether human B10 cells differentiate into memory cells 
first or plasma cells remains unknown. Solid arrows depict known associations and 








































Figure I-5: Phenotypic markers for distinct Breg subsets in mice 
A summary of the phenotypic profiles of IL-10 producing B cells: B10 cells and T2-
MZP. The colour code illustrates shared and unshared markers by both subsets. 
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Table I-2: Regulatory B cell subsets identified in mice and human 
 
Br1, B regulatory 1; DC, dendritic cell; dLN, draining lymph node; IgG4, immunoglobulin G4; MHC, 
major histocompatibility complex; MZ, marginal zone; NK, natural killer; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematosus; T2-MZP, transitional 2 marginal-zone precursor. Table adopted from 
Rosser and Mauri (2015) 
Breg Cell 
Type 
Mouse Human Key Features Reference 
B10 CD5+CD1dhi CD24hiCD27+ Found in mice spleen 
and human blood, 
produce IL-10, and 
suppress effector 




Iwata et al., 
2011, 
Matsushita et 
al., 2010 and 
Yanaba et al., 
2008 
MZ CD19+CD21hiCD23- - Found in spleen, 
produce IL-10, 
induce Treg cells and 
suppress effector 
CD8+ and CD4+ T 
cells 
Bankoti et al., 
2012, Gray et 
al., 2007 and 







- Produce IL-10, found 
in spleen, induce 
Treg cells and 
suppress effector 
CD8+ and CD4+ T 
cells 
Blair et al., 
2009, Carter et 
al., 2011, 




Plasma cells CD138+MHC-11lo 
B220+ 
- Produce IL-10 and 
IL-35, found in 
spleen suppress NK 
cells, neutrophils and 
effector CD4+ T cells  
Neves et al., 
2010 and 




Tim-1+CD19+ - Produce IL-10, found 
in mice spleen and 
suppress effector 
CD4+ T cells 
Ding et al., 
2011 and Xiao 





Produce IL-10, found 
in dLNs (mice) and 
human blood and 
suppress DCs and 







Produce IL-10, found 
in blood and at site of 
inflammation, induce 
Treg cells, suppress 
Th1 and Th17 cells, 
suppress virus 
specific CD8+ T cell 
responses, are 
defective in patients 
with SLE and RA  
Blair et al., 








- CD19+CD27+IgM+ Produce IL-10 and 
found in Human 
blood 
Khoder et al., 
2014 
Br1 cells - CD19+CD25hiCD71
hi 
Found in blood and 
produce IL-10 and 
IgG4 
Van de Veen 
et al., 2013 
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1.6.2.3    Identification of regulatory B cells in humans 
IL-10 producing B cells subsets with regulatory capacity have been recently 
identified in humans (Iwata et al., 2011). Low but detectable numbers of IL-
10+B cells have been found in human blood, tonsils, spleen and neonatal 
cord blood (Candando et al., 2014). The general scheme of human IL-10+B 
cell development appears to follow mouse B10pro cell maturation where their 
response to LPS and CpG stimulation and CD40 ligation induces the 
maturation of B10pro cells into B10 cells that are capable of expressing IL-10 
(Iwata et al., 2011). Some individuals have demonstrated increased IL-10+B 
cell frequencies in response to TLR4 (LPS) and TLR9 (CpG) stimulation, 
suggesting that in humans B10pro cells may respond preferentially to TLR 
stimuli (Candando et al., 2014). Additionally, other studies have observed that 
whereas CD40 signaling promotes B10pro cell maturation, BCR cross-linking 
inhibits this progress in human B cell cultures (Iwata et al., 2011, Duddy et al., 
2007). In contrast, others have reported that human B10pro development is 
most optimally induced by BCR and CpG stimulation and independent of 
CD40 signaling (Bouaziz et al., 2010).  
 
 
1.6.2.4    Immunophenotype of regulatory B cells identified in humans 
Over the last decade, accumulating evidence has defined a subset of IL-10+B 
cells in humans, which represents <1% of PB-derived B cells with varying 
phenotypes (Iwata et al., 2011, Blair et al., 2010). Previous evidence 
highlighted that IL-10+B cells are contained within CD27- naïve B cell 
compartment, while memory B cells were found to produce pro-inflammatory 
cytokines in response to different stimulus (Duddy et al., 2004, Correale et al., 
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2008). Consistent with these findings, Blair et al., elegantly described an 
enriched population of IL-10+B cells in the CD24hiCD38hi B cell subset, a 
phenotype that typically delineates human transitional B cells, which exerted 
IL-10 dependent suppressive function on CD25-CD4+ effector T cell cytokine 
production (Blair et al., 2010, Flores-Borja et al., 2013). Conversely, a subset 
of Breg, analogous to murine B10 cells, was found to be enriched within the 
CD24hiCD27+ B cell subset, of which 60% expressed CD38 (Iwata et al., 
2011). These CD24hiCD27+ B cells exerted suppressive function on CD14+ 
monocyte proliferation and cytokine production. Extensive phenotyping of IL-
10+B cells has also highlighted that they highly express CD48 (B-cell 
activation marker) and CD148 (marker for human memory B cells)(Iwata et 
al., 2011). Thus, the CD24hiCD148+ phenotype of IL-10+B cells may suggest 
that they are enriched in the memory B cell pool or share overlapping markers 
with memory B cells (Iwata et al., 2011, Candando et al., 2014). Further, 
Bouaziz et al, provided evidence of IL-10+B cells that fall within both the 
CD27+ and the CD27-CD38hi transitional compartment (Bouaziz et al., 2010). 
In accord with this finding, 60% of IL-10+B cells were found within the CD27- 
naïve population in relapsing remitting MS patients and within the CD27+ 
subset during relapse (Knippenberg et al., 2011). However, a recent report 
identified that human IgM+CD27+ memory B cells produced greater levels of 
IL-10 than CD27- naïve B cells (Miles et al., 2012). A recent report by Khoder 
et al supported previous studies and in addition showed that IL-10-secreting 
CD19+IgM+CD27+ memory B cells coexist with IL-10+CD24hiCD38hi 
transitional B cells in healthy human donors and significantly suppress the 
proliferation and cytokine production of autologous CD4+ T cells through both 
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IL-10-dependant and cell-to-cell contact mediated mechanisms (Khoder et al., 
2014). Other phenotypes for IL-10 producing CD19+ B cells have also been 
described. Matsumoto et al identified a subset of CD19+CD24hiCD27int IL-10+ 
plasmablast regulatory B cells (Matsumoto et al., 2014). Further, a recent 
study characterized IgG4 expressing human inducible IL-10-secreting B 
regulatory 1 (BR1) cells that had a high expression of surface CD71 and 
CD25 but low CD73 and potently suppressed antigen-specific CD4+ T cell 
proliferation, highlighting a role for Breg in allergen tolerance (van de Veen et 
al., 2013). Thus, although IL-10+B cells can be modestly enriched in selected 
B cell compartments, their ability to produce IL-10 remains the gold standard 
method to unequivocally define Bregs. 
 
1.6.2.5    IL-10 independent mechanisms of regulatory B cell 
suppression 
 
In addition to IL-10 production, Breg have been reported to exert immune-
suppression through other mechanisms including the release of 
immunomodulatory cytokines such as transforming growth factor β (TGF-β) 
and IL-35 (Rosser and Mauri., 2014).  LPS activated B cells have been shown 
to induce both apoptosis of CD4+ T cells and anergy in CD8+ effector cells 
(Tian et al., 2001, Parekh et al., 2003). Additionally, the recent identification of 
IL-35 producing Breg in negative regulation of immunity demonstrated 
increased protection against experimental autoimmune encephalitis but 
markedly improved resistance to Salmonella-induced sepsis in murine models 
as lack of IL-35+ B cell expression augmented Th1 cell responses and the 
number of splenic macrophages (Shen et al., 2014). Further evidence has 
also supported the regulatory function of IL-35+Breg, in which the adoptive 
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transfer of IL-35 producing B cells inhibited experimental uveitis in mice 
(Wang et al., 2014). In addition to cytokine production, granzyme production 
by B cells has been found to initiate apoptosis of infected cells following the 
cleavage of caspases (Trapani and Sutton., 2003). The expression of Fas 
ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
has further identified in a distinct subset of suppressive B cells designated 
‘killer B cells’ (Lundy, 2009). Further, expression of programed death ligand 
(PD-L) 1 and 2 has also been reported to participate in B cell immune-
suppression (Lundy, 2009). Hence in addition to soluble factors, direct cell-to-
cell contact may play a vital role in B cell mediated immune-suppression. 
 
1.6.3  Regulatory B cells in immune regulation 
Bregs have been reported to modulate immune responses through diverse 
mechanisms that target different immune cell types (figure I-6), including 
dendritic cells and Th1 and Th2 cells (Matsushita et al., 2010, Tian et al., 
2001). Previous studies have highlighted the ability of Bregs to suppress T 
cell proliferation and production of IL-17 and IFN-γ by Th17 and Th1 cells, 
respectively (Carter et al., 2012). Consistent with these findings, Yang et al 
further demonstrated a role for Bregs in T-cell plasticity by observing that IL-
10+B cells suppressed Th17 differentiation through attenuating levels of 
pStat3 in an IL-10-dependent fashion (Yang et al., 2012). Additionally, IL-
10+Bregs have been shown to suppress CD4+ T cell proliferation and pro-
inflammatory cytokine production through IL-10 (Khoder et al., 2014, Blair et 
al., 2010) and induce CD4+T cell death by expression of FasL (Tian et al., 
2001). Further, adoptive transfer of GIFT-15 induced Breg has been observed 
to suppress CD4+IFN-γ production and symptoms of EAE (Rafei et al., 2009). 
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Hence, the dynamic and diverse interaction between Breg-CD4+T cells plays 
a pivotal role in immune regulation. 
Moreover, studies have demonstrated that Bregs can not only suppress Th1-
mediated immune responses but also generate conventional Treg cells and 
IL-10 producing T cells from effector T cells through the production of IL-10 
(Carter et al., 2012, Flores-Borja et al., 2013). CD4+ Tregs sustain 
immunological self-tolerance and homeostasis and within the human CD4+ 
Treg compartment exist distinct subsets (Abbas et al., 2013). Firstly, naturally 
occurring FOXP3+ Treg cells that either originate from the thymus or 
peripheral sites (referred to as thymus- or peripherally- derived Tregs) can 
further be divided into three subpopulations by the expression of FOXP3, 
CD45RA and CD25 (Miyara et al., 2014). Additionally, functional activated 
human FOXP3+ Treg cells express a unique pattern of cell surface markers 
(high expression of CD25 and low or negative expression of CD127) that can 
facilitate their isolation (Miaya et al., 2014, Ohkura et al., 2013). Secondly, 
induced FOXP3+ Treg populations are generated in vivo or in vitro through 
the use of TGF- β (Abbas et al. 2013, Ohkura et al., 2013). Although the 
transcription factor FOXP3 plays a pivotal role in Treg function it is not 
sufficient for conferring and maintaining Treg function and phenotype (Ohkura 
et al., 2013). Hence, a third subset of Tregs are described as CD4−Foxp3− 
Treg cells that mediate their suppressive functions primarily through IL-10 and 
TGF- β (Ohkura et al., 2013).  
Carter et al indicated that IL-10-producing B cells partake in a longer period of 
contact with CD4+CD25- T cells than IL-10-deficient B cells, which allows IL-
10+B cells to convert effector T cells into Il-10 producing suppressive T cells 
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(Carter et al., 2011). Further, Carter et al highlighted that lack of Bregs 
coincided with a decrease of peripheral Foxp3+ Treg (Carter et al., 2011). In 
accord with these findings, CD40-stimulated murine B cells were also found to 
generate IL-10+Treg cells from effector T cells (Blair et al., 2009). 
Subsequently, Ray et al reported that the adoptive transfer of wild-type B cells 
restored both the recovery of EAE and Treg numbers in mice (Ray et al., 
2012). Bregs have also been observed to suppress immune responses by 
CD8+T cells (Bankoti et al.,2012). Human transitional B cells have been 
implicated in suppressing HBV-specific CD8+ T cell responses in an IL-10 
dependent fashion (Das et al., 2012). Additionally, IL-10 producing MZ-B cells 
have also been shown to suppress CD8+ T cell responses (Bankoti et al., 
2012). Further to these observations, the effect of Bregs to exert immune-
modulation by cellular interactions has also been noted. Breg can also induce 
dendritic cells to produce IL-4 and downregulate IL-12, thereby affecting 
theTh1/Th2 balance (Moulin et al., 2000). Moreover, induction of IL-10+B cells 
via CD40L interaction on tumor cells can suppress IFN-γ production by NK 
cells (Inoue et al., 2006). Furthermore, CD1d-expressing MZ B cells, which 
share phenotypic characteristics with IL-10+B cells has been observed to 
modulate peripheral tolerance by inducing IL-10 producing T cells in the 
presence of DCs (Sonoda et al., 2002). Moreover, this process is mediated 
through glycolipid presentation via CD1d, which are recognized by NKT cells 
and CD1d−/−mice lacking NKT cells have demonstrated aggravated EAE 
(Croxford et al., 2006). The role of CD1d in Breg-NKT interaction was further 
highlighted in a study where human transitional B cells were shown to activate 
and expand the iNKT pool and thereby indirectly exert their regulatory function 
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in healthy individuals but not in SLE patients as they have defects in CD1d 
(Bosma et al., 2012). Overall, Bregs have been reported to exert their 
regulatory function during immune responses by both direct and indirect 





















Figure I-6: Mechanisms for human Breg-mediated immune-suppression 
The proposed mechanisms by which Breg cells may modulate immune responses 
through IL-10, IL-35 and TGF-β including: suppression of Th1 and Th17 
differentiation and effector cytokine production, suppression of TNFα production by 
monocytes and IL-12-producing dendritic cells, inducing differentiation of Tr1 cells 
and Foxp3+T cells, maintenance of iNKT cells through CD1d expression and 
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1.6.4  Human Regulatory B cells in disease 
IL-10 producing Bregs have been identified in humans as critical regulators of 
immune tolerance in disease pathology such as autoimmunity, tolerance, 
infection and cancer. 
 
1.6.4.1    Regulatory B cells in Autoimmunity 
Extensive studies in mice have highlighted the crucial role of Breg in 
immunosuppression of autoimmune diseases, however the role of human 
Bregs in autoimmunity remains understudied. Blair et al, described a subset of 
IL-10+CD19+CD24hiCD38hi  human transitional B cells that were functionally 
impaired in SLE patients and lacked suppressive capacity associated with 
defective IL-10 production in response to CD40 ligation when compared to 
their healthy counterparts, suggesting that altered Breg function may impact 
the maintenance of immune tolerance in SLE and other autoimmune diseases 
(Blair et al., 2010). Incidentally, following rituximab treatment, SLE patients 
had an increased ratio of CD19+CD24hiCD38hi B cells to memory B cells 
suggesting a role for B-cell depletion in generating tolerogenic B cells 
(Palanichamy et al., 2009, Anolik et al., 2007).  
Moreover, a subset of human B10 cells (CD24hiCD27+) identified by Tedder et 
al that can suppress TNFα production by monocytes was found to be 
expanded in autoimmune disorders such as SLE, RA, autoimmune skin 
disease and MS, supporting their role as a biomarker for autoimmune disease 
activity (Iwata et al., 2011). Subsequently reduced frequency of immature B 
cells has been associated with exacerbation of disease in RA as immature B 
cells re-locate to the inflamed joint (Flores-Borja et al., 2013). Further 
immature B cells isolated from RA patients lack suppressive capacity on Th17 
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differentiation and are unable to generate FOXP3+ T cells from naïve T cells 
when compared to their healthy counterparts suggesting that mechanisms 
other than IL-10 production may be involved in Breg-mediated suppression 
(Flores-Borja et al., 2013). 
The role of B cells as both initiators and contributors to autoimmune pathology 
has been further reported by recent advances in B-cell depletion strategy 
used to treat patients with autoimmune disease (Yanaba et al., 2008). B-cell 
depletion therapy using rituximab in RA patients was found to considerably 
attenuate ongoing joint inflammation; however, recrudescence of disease 
activity was found to be associated with B-cell recovery (Edwards et al., 2004, 
Leandro et al., 2006). Additionally, B-cell depletion in MS patients 
demonstrated beneficial effects after the onset of disease and ameliorated 
disease progression (Hauser et al., 2008). The beneficial effect of rituximab is 
further supported by clinical reports that correlated B-cell depletion with 
improvements in clinical manifestations of SLE (Looney et al., 2004). These 
reports suggest the appreciable role of rituximab as a powerful tool for 
researchers to study Breg function in the treatment of human autoimmune 
disease.  Contrastingly, B-cell depletion has been shown to augment Th1-
mediated immunity and thereby exacerbate ulcerative colitis and trigger 
psoriasis, further supporting a role for Bregs in controlling Th1 responses in 
vivo (Goetz et al., 2007, Dass et al., 2007). Taken together, the role of B cells 
as negative regulators of effector immune responses further supports their  
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1.6.4.2    Regulatory B cells in Cancer 
 
A new wave of research provides evidence that Bregs may play a role in 
cancer progression. DiLillo et al (2013) highlighted an expanded pool of IL-10 
competent CD5+ CD20int B cells in patients with chronic lymphocytic leukemia 
(CLL) that expressed high levels of IL-10 production following activation with 
LPS when compared to healthy controls (DiLillo et al., 2013). Further, high 
plasma levels of IL-10 have been reported in CLL, suggesting that IL-10 
competent CLL cells may regulate immunosuppression and thereby attenuate 
patient responses to immunotherapies including rituximab. In accord with this 
finding, Horikawa et al observed that although B-cell depletion therapy was 
effective in treating non-Hodgkin lymphomas and CLL, some patients present 
resistance to this therapy or eventually relapse as a result of IL-10+ B cells 
that inhibit lymphoma depletion (Horikawa et al., 2011). Hence, IL-10+B cells 
may inhibit the efficacy of therapy in patients with malignant lymphoma, and B 
cell depletion may prevent cancer progression and metastasis. In addition, an 
increased frequency of circulating B cells was identified in human 
hepatocellular carcinoma (HCC) patients with advanced tumor staging (Lin et 
al., 2010). More recently, Shao et al further highlighted that a significantly 
higher percentage of circulating Bregs in HCC patients correlated with 
advanced tumor staging, tumor multiplicity and venous infiltration (Shao et al., 
2014). Bregs promoted HCC growth and invasiveness by directly interacting 
with liver cancer cells through the CD40/CD154 signaling pathway (Shao et 
al., 2014).  
Collectively, the studies highlight that Bregs may sustain malignant expansion 
and support cancer progression in humans.  
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1.6.4.3    Regulatory B cells in Infection 
 
Growing evidence has associated increased frequencies of PB-derived 
immature B cells with immune responses in infectious diseases such as HIV 
and hepatitis B (Malaspina et al., 2006, Das et al., 2012). Human transitional 
B cells have been implicated in suppressing HBV-specific CD8+ T cell 
responses in an IL-10 dependent fashion (Das et al., 2012). Further, in a 
study investigating immune regulation in multiple sclerosis patients, parasitic 
infection has been shown to induce functionally suppressive Bregs that 
attenuate proliferation and IFNγ production by myelin-specific T cells 
(Correale et al., 2008). Additionally, an increased CD1dhi IL-10 producing B 
cell pool was observed in Gabonese children infected with Schistosoma 
haematobium. After treatment children had fewer CD1dhi B cells that 
correlated with reduced inflammation (van der Vlugt et al., 2012).  
Collectively, recent evidence of B regulatory cells in infection indicates a 
potential role for Bregs as potential therapeutic target for infectious diseases 
in humans however, the mechanistics of Breg suppression is not yet fully 
understood.  
 
1.6.4.4    Regulatory B cells in Transplant Tolerance  
 
Accumulating studies support a role for Bregs as crucial mediators of immune 
tolerance in allograft recipients (Pallier et al., 2010, Newell et al., 2010, Silva 
et al., 2012). In one study, an expanded pool of transitional/naïve B cells 
which shared phenotypic similarities with previously identified Bregs was 
found in graft-tolerant renal transplant recipients that were off 
immunosuppressants (Newell et al., 2010 and Sagoo et al., 2010). In addition, 
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increased frequency and absolute counts of peripheral B cell that were 
phenotypically reminiscent of murine B10 cells were reported in a study by 
Pallier et al. These elevated B cells were enriched within the transitional B cell 
compartment and were suggested to contribute to the maintenance of long-
term graft function (Pallier et al., 2010).  
 
1.6.4.5    Regulatory B cells in Pregnancy and Allergy 
Interestingly, during pregnancy, another state of tolerance to alloantigen, IL-
10 producing CD19+CD24hiCD27+ Bregs were reported to increase with 
pregnancy onset (Rolle et al., 2013). These IL-10 producing CD19+B cells 
suppressed effector cytokine production by CD4+T cells, suggesting a novel 
role for Bregs in suppression of maternal T cells and acquisition of tolerance 
during pregnancy (Rolle et al., 2013). Further, a population of IL-10+Bregs 
producing IgG4 isolated from Bee Keepers that are known to exhibit long-term 
tolerance to bee venom allergens were shown to suppress antigen-specific 
CD4+T cells proliferation. These Bregs were induced in allergic patients 
following specific immunotherapy and demonstrated that induction of long-
term tolerance to allergic antigens ay be partially dependent on B suppressor 
cells (van de Veen et al., 2013). The regulatory capacity of B cells to maintain 
tolerance could therefore be exploited for therapeutic purposes by triggering 
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Aims and Hypothesis 
In recent years, a distinct newly described subpopulation of IL-10 producing 
human B regulatory cells, that have been shown to exert significant 
immunoregulatory functions, has been the focus of intense immunological 
research. However, seemingly conflicting data exist as to the phenotypic and 
functional characteristics of these immunomodulatory B cells. Further, little is 
known about these B cell subsets in cord blood. There is therefore, a 
compelling need to characterize human B cell subsets more comprehensively 
to better understand their immune modulatory function, which may in turn aid 
the development of therapeutics to treat immune-mediated diseases. 
 
I hypothesize that an imbalance of effector and regulatory subsets may lead 
to loss of tolerance and induction of allo-reactivity in GVHD. Further, I propose 
that regulatory B cells play a crucial role in modulating the function of immune 
effector cells and the induction of GVHD.  
The results of these laboratory findings will aid our understanding of their role 
in allogeneic HCT and possible application for the prevention and treatment of 
GVHD and a host of other immune-mediated diseases.   
 
The specific aims of this thesis are: 
1. To perform a comprehensive characterization of IL-10 producing 
regulatory B cells in peripheral blood and cord blood  
2. To define the mechanisms of B-cell mediated suppression, specifically 
whether suppression is dependent on IL-10 or requires cell-to-cell 
interaction. 
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3. To study the interaction of Bregs with T cell subsets as well as other 
cells of the immune system (NK cells) that might unravel additional 
undiscovered functions of the nature of B cells in cord blood grafts. 
4. To study the kinetics of Bregs reconstitution post-cord blood transplant 
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Chapter II.  Materials and Methods 	  
II.1 Patients and Healthy Controls 
All samples were collected after written informed consent according to local 
policy guidelines at the MD Anderson Cancer Centre, and in accord with the 
Declaration of Helsinki. The study was approved by the institutional review 
board (IRB). Peripheral blood (PB) samples were collected from 13 
consecutive AML patients [median age was 68 years (range 20–80 years)] at 
presentation. Patient samples were also studied in parallel with PB samples 
from healthy controls (6 female and 8 male, n=14) aged 24-50 years. All 
samples underwent Ficoll density separation (Lymphoprep), freezing and 
storage in liquid nitrogen, and were then used for the isolation of B regulatory 
(Breg) and natural killer (NK) cells. Cord blood transplant recipient samples 
were collected from 16 patients [median age was 42 years (range 21–64 
years)] before and after CBT between 2007 and 2011 and at intervals of 90 
days for up to 1 year post CBT and at 2 years. cGVHD status was classified 
according to the National Institutes of Health (NIH) criteria at the time the 
sample was collected and the modified Seattle criteria for limited versus 
extensive disease. 
 
II.2 Sample processing 
II.2.1 Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated by use of density 
gradient separation technique (Lymphoprep). In summary, EDTA anti-
coagulated whole blood was diluted 1:1 with RPMI 1640 media (GIBCO / 
Invitrogen) and 30 ml of the diluted blood was gently layered into 50 ml falcon 
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tubes containing 15 ml of Lymphoprep (Axis Shield). The tubes were 
centrifuged at 1800 rpm for 30 min and the interface layer containing 
mononuclear cells was collected. Collected PBMCs were washed with RPMI 
twice for 10 minutes at 1400 rpm. Cells were then re-suspended in RPMI 
containing 10% foetal calf serum (FCS) and counted using Trypan Blue for 
cell viability assessment. 
 
II.2.2 Isolation of cord blood mononuclear cells 
Cord blood units were kindly donated by the cord blood bank at MD Anderson 
Cancer Center, Houston, Texas, USA under an IRB-approved protocol. Cord 
blood mononuclear cells (CBMCs) were by use of density gradient separation 
technique (Lymphoprep). In summary, EDTA anti-coagulated whole blood 
was diluted 1:1 with RPMI 1640 media (GIBCO / Invitrogen) and 30ml of the 
diluted blood was gently layered into 50ml falcon tubes containing 15ml of 
Lymphoprep (Axis Shield). The tubes were centrifuged at 2000 rpm for 20 min 
and the interface layer containing mononuclear cells was collected. Collected 
PBMCs were washed with PBS for 10 minutes at 1400rpm. Cells were then 
re-suspended in RPMI containing 10% foetal calf serum (FCS) and counted 
using Trypan Blue for cell viability assessment. 
 
II.2.3 Cell freezing 
PBMC were suspended in freezing media on ice (RPMI 1640 media 
supplemented with 20% FCS) and 20% dimethyl sulfoxide (DMSO) (Sigma‐
Aldrich) and gently aliquoted into 1.5ml cryovials for storage in ‐80° C (max 1 
week) before being cryopreserved in liquid nitrogen at a density of 5 x 106/ml 
cells. 
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II.2.4 Cell thawing 
PBMCS stored in cryovials were transferred from liquid nitrogen on dry ice for 
thawing protocol. Cryovials were thawed at 37 ºC in the water bath and 
immediately transferred into falcon tubes containing 10 ml thawing media 
(RPMI supplemented with 20% FCS and 50,000 units of DNase). PBMC were 
centrifuged at 1100 rpm for 10 min, and washed again in RPMI. Pelleted cells 
were resuspended in media for cell count and viability assessment (PBMC 
viability >76% after thawing). 
 
II.3 Cell lines 
II.3.1 L cells and control cells 
Frozen aliquots of CD154 (CD40L)-transfected fibroblasts (L cells) and 
CD154-negative control cells were stored in the -81° C freezer and thawed as 
per the protocol described in II‐2.4. L cells were grown in complete media 
(CM) (complete RPMI 1640, supplemented with 5 µM HEPES, 12.5 µg/ml 
Gentamicin and 10% FCS). Once confluent in the T25 vented culture flasks, 
adherent L cells were incubated for 4 min at 37°C with 5 ml of 0.05% Trypsin-
EDTA (GIBCO/ Invitrogen) after removing the culture media. Following gentle 
tapping of the flask, once the L cells were detached, an equal volume of CM 
was added and cells were centrifuged at 1200rpm for 10 min. To determine 
the expression of CD40L on transfected L cells, cells were stained with 
CD154-PE mAb and analyzed periodically by Fluorescence‐activated cell 
sorting (FACS) analysis figure (II‐1), to ensure that the CD40L expression 
was not affected by frequent passaging. L cells were sent to microbiology lab 
for testing of mycoplasma contamination every 6 months. After cells were 
trypsinized, the viability of L cells and expression of CD154 was assessed to 
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exclude any impact of trypsin. Following the wash, cells were frozen as 
described in II‐2.3 and stored at – 81 ° C. 
 
II.3.2 K562 cell line 
Frozen aliquots of K562 tumour target cell line were stored in the -80° C 
freezer and thawed as required following the protocol outlined in II‐2.4. K562 
cells were grown in CM. Once confluent in the T25 vented culture flasks, non-
adherent K562 cells were washed by centrifugation at 1200rpm for 10 
minutes. After washing, the viability of K562 cells was assessed and cells 
were frozen as outlined in section II‐2.3 and stored at – 80 ° C and then 








Figure II-1: CD154 (CD40L) expressing transfected L cells and their controls 
A. Staining of CD154-control cells (white) and the isotype (tinted grey) and B. 
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II.4 Cell selection 
II.4.1  B cell selection 
Following the manufacturer’s protocol, untouched B cells were selected from 
either fresh or frozen PBMC using the human B cell isolation kit II (Miltenyi 
Biotec Ltd). In summary, PBMC were washed using MACS Buffer (MACS 
BSA and autoMACSTM rinsing solution from Miltenyi Biotec Ltd). Upon 
determining the cell number, 107 cells were re‐suspended in 40 µl of MACS 
buffer and 10 µl of Biotin‐antibody cocktail against CD2, CD235a, CD36, 
CD16, CD43, and CD14 and incubated at 4°C for 10 minutes; 30µl/107 of 
MACS buffer and 20 µl/107 of anti‐Biotin micro‐beads were then added to the 
cells and further incubated for 15 minutes at 4°C. After incubation, cells were 
washed with MACS buffer and re-suspended in 500 µl of MACS buffer. The 
cells were applied to primed LD MACS columns (Miltenyi Biotec Ltd) followed 
by 3 washes of the column. The pass-through containing purified population 
of negatively isolated B cells was collected and centrifuged at 1200 rpm for 10 
minutes. Cells were re‐suspended in CM at the required cell concentration 
and stained with anti‐CD19 PE (BD PharmingenTM Cat# 555413) to confirm 









Figure II-2: B cell selection purity check 
Purity of selected CD19+ B cells from a healthy donor stained with CD19 PE 
Comp-­‐PE-­‐A::CD19	  	   Comp-­‐PE-­‐A::CD19	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II.4.2  T cell selection 
II.4.2.1  Total CD4+ T cell selection 
Untouched CD4+ T cells were negatively isolated from fresh PBMC using 
human CD4 T cell isolation kit II (Miltenyi Biotec Ltd), following the 
manufacturer’s protocol. Briefly, isolated PBMC were washed using MACS 
Buffer. Upon determining the cell number, the cell pellet was resuspended in 
40µl per 107cells of MACS buffer. Subsequently, 10 µl per107 cells of Biotin‐
antibody cocktail against CD8, CD19, CD16, CD14, CD123, CD56, CD36, 
TCR γ/δ, and CD235a was added to the cells and incubated for 5 minutes at 
4°C. Following incubation, 30 µl of MACS buffer and 20 µl of anti‐Biotin micro‐
beads per 107 cells were added to the tube and incubated for a further 10 
minutes at 4°C. The cell suspension was then applied onto the primed LD 
MACS columns and an additional 3 ml of MACS buffer was used to wash the 
columns 3 times. The pass-through containing a population of enriched CD4+ 
T cells was collected and centrifuged at 1400 rpm for 10 minutes. Cells were 
re‐suspended in RPMI/10%FCS  at the required cell concentration and 
stained with anti‐CD4 APC (BD Cat# 340443) to assess the purity of selected 












Figure II-3: T cell selection purity check 
Purity of healthy donor derived selected CD4+ T cells was determined by staining 
with CD4 APC 
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II.4.2.2  CD4+CD127loCD25- Treg magnetic selection/ “Treg 
depletion” 	  	  
CD4+CD127loCD25‐ cells were selected by a two step labelling procedure for 
the isolation of Treg cells from fresh PBMC using CD4+CD25+CD127dim/‐ 
regulatory T cell isolation kit II human (Miltenyi Biotec Ltd), as per the 
manufacturer’s protocol. In summary, PBMC cell number was determined and 
cells were washed using MACS Buffer. The cell pellet was resuspended in 
40µl/107 cells of MACS buffer and 10 µl/107 cells of Biotin‐antibody cocktail 
was added to magnetically remove CD4- and CD127 hi cells. Cells were 
incubated for 7 minutes at 4°C, after which 30 µl of MACS buffer and 20 µl of 
anti‐Biotin micro‐beads per 107 cells was added to the cells and further 
incubated for 10 minutes at 4°C. Cells were washed and resuspended in 500 
µl of MACS buffer and applied to LD MACS columns. Columns were washed 
three times with 3 ml of MACS buffer and the flow‐through containing a 
population of enriched CD4+ T cells was collected and centrifuged at 1200 
rpm for 10 minutes. The cell pellet was re‐suspended in 90 µl of MACS buffer 
followed by 20 µl of CD25 MicroBeads per 107 cells and incubated for 15 min 
on ice for the second step of the labeling procedure. Cells were passed 
through an MS MACS magnetic column and the pass-through containing 
untouched CD4+ cells depleted of Treg cells (CD4+CD127loCD25hi) were 
collected. 1ml of MACS buffer was added to the column and labeled Treg 
cells were eluted by firmly pushing the plunger into the column. Cell number 
and viability were determined and cells were plated as required. Cells were 
stained with anti‐CD25, anti‐CD4 and anti‐CD127 to confirm the purity of the 
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Figure II-4: Treg cell selection purity check 
 
A. Purity of healthy donor derived selected Treg cells was determined through 
staining with CD4 PerCP, CD127 PE and CD25 APC  B. Phenotype of flow through 
(enriched CD4+ T cells depleted of Treg) shows CD4 purity of 94.8% and lower 
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II.4.3 NK cell selection 
Isolation of untouched NK cells from fresh or frozen PBMCs was performed 
using the human NK cell Isolation kit according to the manufacturers’ protocol. 
In summary, PBMC were washed using MAC buffer and the cell number was 
determined. Cells (107) were suspended in 40 µl MACS buffer; 10 µl per107 
cells of biotin‐antibody cocktail against antigens not expressed by NK cells 
was added to the cells for 5 minutes at 4°C. Following incubation, 30 µl of 
MACS buffer and 20 µl of anti‐Biotin micro‐beads per 107 cells was then 
added and incubated for a further 10 minutes at 4°C. Cells were washed and 
the cell volume was adjusted to 500 µl and applied onto the primed LD MACS 
columns. An additional 3 ml of MACS buffer was used to wash the columns a 
total of three times. The flow-through containing an enriched population of 
unlabeled NK cells was collected and centrifuged at 1400 rpm for 10 minutes. 
Cells were re‐suspended in CM to achieve the required cell concentration. 
Post-selection purity was confirmed using anti‐CD56 Bv605 (BD Biosciences) 
and CD3 APC-Cy7 mAbs (Biolegend). Purity was consistently between 92%‐













Figure II-5: NK cell selection purity check 
Purity of healthy donor-derived selected CD56+ NK cells was determined by staining 
with CD56 Bv605. 
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II.5 Cell sorting for B cell subsets 
 
II.5.1 Cell sorting for peripheral blood-derived B cell subsets 
B cell sorting was performed at the FACS core facility, Department of stem 
Cell Transplantation and Cellular therapy, MD Anderson Cancer Centre using 
BD FACS Aria IIIu instrument. In summary, 20 x107 freshly isolated PBMC 
were stained with 8 µL of anti‐CD24-FITC (BD Biosciences), 10 µL of anti‐
CD19-APC (BD Biosciences), 7 µL of anti-CD38-Pe-cy7 (eBiosciences) and 7 
µL of anti‐IgM-PerCP cy5.5  (BD Biosciences) for 20 min. Positive controls 
stained for each parameter were included in each experiment in addition to 
unstained (negative) control. To prevent aggregates from clogging the 70 µm 
nozzle, all samples were filtered prior to sorting. A total of 107 cells/ml of PBS 
was used to achieve a sorting efficiency of > 80%. The gating strategy 
performed for B cell subset sorting is illustrated in figure (II‐6). Sort-purified 
CD19+ B cell populations including CD19+CD24hiCD38hiIgMhi transitional 
(mean purity 92.1%), CD19+IgM+CD24hiCD38–/lo IgM memory (mean purity 
93.6%), CD19+CD24intCD38intIgM+ naïve (mean purity 91.4%) and CD19+IgM-
CD24hiCD38–/lo switched memory (mean purity 92.5%) B-cell subsets were 
collected in purity sorter mode; figure (II-7). At the end of each sort, purity 
checks were undertaken to ensure high purity populations >90%. 
 










Figure II-­‐6: Gating strategy of PB B cell sorting  
Multi-parametric flow cytometric gating strategy for B cell subset sorting on BD FACS 
ARIA IIIu. Following lymphocyte gate and cell doublet discrimination, CD19+ B cells 
are then sort-purified based on CD24 and CD38 expression into 3 subsets, namely 
memory, transitional and naïve. Memory B cells are further divided into switched 
















Figure II-­‐7: Purity checks of PB B cell sorting 
FACS plots illustrating the high purity of sorted B cell subsets are shown within the CD19+ 
gate including CD19+CD24hiCD38hiIgMhi transitional (mean purity 92.1%), 
CD19+IgM+CD24hiCD38–/lo IgM memory (mean purity 93.6%), CD19+CD24intCD38intIgM+ 
naïve (mean purity 91.4%) and CD19+IgM-CD24hiCD38–/lo switched memory (mean purity 
92.5%) B-cells (n=48) 
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II.5.2 Cell sorting for cord blood derived B cell subsets 
Cord blood-derived B cell subsets were sort-purified on FACSAria IIIu 
instrument (Becton Dickinson) at the FACS core facility, Department of stem 
Cell Transplantation and Cellular therapy, MD Anderson Cancer Centre.  
Following staining with CD19 APC, CD24 FITC (all from Becton Dickinson, 
USA) and CD38 Pecy7 (eBiosciences, San Diego, USA). 
Briefly, freshly prepared 10 x107 PBMC were stained with 8 µL of FITC-
labelled anti‐CD24 (BD Biosciences), 10 µL of  anti‐CD19-APC (BD 
Biosciences) and 7 µL of anti-CD38-Pe-cy7 (eBiosciences) for 30 min. 
Positive controls for each individual parameter were included in addition to 
unstained (negative) control.  
To prevent aggregates from clogging the 70 µm nozzle, all samples were 
filtered prior to sorting. A concentration of 107 cells/ml of PBS was determined 
to achieve a sorting efficiency of > 80%. The gating strategy performed for CB 
B cell subset sorting is illustrated in figure (II‐8).  
Two distinct sort-purified CD19+ B cell populations, namely 
CD19+CD38hiCD24hi transitional B cells (a population that includes immature 
B cells) and CD19+CD38intCD24int naïve B cells (primarily mature B cells) 
were obtained in purity sorter mode; figure (II-9). At the end of each sort, 













Figure II-­‐8: Gating strategy of CB B cell sorting  
Multi-parametric flow cytometric gating strategy for sorting B cell subsets on BD FACS 
ARIA IIIu. Following lymphocyte gate and cell doublet discrimination, CD19+ B cells are 
then sort purified based on CD24 and CD38 expression into 2 subsets, CD19+CD38hiCD24hi 






Figure II-­‐9: Purity checks of PB B cell sorting 
FACS plots illustrating the high purity of sorted B cell subsets are shown within the CD19+ 
gate, namely CD19+CD38hiCD24hi transitional B cells (mean purity 90.8%) and 
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II.6 Phenotypic and functional characterization of peripheral B 
cells using flow cytometry 
 
 
II.6.1 B cell Phenotyping using an extended panel of surface antibodies 
A laser-based, biophysical technology of flow cytometry enables simultaneous 
multiparametric analysis of particular cell populations of interest based on 
their properties through biomarkers with use of specific fluorochromes and 
different gating strategies. Fluorochromes are selected based on intended cell 
markers, commercially available options and instrument configuration. For B 
cell phenotyping, an antibody panel of 9-fluorochrome markers (as defined in 
Table II-1) was customized to determine the following B cell subsets: 
 
Transitional B cells: CD19+, CD24hi, CD27‐, CD38hi, CD10+, CD21‐/lo,   
IgMhi and IgD+ 
 
Naïve B cells: CD10‐, CD19+, CD21+, CD24‐/lo, CD27‐, CD38+, IgM‐ and  
IgD+ 
 
Pre Germinal Centre: CD10+, CD19+, CD21hi, CD24‐, CD27+, CD38hi, IgM+  
and IgD+ 
 
Memory B cells; isotype switched: CD10‐, CD19+, CD21+, CD24‐/lo, CD27+,  
CD38+/‐, IgM- and IgD- 
 
IgM memory or marginal zone B cells (MZB cell): CD10‐, CD19+, CD21+/hi,  
CD24‐/lo, CD27+ CD38 lo/‐, IgM+/lo and IgD+/lo 
 
Tissue like memory cell, exhausted B cells: CD10‐, CD19+, CD21‐, CD24‐,  
CD27‐, CD38 ‐, IgM‐ and IgD- 
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II.6.2 Cell staining and FACS acquisition 
Briefly, 1x106 cells derived from fresh or thawed PBMC were stained with 1 µl 
of cell viability marker (invitrogenTM LIVE/DEAD Fixable Aqua Dead cell stain 
Kit) for 30 minutes at room temperature in the dark. Following incubation, cells 
were washed and incubated with an antibody cocktail for various cell markers 
(Table II‐1) at titrated concentrations in x1 PBS for a further 30 min. Stained 
cells were washed with 2 ml of PBS and acquired on LSR Fortessa (BD 
Biosciences) at MD Anderson. The instrument was standardized by running 
Cytometer Settings & Tracking (CST) beads (Becton Dickinson) at designated 
PMT voltages daily to reduce variation between experiments or samples. 
Compensation controls (single stained controls) for each fluorochrome were 
made using pre mixed negative and positive antibody capture beads (BDTM 
Comp Beads), which were stained singly with each antibody. The 
Antibody	   Volume	  µl	   Manufacturer	   Description	   Clone	  CD19	  APC	  H7	  	   4	   BD	  PharmingenTM	   B	  cell	  lineage	  differentiation	  marker	   SJ25C1	  	  CD38	  	  	  PE	  Cy7	  	   3	   eBioscience	   Surface	  antibody	  involved	  in	  calcium	  signalling	   HIT2	  	  CD24	  FITC	  	   4	   BD	  PharmingenTM	   B	  cell	  maturation	   HB5	  	  CD21	  APC	  	   4	   eBioscience	   complement	  receptor	  2	  	   HB5	  	  CD27	  PE	  	   4	   BD	  PharmingenTM	   Tumor	  necrosis	  factor	  receptor	  	   M-­‐T271	  IgD	  v450	   4	   BD	  PharmingenTM	   Surface	  antibody	   IA6-­‐2	  	  IgM	  PerCP	  cy5.5	  	   3	   BD	  PharmingenTM	   Surface	  antibody	   G20-­‐127	  	  CD10	  Qdot®	  605	  	   1	   InvitrogenTM	   membrane	  metallo-­‐endopeptidase	   MEM-­‐78	  Aqua	  florescent	  reactive	  dye	  	   1	   InvitrogenTM	   Live/Dead	  marker-­‐	  binds	  to	  intracellular	  amines	  of	  dead	  cells	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compensation controls were recorded at 5000 events per tube individually to 
ensure that each fluorochrome marker was the brightest in its channel. 
FACSDiva software was used to compute the automated compensation 
matrix of the controls. PMT voltages were also adjusted using unstained cells 
in order to exclude auto-fluorescence and control the background intensity i.e. 
by restraining the negative population below log 102. Manual compensation 
was used occasionally when the software did not allow optimal adjustment of 
the spectral overlap between the different fluorochromes. Acquired data was 
analysed using FlowJo (v.7.6.5) software (Tree Star). 
 
 
II.6.3  B cell activation 
Total CD19+ B cells selected from either fresh or frozen PBMC were plated at 
a concentration of 2x105 cells/well in a total volume of 200 µl of CM in flat-96‐
well plates (nunc). B cells were stimulated for 24, 48 and 72 hours with either 
CpG OND200‐ 5G (InvivoGen, USA) at a dose of 0.2 µg/ml in a humidified 
incubator at 37 °C with 5% CO2, or L cells  that were irradiated (60 Gy), 
rested for a minimum of 1 hour and plated with CD19+ selected B cells at a 
ratio of 1:10 (L cell to B cells), or with 0.6 µg/ml of F (ab’) 2 Goat anti Human 
IgG+ IgM (H+L) (Jackson ImmunoResearch Laboratories, USA). At the end of 
culture, the plates were centrifuged at 1800rpm for 5 minutes and 150 µl of 
the supernatant was collected from each well for ELISA analysis. Cells were 
collected for detection of IL-10-producing B cells by intracellular staining and 
flow cytometric analysis.  
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II.6.4  Quantitative ELISA for IL-10 
Detection of IL-10 by ELISA was performed using OptEIA ELISA kits (BD 
PharmingenTM, San Diego, CA), following the manufacturers’ protocol. Briefly, 
following washing and blocking of the ELISA plate with 50 µl of ELISA diluent, 
100 µl of sample collected from each culture condition was plated and 
incubated for 2 h at room temperature. Supernatants collected from un-
stimulated B cells, CD154 positive fibroblasts and their CD154 negative 
control cells cultured alone were also used as controls to validate detection of 
IL-10 from CD19+ B cells. After 5 washings, 100 µl of detection antibodies 
were incubated with the samples for 1 h. Following a further 7 washings, 100 
µl of the provided tetramethylbenzidine (TMB) was added to each well to 
develop colour for 30 minutes in the dark. 50 µl of stop solution was added to 
each well and the absorbance was read within 30 minutes at 450nm using 
microplate reader Gen5 2.0 data analysis software (BioTek). The linear 
ranges of detection were obtained using the dilution series of standard 
cytokine (1.95pg/ml – 500pg/ml) provided and were determined accordingly 
(figure II-10)  
Un‐stimulated selected B cells (mean purity 92%± 3.75) from 4 healthy donors 
produced either no detectable cytokine or only small amounts of IL-10 (mean 
18±7.5 pg/ml, n=4). Of note, irradiated CD154 expressing fibroblasts (L cells) 
and their control counterpart also produced negligible amounts of IL-10 (mean 
6.5± 2.4 and 21± 1.2 pg/ml respectively, n=3). Purified B cells stimulated with 
L cells at a ratio of 1:10 produced higher levels of IL-10 than B cells 
stimulated with BCR crosslinking or CpG in a time dependent manner.  
 
 
















  Figure II-10: Example of a standard linear curve analysis for IL-10  
         detection 
        using microplate reader Gen5 2.0 data analysis software    
          (BioTek) 
 
II.6.5  Intracellular cytokine assay for detection of IL-10+ B cells 
Based on the ELISA experiments and a previously optimized protocol from 
our laboratory (Khoder et al Blood 2014), I used L cells for stimulation to 
optimise IL-10 intracellular cytokine (IC) staining of both selected and gated 
CD19+ B cells derived from fresh or frozen PBMC.  In order to determine the 
optimal time point at which maximal IL-10 production could be achieved 
without major activation-induced alterations of B cell phenotype, I performed 
kinetics of CD19+ IL-10 production using IC assay in which CD19+ selected B 
cells or total PBMC were cultured with irradiated L cells at a ratio of (1:10) for 
12, 18, 24, 48 and 72 hrs. PMA (50ng/ml), ionomycin (250 ng/ml) and 
brefeldin A (5 µg/ml) were added for the last six hours of the incubation. After 
incubation, cells were harvested and washed in staining buffer (1x PBS, 2% 
heat‐inactivated FCS, 0.1% Sodium Azide) and incubated for 25 min in the 
dark at room temperature with a cocktail of CD19-PE, CD24 FITC, IgM PerCP 
Cy5.5, CD27 PE, all from BD Pharmingen and CD38 PE cy7 (eBiosciences). 
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Cells were then washed again and fixed/permeabilized for 45 min at 4°C with 
foxp3/transcription factor intracellular staining kit (eBioscience). Cells were 
then further incubated with 0.5 µl of either APC-conjugated IL-10 or IgG2aК 
isotype antibodies for 30 min at 4°C. As negative controls I used both the 
manufacturer’s recommended isotype control, (IgG2aκ) (to control for non-
specific binding effects of antibody and the fluorescence resulting from non-
specific intracellular protein interactions), fluorescence minus one control (to 
control for autofluorescence) and unstimulated control incubated with BFA 
alone (unstimulated, BFA) and appropriately stimulated B cells without the 
addition of BFA (stimulated, no BFA).  
Optimized volume of IL-10 monoclonal antibody was determined by MFI and 
maximal percentage of positively-stained cells with minimum background 
(negative control) experiments performed by previous member of the 
laboratory in dose titration experiments. Cells were washed 3 times with perm‐
wash and re‐suspended in staining buffer prior to acquisition using BD 
LSRFortessa (Becton Dickinson). Data analysis was performed using FlowJo® 
software; figure (II‐11). Stimulating gated or selected CD19+ B cells with L 
cells for 15h appeared to be optimal for sufficient numbers of IL-10 producing 
B cells to be recorded without significant changes in the overall B cell 
phenotype. I used combinations of 4-colour surface antibody panels, to 
determine the phenotype of IL-10+ B cells since combining these markers in 
one extended panel to confirm this phenotype with IC staining was 
unsuccessful due to the poor separation of IL-10- and IL-10+ populations 
(data not shown). 
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Figure II-11: Intracellular staining of IL-10 production by CD19+ B cells 
A representative FACS plot depicting IL-10 production through intracellular staining 
when PBMC from a healthy control were stimulated with L cells for 48 hours (A). 
CD19+IL-10+ cells B IgG2ak isotype control (B) and fluorescence minus one control 




II.7       Phenotypic and functional characterization of cord blood 
derived B cells  
 
II.7.1 Phenotypic characterization of cord blood derived B cells 
A panel of 9 antibodies (as defined in Table II-1) was customized to 
determine the cord blood B cell subsets. Briefly, 1x106 fresh or thawed 
CBMNC were stained with 1µl of the viability marker (invitrogenTM LIVE/DEAD 
Fixable Aqua Dead cell stain Kit) for 30 minutes at room temperature in the 
dark. Cells were then washed and incubated with the cocktail of mAb for 
various cell markers (Table II‐1) at the titrated concentrations in x1 PBS for a 
further 30 min. Following incubation, stained cells were washed once more 
and then acquired on LSR Fortessa (BD Biosciences) at MD Anderson 
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II.7.2  Cord Blood B cell activation 
Total CD19+ B cells or sort-purified B cell subsets selected from either fresh 
or frozen CBMNC were plated at a concentration of 2x105 cells/well in a total 
volume of 200µl of CM in flat-96‐well plates (nunc). To determine the optimal 
condition for CB B cell activation, B cells were stimulated for various time 
points: 24, 48 and 72 hours with either CpG OND200‐ 5G (InvivoGen, USA) at 
a dose of 0.2, 0.6 or 0.8 µg/ml in a humidified incubator at 37 °C with 5% 
CO2; or L cells that were irradiated (60 Gy), rested for a minimum of 1 hour 
and plated with CD19+ selected B cells at a ratio of 1:10 and 1:5 (L cell to B 
cells); or with 0.1, 0.6 or 1 µg/ml of F (ab’) 2 goat anti Human IgG+ IgM (H+L) 
(Jackson ImmunoResearch Laboratories, USA). At the end of culture, the 
plates were centrifuged at 1800 rpm for 5 minutes and 150µl of the 
supernatant was collected from each well for ELISA analysis. 
 
II.7.3  Detection of IL-10+ B cells through ELISA 
Detection of IL-10 by ELISA was performed using OptEIA ELISA kits (BD 
PharningenTM, San Diego, CA), following the manufacturers’ protocol. Briefly, 
following washing and blocking of the ELISA plate with 50 µl of ELISA diluent, 
100 µl of sample collected for each condition was plated and incubated for 2h 
at room temperature. Supernatants collected from un-stimulated B cells, 
CD154 positive fibroblasts and their CD154 negative control cells cultured 
alone were also used as controls to validate detection of IL-10 from CD19+ B 
cells. After 5 washings, 100 µl of detection antibodies were incubated with the 
samples for 1h. Following a further 7 washings, 100 µl of the provided 
tetramethylbenzidine (TMB) was added to each well to develop colour for 30 
minutes in the dark. 50 µl of stop solution was added to each well and the 
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absorbance was read within 30 minutes at 450nm using microplate reader 
Gen5 2.0 data analysis software (BioTek). The linear ranges and sensitivities 
were obtained using the standard cytokine and test sample dilutions provided 
and were determined accordingly (figure II-10).  
Unstimulated selected B cells (mean purity 97%) from 4 healthy donors 
produced either no detectable cytokine or only small amounts of IL-10 (mean 
1.2, n=6). Of note, irradiated CD154-expressing fibroblasts (L cells) also 
produced negligible amounts of IL-10 (mean 5.0± 3.5, n=6). Selected B cells 
stimulated with a combination of L cells at a ratio of 1:10, BCR crosslinking at 
1µg/ml and 0.6µg/ml of CpG produced higher levels of IL-10 than B cells 
activated with these conditions alone in a time dependent manner.  
 
II.8 In vitro suppression Assay of CD4+ T cells 
II.8.1 Proliferation Suppression 
To determine the suppressive ability of CB or PB derived sort-purified B cell 
subsets on proliferating CD4+ T cells, B cells were co‐cultured with CFSE+ 
CD4+ T cells in vitro. Total CD4+ T cells were magnetically isolated as 
described in section II.4.2.1, and labeled with 2 µL per ml of prepared sample 
of aliquoted CFSE (65‐0850; eBioscience, USA) from a stock solution 
(500µg/ml; stored at ‐20oC in DMSO) to achieve a final concentration of 2 µM 
CFSE. Cells were mixed well by vortexing and incubated for 8-10 minutes in 
the dark at room temperature after which 3 volumes of neat FCS was added 
to the cells for a further 5 minutes to stop CFE labeling. CFSE+CD4+ T cells 
were then plated into a flat bottom 96-well tissue culture plate at a 
concentration of 1x 105 per well in 100µl of CM with sort purified B cell 
subsets at a ratio of 1:1 to achieve a cell count of 2x105 per well.  
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Dynabeads® human T‐ activator CD3/CD28 (InvitroGen, Oslo, Norway) were 
added to each well for T cell activation at a concentration of 1 cell: 1 bead 
ratio (2µl/8x105) cells following the manufacturer protocol and incubated for 
96h at 37ºC with 5% CO2. CFSE+CD4+ T cells were also cultured alone with 
CD3/CD28 coated beads (positive proliferation control) and without 
stimulation (negative control) for each experiment. Additionally, selected Treg 
cells were co‐cultured with autologous CD4 T cells as quality control of 
suppression. Following 96 hours of culture, supernatants from each well was 
collected for analysis of secreted cytokine by ELISA (II.8.3) and cells were 
harvested and stained with APC anti‐CD4 APC and anti‐CD19 PE (both from 
BD Biosciences) for 25 min prior to acquisition on LSRFortessa. The 
percentage of dividing cells and proliferation index (to control for asymmetrical 





















Figure II-12: Gating strategy for CD4+ T cell proliferation.  
A. anti CD3/CD28 activated CD4+ T cells are gated on CFSE+CD4+ T cells. A representative 
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dot plot and histogram analysis of proliferating T cells (purple) gated on negative control 
(grey) illustrates the cell division with serial dilution of CFSE B. Generation of the proliferation 




II.8.2 Suppression of cytokine production through flow cytometry 
To assess the suppressive ability of CB or PB-derived sorted B cell subsets 
on CD4+ T cell cytokine production, magnetically-selected CD4+ T cells were  
co-cultured with B cell subsets at a B cell‐to‐effector T cell ratio of 1:1 into a 
96‐well flat‐bottom tissue culture plate. Although in healthy PB the B to T cell 
ratio is approximately 1:4, the relevance of testing 1:1, 5:1 and 10:1 B cell to 
effector T cell ratio not only provides a model to understand Breg function but 
also contributes to gaining a better understanding of an altered ratio of 
regulatory-to-effector cells in diseases with expanded B cell frequencies or in 
transplant recipients in the context of immune reconstitution (associated with 
early B ell recovery and T cell lymphopenia) and cGVHD. Dynabeads® 
human T‐ activator CD3/CD28 (InvitroGen, Oslo, Norway) were added to each 
well for T cell activation at a concentration 1 bead: 1 cell (2µl/8x105 cells) 
following the manufacturer’s protocol. Stimulated CD4+ T cells were also 
cultured alone (positive control) and un-stimulated T cells (negative control) 
for each experiment. The plate was incubated for 48 hours in the presence of 
5% CO2 at 37ºC. During the last 5 hours of incubation, 10µg/ml of Brefeldin‐A 
(BFA) 
(Sigma 5mg/ml DMSO cat# B‐7651) was added. After 48 hours of culture, 
cells were harvested from each well and transferred into FACS tubes and 
washed with PBS. Cells were then stained with CD19 PE, CD4 PerCP (both 
from BD Biosciences) for 25 minutes and fixed and permeabilized using the 
eBioscience FoxP3 Staining Buffer Set (cat.72‐5776) and eBioscience 
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Permeabilization Buffer (1x) (cat. 00‐8333) for 45 minutes. Cells were washed 
again and stained with intracellular antibodies, IFNγ FITC and TNFα APC for 
30 minutes, after which cells were washed once more and acquired on BD 
LSRFortessa and analyzed using FlowJo. 
 
II.8.3 Detection of cytokine through IL-2, IFN-γ, TNF-α TGF-β and 
CD40L ELISA 	  
Detection of secreted cytokines by ELISA was performed using ELISA kits 
obtained from R&D Systems for IFN-γ (cat# DIF50), TNF-α (cat# DTA00C), 
IL-2 (cat# D2050), TGF-β (cat# DB100B) and CD40L (cat# DCDL40) with 
aliquots taken from B cells/T cell co-cultures, following the manufacturers’ 
protocol. Briefly, following adding of 100µl of assay diluent to each well, 100µl 
of samples or a dilution series of standard controls for appropriate cytokines 
were added to the appropriate wells and incubated at RT for 2 hours. The 
appropriate calibrator diluent served as the zero standard (0 pg/ml). Each well 
was then aspirated and washed a total of three times with wash buffer before 
addition of 200µl of conjugate to each well. The plate was sealed and 
incubated at RT for a further 2 hours. Following incubation, the wells were 
aspirated and washed again a total of three times and substrate solution was 
added to each well. The plate was further incubated at RT for 30 minutes -1 
hour in the dark. 50 µl of stop solution was added to each well and the plate 
was read at 450 nm within 30 minutes. A standard curve was created by 
drawing a best-fit curve through the points plotted for the mean absorbance 
for each standard (y-axis) against the concentration (x-axis) using microplate 
reader Gen5 2.0 data analysis software (BioTek).  
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II.8.4 Luminex ProcartaPlex assay to measure T cell cytokine 
production following coculture with B cells  
 
Detection of secreted cytokines by CD4+T cells in B cell/T cell co-cultures 
was assayed by ProCartaplex Human Th1/Th2/Th9/Th17/Th22/Treg Cytokine 
Panel (18 plex) assay (eBiosciences), as per the manufacturer’s protocol. 
Briefly, antibody coated capture beads were prepared and added to each well 
for 2 min and then washed by 1X wash buffer. 25 µl of sample or standard 
controls were then added to the corresponding wells in duplicates and 50 µl of 
cell culture medium was added to the blank wells. The plate was then sealed 
and protected from light and incubated at RT for 2 hours on a plate shaker at 
500 rpm. The wells were then washed again a total of 7 times and detection 
antibody was added to each well and incubated for 30 min. After a series of 7 
washes, streptavidin phycoerythrin was also added to each well and 
incubated for a further 30 min after which wells were washed again and 
prepared for analysis on a luminex instrument by adding 120µl of reading 
buffer into each well. 
  
II.8.5 Blocking experiments 
Sort-purified B cells subsets and CFSE-stained CD4+ T cells were cocultured 
in 96-flat bottomed plates at a 1:1 ratio and were stimulated with anti-CD3/anti 
CD23 Dynabeads in the presence or absence of 5 µg/ml of anti-IL-10 (JEs#-
9D7), anti–IL-10 receptor (3F9), anti-CD80 (10 mg/ml), anti-CD86 (10 mg/ml) 
(IT2.2), 10µg/ml anti-CTLA-4 (BNI3.1, Pharmingen) or anti–TGF-β (2 mg/ml) 
(TB21) for 96 hours. After co-culture, cells were harvested and stained with 
CD4 APC and CD19-PE (both from BD Biosciences) and washed with 2ml of 
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PBS before acquisition on the BD LSRFortessa. Gating on proliferating 
CD4+CFSE+ T cells assessed the impact of blocking cytokines. 
For analysis of cytokine secretion, supernatants collected from cell cultures of 
sort purified B cells cultured with CD3/CD28-activated CD4+ T cells either 
directly or in separate transwell chambers after 96 hours was assayed by 
ELISA (R&D Systems) as described in II.8.3 or luminex ProCartaplex 
(eBiosciences) according to the manufacturer’s instructions (II.8.4). 
 
II.8.6 Transwell assays 
A transwell system (Millicell, 1.0µm; Millipore) was used to block direct cell-to-
cell contact between sort-purified B cell subsets (transitional, IgM memory, 
naïve and switched memory B cells) and selected CFSE+CD4+ T cells 
stimulated with anti-CD3/CD28 Dynabeads (Life Technologies).  1x 105/100µl 
CFSE+CD4+ T cells were either directly cultured with sorted B cell subsets at 
a ratio of 1:1 or placed in transwell chambers in the same well. After 96 hrs, 
cultured cells were harvested and analyzed for proliferating CFSE+CD4+ T 
cells. Supernatants from each well were also harvested for analysis of 
cytokine secretion by ELISA (R&D Systems) as described in II.8.3 or luminex 
ProCartaplex (eBiosciences) according to the manufacturer’s instructions 
(II.8.4). 
 
II.9 In vitro suppression Assay of CD56+CD3- NK cells 
II.9.1   Proliferation suppression 
NK cells were negatively bead-selected (Miltenyi Biotech) as described in 
II.4.3 and labelled with 5-carboxyfluorescein-diacetate-succinimidyl ester 
(CFSE) (eBioscience) as described previously (II.8.1). Briefly, labelled NK 
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cells were plated into 96-well flat-bottom tissue culture plates in Serum-free 
Stem Cell Growth Medium (SCGM) [CellGro® / CellGenix™] supplemented 
with 5% glutamine, 5 µM HEPES (both from GIBCO/ Invitrogen), and 10% 
FCS (Biosera) in the presence of 500 IU/ml of rhIL-2 (Proleukin, Chiron, CA, 
USA) for 8 days at 37°C in a 5% CO2 humid atmosphere. Sort-purified B cell 
subsets (transitional, IgM memory, switched memory and naïve B cells) were 
then added to NK cells at a 1:1 ratio. CFSE-stained NK cells cultured alone 
with no stimulation (negative control) or with rhIL-2 (positive control) were 
included in each experiment. Magnetically selected Tregs (II.4.2.2) were co-
cultured with autologous NK cells as a suppression control. The culture 
medium was replenished with fresh medium containing IL-2 every 2-3 days 
throughout the culture period. After the culture period, cells were stained with 
CD56 BV605, CD19 PE and PI (all from BD Biosciences) for 20 min and 














Figure II-13: A representative dot plot and histogram analysis of proliferating 
NK cells  
Proliferating NK cells (purple) gated on negative control (grey) illustrates the cell 
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II.9.2   Suppression of cytokine production in NK cells by Bregs 
For studies of NK cell suppression by Bregs, magnetically selected NK cells 
were cultured in Serum-free Stem Cell Growth Medium (SCGM) [CellGro® / 
CellGenix™] supplemented with 5% glutamine, 5 µM HEPES (both from 
GIBCO/ Invitrogen), and 10% FCS (Biosera) in 96-well flat-bottomed plates 
(Nunc) at 100,000/100µl in the presence of 5ng/ml of recombinant human IL-
15 obtained from R&D Systems. NK cells were co-cultured either alone 
(positive control) or with autologous sort-purified B cell subsets at a 1:1 ratio 
for 48hrs at 37 °C. During the last 5 hours of incubation, K562 cell line target 
cells were added to the culture at an optimized E:T ratio of 10:1 together with 
CD107a PE-CF594 (BD Biosciences), monensin (BD GolgiStopTM) and BFA 
(Brefeldin A, Sigma). NK cells were incubated without targets as the negative 
control and stimulated with PMA (50 ng/mL) and ionomycin (2 mg/mL, Sigma 
Aldrich) as positive control. Furthermore, magnetically purified PB Treg cells 
isolated by negative selection (Miltenyi Biotec) were co-cultured with 
autologous NK cells as a suppression control.   
Cells were collected, washed and surface stained with surface antibodies 
(table II-2) for 30 minutes at RT in the dark. Cells were then washed and 
fixed/permeabilized (BD Biosciences) and stained with intracellular antibodies 
IFN-γ v450 and TNF-α Alexafl700 (both from BDBiosciences). Cells were 
analyzed on a BD LSRFortessa flow cytometer equipped with FACS DIVA™ 
software. Secretion of TNF-a, IFN-y, IL-10, TGF-B (all from R&DSystems), 
granzyme B (eBiosciences) and perforin (MABTECH) was assessed in the 
supernatant collected after 48hours of B cell and NK co-culture by ELISA 
assays as per the manufacturers protocol (II.8.3). 
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II.9.3 Phenotypic characterization of inhibitory and activating 
markers on NK cells 
 
The effect of B cell and NK cell co-culture on inhibitory and activating marker 
expressed on NK cells was assessed by using 10-colour multiparameter flow 
cytometry. Magnetically-selected NK cells were cocultured alone or with sort 
purified B cell subsets (transitional, IgM memory, switched memory and naïve 
B cells) at a 1:1 ratio at total concentration of 2x105 cells/200µl in SCGM for 
48 hours as described in II.9.2. Cells were then collected and washed with 
PBS and stained for surface expression of CD56 BV605, CD3 APC cy7, 
CD16 BV650, NGD2D PE, NTB-A PE, NKp30 Biotin in conjugation with 
Qdot800 Streptavidin (Invitrogen), DNAM-1 FITC (all Biolegend), NKp44 
PerCP eflour710, NKp46-BV711 (eBioscience), NKG2A PEcy7, ILT2 PE (all 
Beckman Coulter), Pan KIR FITC (R&D Systems), Siglec-7 Pacific blue 
(Miltenyi Biotec) and 2B4 APC (Becton Dickenson) as shown in Table II.2, for 
30 minutes in the dark at RT. Cells were washed and acquired on a BD LSR 
Fortessa flow cytometer equipped with FACS DIVA™ software and all data 
were analyzed using FlowJo software (Tree Star, San Carlos, CA, USA). Data 
are expressed as mean values of mean fluorescence intensity 
(MFI) ± standard error of mean (SEM).	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Table II-2: Antibodies used for characterizing NK cells 
	  	  	  	  	  
Antibody Volume 
(µl) 
Manufacturer Description Clone 
CD56 BV605 3 Biolegend Surface antibody HCD56 
CD3 APC cy7 4 Biolegend T cell co-receptor HIT3a 
CD16 BV650 3 Biolegend Activates NK cells 3G8 
NKG2D PE 4 Biolegend Activating receptor 1D11 
NTB-A PE 4 Biolegend Co-receptor in NK 
Activation 
NT-7 
NKp30 Biotin 3 Biolegend Natural cytotoxicity 
triggering receptor 3 
P30-15 




4 eBioscience Natural cytotoxicity 
triggering receptor 2 
44.189 
NKp46 BV711 3 BD Biosciences Natural cytotoxicity 
triggering receptor 1 
9E2 
NKG2A PE cy7 3 Beckman 
Coulter 
Transmembrane protein Z199 
ILT-PE 4 Beckman 
Coulter 
involved in inhibition of NK 
and T cell cytokine 
production 
HP-F1 












Modulates NK cell activity 
Marker of degranulation 
2-69 
H4A3 
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II.9.4 Suppression of NK cell mediated antibody dependent cell-
mediated cytotoxicity (ADCC) 
 
In brief, magnetically-selected NK cells were cocultured with sort-purified B 
cell subsets at a ratio of 1:1 at a concentration of 2x105cells/200µl in SCGM in 
a 96-well flat-bottomed plate at 37C°. 96-well non-tissue culture plates were 
coated with 10 µg/ml of purified CD16 mAb (clone 3G8, BD Pharmingen) and 
incubated overnight at 4C°. The plate was then washed with 300µl of PBS per 
well a total of 3 times. During the last 5 hours of incubation, 1x105 negatively 
selected NK cells were plated in the presence of CD107a, BFA and monensin 
either alone (positive control) as described in II.9.2 or with pre cultured NK 
and sort-purified B cell subsets, for 5 hours at 37C°. NK cells cultured without 
CD16 mAb were included in each experiment as a negative control. Cells 
were collected, washed and surface stained with CD3 APC cy7, CD56 BV605, 
fixed/permeabilized (BD Biosciences) and stained with IFN-γ v450 and TNF-α 
Alexafl700 (BDBiosciences) antibodies as described in II.9.2. 
 
II.9.5   Blocking experiments 
Purified B and NK cells were co-cultured and stimulated with K562 target cells 
as described in section II.9.2, in the presence or absence of 5 µg/ml of anti-IL-
10 (JES#-9D7), anti–IL-10 receptor (3F9) (both from BD Pharmingen), anti-
CD48 (5 µg/ml) (clone TU145 BD Biosciences), anti-2B4 (5 µg/ml) (clone 
C1.7 Beckman coulter, Fullerton, CA, USA), or anti–TGF-β (20 mg/ml) (clone 
TB21 Abcam). For analysis of cytokine secretion, sort-purified B cells were 
cultured with K562-activated CD56+CD3- NK cells either directly or in separate 
transwell chambers for 48hrs as per the NK cytotoxicity assay described 
previously in II.9.2. Supernatants from cell cultures were collected after 48hrs, 
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and cytokine secretion was assayed by TNF-α and IFN-γ ELISA (R&D 
Systems) as per the manufacturer’s instructions (II.8.3). For analysis of NK 
proliferation, sort-purifed B cells were cultured with CFSE+CD56+CD3- NK 
cells either directly or in separate transwell chambers (cultured with or without 
blocking mAbs) for 8 days, as described for the NK proliferation assay in II.9.1 
Cells were collected and stained for CFSE+CD56+CD3- NK population. 
 
 
II.9.6   Transwell assay 
Magnetically selected NK cells (1x 105) were either directly co-cultured with 
sort-purified B cell subsets at a ratio of 1:1 or placed in transwell chambers 
(Millicell, 1.0 µm; Millipore) for 48 hours at 37°C. K562 target cells were added 
to NK cells for the last 5 hours of culture with CD107a, BFA and monensin for 
cytotoxicity assays (II.9.2). After 48 hours, cultured cells were harvested to 
measure NK cell cytotoxicity or proliferation and analyzed by flow cytometry. 
 
II.10  Intracellular signalling 
II.10.1  Phosflow analysis of JAK/STAT pathway in B cells 
Sort-Purified B cell subsets were rested for 48 hours in medium alone 
(negative control) or with either L cells (1:10), magnetically selected NK cells 
at a 1:1 ratio or CD4+ T cells at a ratio of 1:1. Previous studies from our lab 
have shown that CD3/CD28 activated T cells are capable of inducing B cells 
to produce IL-10 via upregulation of CD154. After 48 hours of incubation, cells 
were surface stained with CD19 APC for 30 min in the dark at room 
temperature. Stained cells were washed with PBS and stimulated by 
incubation with 10 µg/ml of F(ab’) 2 goat anti-human IgG+ IgM (H+L) (Jackson 
ImmunoResearch Laboratories) for 1 min at 37C°. 50 mM of hydrogen 
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peroxide solution (Sigma Aldrich) was added to positive control cells for 15 
min at 37C°. Cells were then fixed for 10 min in the dark using the PerFix Kit 
for Phosflow assays (Beckman Coulter). After two washings, 1mL of X1 perm 
solution was added for 5 minutes at 37C°. Cells were washed twice and re-
suspended in staining buffer (Beckman Coulter) for intracellular staining. 
Phosphorylated Stat3-PE (pSTAT3-PE) mAb Phosflow antibody (BD 
Biosciences) was used to stain the cells for 30 minutes in the dark at room 
temperature. Cells were then washed once more using staining buffer prior to 
acquisition, and gated on CD19+pSTAT3+ cells using both unstimulated B 
cells (negative control) and FMO (fluorescence minus one) control for 















Figure II-14: Activated B cells upregulate JAK/STAT3 pathway.  
A. A representative gating strategy-illustrating cells first gated on lymphocyte 
population and then sort purified CD19+ B cells. B. CD19+ B cell subsets were 
cultured with NK cells (1:1 ratio) for 48 hours and stimulated with 10µg/ml anti-BCR 
for 1 minute. CD19+STAT3+ cells (blue) were determined by PE FMO as indicated 
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II.10.2  Analysis of SAP expression on NK cells 
Intracellular staining of the 2B4 signaling adaptor molecule SLAM-associated 
protein (SAP) was performed in negatively selected NK cells (Miltenyi 
Biotech) cultured either alone (positive control) or with sort-purified B cell 
subsets, namely, transitional, naïve, IgM memory and switched memory B 
cells at varying time points (figure II-14) to establish the optimum condition for 
B cell mediated NK+SAP+ suppression (in the presence or absence of 5 
µg/ml of anti-IL-10 anti–IL-10 receptor, anti-CD48 (5 µg/ml) and anti-2B4 (5 
µg/ml) for 48 hours at 37°C. Cells were collected and washed with 2 ml of 
PBS at 1400rpm for 10 min. Cells were then surface stained with CD56 
BV605 (Biolegend) for 20 minutes at room temperature in the dark. Cells were 
then washed and fixed/ permeabilized for 45 minutes using the 
foxp3/transcription factor staining buffer set. Cells were washed using staining 
buffer and stained with anti-SAP PE (eBiosciences) for 30 minutes in the dark 
at RT. Cells were then washed again with 2 ml of staining buffer and analyzed 















Figure II-15: A graph illustrating the relationship between B cell mediated 
suppression of NK+SAP+ cells and upregulation of inhibitory NK+pSHP-1 
expression in a time dependent manner (N=3)	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II.10.3  Phosflow analysis of pSHP-1 expression on NK cells 
The flow cytometry based measurement of pSHP1-Y536 in human PBMCs 
has been previously described. In brief, selected NK cells (1 x 106/ml) were 
cultured either alone or with sort-purified B cell subsets at a 1:1 ratio at 
varying time points to determine the optimized condition for upregulation of 
pSHP-1 expression in NK cells after B cell: NK cell co-culture (figure II-14). 
Having optimized the upregulation of pSHP-1 expression, cells were cultured 
for 48 hours at 37C°. Cells were harvested and suspended in PBS 1X at room 
temperature and stained with 2µg/ml of purified CD16 mAb (BD Pharmingen) 
for 20 min at 4C° for NK stimulation. After two washings with 2ml PBS 1X, 
2µg/ml of goat anti-mouse IgG, F (ab’)2 fragment specific Ab (Jackson 
Immuno) was immediately added and cells were incubated at  37C° for 10 
min. After stimulation, cells were fixed for 10 minutes at 37°C with fix solution 
1 (Beckman Coulter, USA). After a further two washings, a 30 min surface 
staining was performed with anti-CD56 ECD (Beckman Coulter) and CD19 
APC (BD Bioscience). Cells were washed and 1mL of perm solution2 was 
added for 5 min at 37°C. Cells were washed twice and stained with  
intracellular antibody pSHP-1 [p-SH-PTP1 Antibody (Tyr 536) Santa Cruz] self 
conjugated with Alexa Fluor® 488 Antibody Labeling Kit (Invitrogen) for 40 
min in the dark at RT. After washing, cells were ready to be analysed on 
LSRFortessa (BD Biosciences) and gated on CD56+pSHP-1+ cells using both 
unstimulated B cells (negative control) and FMO (fluorescence minus one) 
control for pSHP-1 FITC figure (II-15).  
 
Figure II-16: Gating strategy of CD56+SHP-1+ cells  
Cells were gated on lymphocyte population and then CD56+NK cells. CD56+SHP-1+ 
cells (blue) were determined by SHP-1 Alexa Fluor488 FMO (shaded grey). 
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II.11  Statistical Analysis 
All values are expressed as mean, median and range as stated in the legends 
of each figure. We performed analysis of significance in Prism (GraphPad, La 
Jolla, USA) by unpaired or paired 2-tailed Student t test analysis and by 
nonparametric analysis of variance (ANOVA), as appropriate. Where p value 
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Chapter III.  IL-10 producing B Cells With Immune Regulatory Capacity 
are Enriched Within Both the IgM Memory and Transitional 
B Cell Subset And Suppress CD4+ T cells 
 
III.1 Introduction 
In recent years, a distinct newly described subpopulation of interleukin-10 (IL-
10) producing human B regulatory (Breg) cells, that have been shown to exert 
significant immunoregulatory functions both in vitro and in vivo, has been the 
focus of intense immunological research (Mauri and Bosma., 2012). In this 
chapter, I document work (introduction, findings and illustrations and 
discussion) from my recent published work (Khoder et al., Blood 2014) titled 
Regulatory B cells are enriched within the IgM memory and transitional 
subsets in healthy donors but are deficient in chronic GVHD. Blood, 124(13), 
2034.  
The concept that suppressor B cells with regulatory properties could modulate 
the immune response, originated in the 1970’s; however, the designated term 
‘B regulatory cells’ (Breg) was first introduced nearly 30 years later (Katz et 
al., 1974, Neta and Salvin., 1974, Mizoguchi and Bhan., 2006). Despite the 
extensive body of evidence gathered, in the ensuing years since these studies 
were published, some controversy over the paucity of markers that can 
identify Bregs, particularly in humans, still exists. Tedder et al (Kalampokis et 
al., 2013) recognized IL-10-producing B cells as an emerging class of 
lymphocytes defined by an important set of regulatory functions that could be 
harnessed for therapeutic purposes.  These Bregs have been shown to 
suppress inflammatory responses in murine models of experimental 
autoimmune encephalomyelitis (EAE) (Fillatreau et al., 2002), collagen-
induced arthritis (CIA) (Mauri et al., 2003), colitis (Mizoguchi et al., 2002) and 
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the generation and maintenance of T-helper (Th) and T-regulatory (Treg) cells 
in the periphery (Wei et al., 2005). Thus far, a number of Breg phenotypic 
markers have been identified in murine models (Mauri and Bosma., 2012). 
Tedder et al demonstrated that IL-10-producing B cells  (B10 cells) 
predominantly expressed CD1dhiCD5+ and shared phenotypic features 
common to marginal zone (MZ), T2-MZ precursor, and CD1dhi CD5+ B-1a B 
cells, but did not exclusively belong to one of these B cell sub populations 
(Yanaba et al., 2008, Iwata et al., 2011). Hence, most current strategies to 
definitively identify Bregs in a reproducible manner rely on the detection of IL-
10, which inhibits proinflammatory cytokine production and differentiation of 
effector T cells (Matsushita and Tedder., 2011). Thus, a more detailed 
investigation of the Breg ‘signature’ is needed to permit meaningful 
exploration of therapies based on B cells with regulatory potential. 
 
The study of human Bregs, which share many functional characteristics with 
murine Bregs (Blair et al., 2010, Iwata et al., 2011) has been largely limited to 
IL-10-producing immature/transitional B cells in a small group of autoimmune 
diseases, including systemic lupus erythematous (SLE) (Blair et al.,2010), 
immune thrombocytopenia (ITP) (Li et al.,2012), multiple sclerosis (Correale., 
2008) and more recently implicated in cGVHD (Khoder et al., 2014, Huu et al., 
2013, de Masson et al, 2015). However, conflicting data exist as to the 
phenotypic characteristics of these cells. In the study by Blair et al (2010), IL-
10+ Breg were shown to be enriched within the CD24hi CD38hi immature 
transitional B cell compartment.  On the other hand, Tedder et al (2011) 
reported IL-10+ Breg to be enriched within the mature CD24hi CD27+ memory 
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B cell subset. Although, the exact mechanism by which IL-10 producing 
regulatory B cells mediate immunosuppression is not clearly understood. 
Despite compelling evidence to support the role of Breg dysfunction in a 
number of autoimmune conditions, (Mauri and Bosma., 2012), very little is 
known about their role in immune regulation after allogeneic hematopoietic 
transplantation (HSCT) and their activities in chronic graft-versus-host disease 
(cGVHD), where CD4+CD25+ Treg cells have attracted the lions' share of 
attention (Rezvani et al.,2006, Mielke et al., 2007).  
 
In this chapter my aim was to determine the presence of IL-10 producing 
regulatory B cells derived from peripheral blood mononuclear cells (PBMC) 
and to assess their suppressive potential on CD4+ T cell proliferation and 
effector function. My results demonstrate the presence of IL-10-secreting 
CD19+CD24hiCD38-/loIgM+ memory B cells that coexist with IL-
10+CD24hiCD38hi transitional Breg cells in healthy human donors. Moreover, 
the regulatory capacity of these human Bregs on CD4+ T cell proliferation and 
cytokine production is depended on cell-cell contact through CD80/CD86 co-
stimulatory signalling as well as IL-10 production.  	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III.2 Results 
III.2.1 Phenotypic characterization of CD19+ B cell subsets 
B cell characterization has been highlighted by a number of studies that 
recognize a number of classifying schemes, which are essential to the study 
of B cell biology in health and disease. Carsetti et al (2004) proposed to 
classify B cells through the CD24/CD38 expression profile, which 
characterizes B cell subsets as CD24hiCD38hi transitional B cells, 
CD24+CD38+ naïve B cells, CD24hiCD38lo/- memory B cells and CD24-CD38hi 
plasmablasts. The use of additional markers such as IgM can further 
distinguish between switched memory and IgM+ memory B cells (Suryani et al 
2010, Palanichamy et al, 2009). Additionally, Bohnhorst et al (2001), 
highlighted a classifying scheme referred to as Bm1-Bm5, which 
characterizes 5 B cell populations based on the phenotypic expression of IgD 
and CD38; Bm1 subset of naïve cells (IgD+CD38−); Bm2` subset of pre‐GC 
cells (IgD+CD38++); GC cells (IgD−CD38++); and Bm5 memory cells (early 
IgD−CD38+ and late IgD-CD38-). Further, phenotypic expression of CD27 
and IgD has also been proposed as a classification scheme to distinguish 
between CD27- antigen-naïve B cells and CD27+ memory B cells by Maurer 
et al (1992). However some memory B cells are also CD27-, of which 20% are 
IgM-IgD-. Additionally, as transitional cells are also CD27-, further markers 
must be used to distinguish between the phenotypic differences of naïve and 
transitional subsets. With respect to the classification of B cells based on the 
CD24 and CD38 phenotype expression, I implemented this strategy to 
characterize B cell subsets and correlated the expression of transitional, naïve 
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and memory B cells with IgD/CD27, IgM/CD27 and IgD/CD38 axis (figure III-
1). 
 
Figure III-1: CD19+ B cells subsets 
Transitional (orange), naïve (green), IgM memory B cells (blue) switched B cells 
(black) were gated on CD38 and CD24 axis and correlated with different B cell 





CD19+CD34hiCD24hi transitional B cells were further characterized as CD27-
IgMhi and IgD+, CD19+CD24+CD38+ naïve B cells were further characterized 
as CD27-IgM+ and IgD+, CD19+CD24-/loCD38hi memory B cells were further 
characterized as IgM+CD27+IgD+/lo. However some IgM memory cells also 
contained CD27-IgD- memory cells. CD19+CD24-/loCD38+ switched memory B 
cells were IgM-, CD27+ and IgD-. 
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Further, in accord with previous studies (Suryani et al., 2010, Carsetti et al., 
2004, Palanichamy et al., 2009), extended phenotypic characterization of B 
cells in 10 healthy donors using an extended panel outlined in table II-1, 
highlighted that PB-derived subpopulations of T1, T2 and T3 transitional 
subsets could be further characterized through the differential expression of 
CD10 and CD21 pattern where T1 cells illustrated highest expression of 
CD10, which is lost as the cells mature and acquire expression of CD21. T3 
subsets had lower expression of CD10 and high expression of CD21, a 













Figure III-2: Differential expression of CD10 and CD21  
CD10 and CD21 expression distinguishes between T1 (most immature transitional 




Full phenotypic analysis of all four B cell subsets based on the expression of 
markers used in the extended B cell phenotype (section II.2.6.2) characterized 
transitional B cells as CD19+CD24hiCD38hiIgMhiCD27-CD10hiCD21-IgDhi, 
naïve B cells as CD19+CD24+CD38+IgM+CD27-IgD-CD10-CD21+, IgM+ 
memory B cells as CD19+CD24-CD38hiIgM+CD27+IgD+/loCD10-CD21+ and 
switched memory B cells as CD19+CD24-CD38hiIgM-CD27-IgD-CD10-CD21+. 
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III.2.2 Peripheral blood B cell subset frequencies 
B cell subsets in 10 healthy donors were characterized based on CD19+, 
CD38, CD24 and IgM expression as detailed in section II.6.2.  The frequency 
of CD19+ B cells in healthy PBMCs was 6.0% (3.21%-13.1%); 4.7%(2.55%-
7.3%) of total CD19+ B cells constituted of CD24hiCD38hi transitional B cells, 
56.4%(38.9%-69.5%) were CD24+ CD38+ naïve B cells, 20.3%(12.9%-28.1%) 
were CD24hi CD38lo CD27+IgM+ memory B cells and 14.3%(10.6%-17.4%) 
CD24hi CD38lo CD27+IgM- switched memory B cells (figure III-3). Further, I 
found no statistically significant difference on the impact of age on different 
subpopulations of CD19+ B cells. Additionally, there was also no significant 
difference in B cell subsets between gender groups, in females compared to 
males. This observation is in accord with previous reports that also did not 














Figure III-3: Frequency of B cell subsets in healthy control PBMCs (n=20)  
Frequency of B cell subsets out of total CD19+ B cells was determined through flow 
cytometric analysis of B cells subsets with respect to the CD24 and CD38 
parameters. IgM+ and IgM- memory cells were subdivided as per expression of IgM. 




I next validated the effect of freezing on the signal intensity and the frequency 
of CD19+ B cell populations against the CD24 and CD38 axis and IgM 
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expression in the same 10 fresh healthy donor samples that were frozen at -
80°c for a minimum of 8 days. No significant differences were found in the 
signal intensities or B cell subsets in paired fresh and frozen PBMC CD19+ B 














Figure III-4: Effect of cryopreservation on B cell phenotype  
A. Representative FACS plots illustrating gating strategy of phenotyping CD19+ B 
cell subsets in both fresh and frozen samples. Cells gated on lymphocytes, live cells, 
CD19+ B cells and B cell subsets using CD24/CD38 axis. B. Each subset is 
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illustrated as bivariate plots representing data acquired from 10 paired fresh and 
frozen samples for transitional B cells (p= 0.0779), naïve B cells (p=0.8687), IgM 
memory (p=0.0969) and switched memory (p=0.3688) and analyzed using a paired t-
test 
 
III.2.3 Detection of IL-10 production by B cells isolated from PBMC 
A number of studies have recognized the ability of PB-derived B cells to 
produce IL-10 in response to activation with CD40L, anti-BCR and CpG. 
Using the method described in II.6.3, I tested the kinetics of IL-10 production 
by freshly selected PB B cells from 14 healthy controls, stimulated with 
irradiated CD154 expressing fibroblasts (L cells), BCR crosslinking and CpG. 
Un-stimulated purified B cells, L cells and CD154- fibroblasts were also 
cultured alone as negative controls. I found that un‐stimulated B cells 
produced negligible amounts of IL-10 (mean 14±4.5 pg/ml) and irradiated L 
cells and CD154- fibroblasts also produced small amounts of IL-10 (mean 
5.5± 6.5 and 21± 12 pg/ml respectively). Activated CD19+ B cells produced 
IL-10 in a time dependent manner. In addition, B cells stimulated with L cells 
at a ratio of 1:10 produced higher levels of IL-10 than B cells stimulated with 








Figure III-5: Cumulative data illustrating levels of IL-10 production by L cell, 
CpG and BCR activated PB-derived total CD19+ B cells. 
 
Based on these results I next determined the effect of cryopreservation on the 
ability of B cells to produce IL-10 in response to L-cells. PBMCs from the 
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same healthy donors were frozen at -80° C as described in II.2.3 for a 
minimum of 3 weeks. Cryovials were thawed as described in II.2.4 and rested 
for a minimum of 4 hours at 37° C before B cell selection was performed 
(II.4.1). Cells were activated as described previously and supernatant was 
assayed for IL-10 by ELISA. Minimal differences were observed in IL-10 
levels between fresh and frozen paired samples and overall no significant 
differences were found (figure III-6). The results validate the use of frozen 











Figure III-6: Effect of cryopreservation on IL-10 production by B cells activated 
by L cells for 24, 48 and 72 hours.  
Data was acquired from 10 paired fresh and frozen samples at 24 hours (p=0.4536), 
48 hours (p=0.0717) and 72 hours (p=0.0934). Each sample is depicted on bivariate 
plot and analyzed using a paired t-test, p<0.05; ns,no significant difference 
 
 
III.2.4 Detection of IL-10 production by B cells by intracellular staining 
Based on ELISA results, I used L cells to study the kinetics of IL-10 
production by B cells at different lengths of incubation (16hr, 24hr, 48hr and 
72hr) by intracellular staining as described in II.6.5. PBMC or selected B cells 
were gated on CD19+IL-10+ population to determine the production of IL-10 
in response to L cell activation. Un-stimulated cells, CD154- fibroblasts and an 
isotype control were used to validate the production of IL-10 by activated B 
cells. (figure III-7A). 
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producing B cells, which suggests that B cells exist as 2 functionally distinct 




































Figure III-7: Detection of CD19+ B cell IL-10 production by intracellular staining  
A. Gating strategy for IL-10 producing CD19+ B cells. Gated CD19+ B cells from 
lymphocyte population were assessed for CD19+IL-10+ B cells B I gated on the 
CD19+IL-10+ population within PBMC or selected B cells to determine IL-10 
production after 24 hours of coculture with L cell. The specificity of IL-10-producting B 
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(IgG2aκ), unstimulated B cells incubated with BFA alone, PBMCs cultured with 
CD154- fibroblast (control cell line) and appropriately stimulated B cells without the 
addition of BFA. C. The IL-10-producing B cell population was distinct from IFN-y 
producing B cells 
 
Further, gated CD19+ B cells produced IL-10 in a time dependent manner 
(figure III-8A). I next determined the effect of cryopreservation on B cell IL-10 
production by intracellular staining. Paired PBMC from the same healthy 
donors (n=10) were frozen at -80° C as described in II.2.3 for a minimum of 3 
weeks. Cryovials were thawed as described in II.2.4 and rested for a minimum 
of 4 hours at 37° C before the assay was performed (II.4.1). Minimal 
differences were observed in frequencies of IL-10 production between fresh 
and frozen paired samples after 24 hours of stimulation and overall no 
significant differences were found (1.98% vs. 1.65%; p=0.095) respectively 
(figure III-8B). The results validate the use of frozen samples for the detection 






Figure III-8: Production of IL-10 from CD19+ B cells  
A. Gated CD19+ B cells produce IL-10 in a time dependent manner (n=10) no 
significant was observed using an ANOVA test B. no significant difference was 
observed in the signal intensity of CD19+IL-10+ B cells between fresh and frozen 
paired healthy PBMC samples after 24 hours of stimulation (n=10)   
 
III.2.5 Phenotypic characterization of IL-10 producing B cells  
I next determined the phenotype of IL-10 producing B cells by using a panel of 
surface antibodies (CD19, CD24, CD38, CD27 and IgM) that have previously 
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been shown to identify a subset of IL-10 regulatory B cells (Khoder et al., 
2014, Blair et al., 2010) in combination with intracellular IL-10 staining as 
detailed in section II.6.5. PBMC were stimulated with L cells at varying time 
points of 15h, 24h, 48 and 72hr. In accord with previous results from our 
laboratory (Khoder et al., et al 2014) I observed that the phenotype of B cells 
changes significantly within 24 hours of activation, characterized by 
downregulation of CD24 and the appearance of a population of plasmablasts 
(CD24-CD38hi). Therefore, in agreement with previous data from our lab, I 
found that 15 hours of B cell activation with L cells was optimal for IL-10 
production without inducing significant changes in B cell phenotype. The 
majority of IL-10 producing B cells appeared to be enriched within the 
CD19+CD24hiCD38hiIgMhiCD27- transitional and CD19+CD38-/lo CD24hi 
CD27+IgM+ memory B cell population and relatively fewer in the 
CD19+CD38+CD24+CD27- naïve and CD19+CD24hiCD38-/loCD27+IgM- 
switched memory B cell subsets. Median-fold increases in the frequency of IL-
10 producing cells for IgM memory were 3.6 (range 2.5-4.6) and transitional 
were 4.42 (range 3.78-6.59) in comparison to naïve 0.48 (range 0.33-0.78) 
and switched 0.60 (range 0.43-0.80) B cell subsets (figure III-9A). In addition, 
CD19+IL-10+ B cells had a higher expression of CD24, CD27 and IgM. To 
validate if IL-10-producing B cells are enriched within transitional and IgM 
memory B cell subsets, I also measured IL-10 concentrations in the 
supernatants collected from sort-purified B cell subsets cultured with 
irradiated L cells. In keeping with my intracellular cytokine data, the highest 
level of IL-10 production was found in supernatants collected from transitional 
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and IgM memory B cell cultures, when compared to supernatants from naïve 







Figure III-9: IL-10 producing B cells are enriched within transitional and IgM 
memory B cell subsets  
A. Transitional and IgM memory B cells expressed higher proportion of IL-10 
producing B cells (frequency of IL-10 producing B cells/total B cell subset frequency) 
n=3 B. Sort purified transitional and IgM memory B cells secreted higher levels of IL-
10 by ELISA after stimulation with naïve and switched memory B cell subsets (n=3). 
Bars in A and B represent median values, and upper whisker of error bar represents 
the range. P < 0.05 by nonparametric ANOVA. 
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 




III.2.6 IL-10 producing transitional and IgM memory B cells inhibit CD4+ 
T cell proliferation  
 
I next examined whether IL-10 producing transitional and IgM memory B cell 
subsets also exhibited regulatory capacity on CD4+ T cell function. To 
evaluate this, I sort-purified transitional (CD19+CD24hiCD38hi), naïve 
(CD19+CD24+CD38+), IgM memory (CD19+CD38-/lo CD24hiIgM+) and switched 
memory (CD19+CD38-/lo CD24hiIgM-) B cells by flow cytometry from 20 healthy 
donors and cultured them with CFSE stained and anti-CD3/anti-CD28 bead-
stimulated CD4+ T cells to assess their effect on proliferating CD4+ T cells. 
The gating strategies and post-sort purity checks of B cell subsets are shown 
in figure III-10. The percentage of proliferating CD4+ T cells was assessed by 
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flow cytometry using CFSE dilution after 96 h of incubation as detailed in 
II.8.1. Results illustrated that IgM memory B cells and transitional B cells 
significantly suppressed CD4+ T cell proliferation [median percent proliferating 
CD4+ T cells 54.5%; (33%-76.5%)] and 49.8% (25%-66%)], respectively 
when compared with anti-CD3/anti-CD28 stimulated CD4+ T cells cultured 
alone (positive control) [87% (77%-92%], or with naïve; [89.0%; (77%-97%] or 



















	   135	  
Figure III-10: Gating strategy and purity check of PB B cell sorting  
A. Multi-parametric flow cytometric gating strategy for B cell subset sorting on BD 
FACS ARIA IIIu based on CD24 and CD38 expression B. FACS plots illustrating the 







Figure III-11: IL-10 producing Transitional and IgM memory B cells suppress 
CD4+ T cell proliferation  
A. Representative FACS plots illustrating the gating strategy of CD4+CFSE+ T cells. 
Gated CD4+ T cells from lymphocyte population were assessed for CFSE dilution by 
flow cytometry after 96 hours. Histogram overlay illustrates CFSE+ CD4+ T cells 
(blue) and negative control (grey) B. Magnetically selected and CD3/CD28 activated 
CD4+ T cells were labeled with CFSE (eBioscience) and plated either alone (positive 
control (proliferation index 2.27 – Blue) or at a 1:1 ratio with transitional (proliferation 
index 1.24 -yellow), IgM memory (proliferation index 1.65-red), naïve (proliferation 
index-2.19-orange) or switched memory (proliferation index 2.50-green) B cells. 
CFSE-stained T cells cultured with no stimulation (negative control –grey) were 
included in each experiment. C. Suppressive effects of CD19+ B-cell subsets (1:1 
ratio) on frequency of CD4+ T cell proliferation. Bars represent median values, and 
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nonparametric ANOVA. D. Suppressive effects of CD19+ B-cell subsets on T cell 
proliferation index (n=20). Bars represent median values, and upper whisker of error 
bar represents the range. *P < 0.05  vs positive control by nonparametric ANOVA. 
This research was originally published in Blood. Khoder, A., Sarvaria, A., Alsuliman, A., 
Chew, C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., 
Liu, E., Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., 
Molldrem, J., Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. 
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy 
donors but are deficient in chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the American 




The inhibitory effect of transitional and IgM memory B cells on CD4+ T cell 
proliferation was cell dose dependent, with the highest suppression observed 
at a ratio of 5:1 (figure III-12). I also compared the suppressive ability of IgM+ 
memory B cells and transitional B cells with that of magnetically selected 
CD25hi CD127- CD4 T cells regulatory T cells on autologous CD4+ T cell 
proliferation at a ratio of 1:1 (n=4). The suppressive ability of transitional and 
IgM memory was comparable to that of T regulatory cells (% suppression 
48.3% vs. 53.6%; 58% respectively;) as shown in figure III.13 indicating that 
transitional and IgM memory B cells exert similar suppressive function on 








Figure III-12: Suppressive effect of transitional and IgM memory B cells on 
CD4+ T cell proliferation was dose dependent as indicated at the B cell: T cell 
ratios (n=4)  
Error bars represent mean with standard deviation.  
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 
chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the American Society of Hematology. 












































Figure III-13: Suppressive effect of transitional and IgM memory B cells on 
CD4+ T cell proliferation was comparable to that of T regulatory cells  
Results illustrated that IgM memory B cells and transitional B cells significantly suppressed CD4+ T 
cell proliferation in a manner comparable to T regulatory cells after 96 hours of B cell/T cell co-
culture, when compared with anti-CD3/anti-CD28 stimulated CD4+ T cells cultured alone (positive 
control). Bars represent medians and upper ranges for 4 healthy donors. *P < .05 for individual 
comparisons with controls by nonparametric ANOVA; ns, not significant. This research was 
originally published in Blood. Khoder, A., Sarvaria, A., Alsuliman, A., Chew, C., Sekine, T., Cooper, 
N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., Muraro, P.A., Alousi, A., 
Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., Rouce, R., Champlin, R., 
McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells are enriched within the IgM 
memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014; 
124(13): 2034-2045. © the American Society of Hematology. 
 
 
III.2.7 IL-10 producing transitional and IgM memory B cells inhibit CD4+ 
T cell proinflammatory cytokine production 
 
In order to assess the suppressive effect of sort-purified transitional and IgM 
memory B cell subsets on CD4+ T cell effector function, sort-purified B cell 
subsets were co-cultured with anti-CD3/anti-CD28 stimulated magnetic-bead 
purified CD4+ T cells and the relative frequencies of CD4+IFNγ+ and 
CD4+TNF-α+ cells were assessed by flow cytometry. Both transitional and 
IgM memory B cells suppressed cytokine production by CD4+ T cells 
compared with CD4+ T cells cultured either alone or with naïve or switched 
memory B cell subsets (figure III-14). Consistent with these data, using 
ProcartaPlex Luminex assay, I also found suppression of IFN-γ, TNF-α and 
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transitional and IgM memory B cells cocultured with CD4+ T cells. In contrast, 
naïve and switched memory B cell subsets failed to suppress production of 
proinflammatory cytokines by CD4+ T cells. Additionally, the suppressive 
ability of IgM memory and transitional B cells on CD4+ cytokine production 
was also comparable to that by T regulatory cells (figure III-15). Collectively, 
these results suggest that the suppressive capacity of transitional and IgM 
memory B cells on CD4+ T cell proliferation and cytokine production is 
comparable to T regulatory cells.  
 
III.2.7 Depletion of Treg cells does not influence the suppressive ability 
of transitional and IgM memory B cells 
 
I then examined if Treg cells are important for the in vitro suppressive effect of 
transitional and IgM memory B cells by depleting CD127- CD25hi Tregs from 
CD4+ T cells, using magnetic cell purification as detailed in II.4.2.2. 
Transitional and IgM memory B cell subsets were then cultured with anti-
CD3/anti-CD28 stimulated and CFSE-stained Treg depleted-CD4+ T cells at a 
ratio of 1:1. IgM memory and transitional B cells significantly suppressed the 
proliferation of Treg-depleted CD4+ T cells compared with the positive control; 
57.9% (47.5-59) vs. 58.9% (49-62.7%) vs. 89.2 (85.8-92.1) respectively, 
figure III-16, while neither naïve nor switched memory B cells exerted any 



























Figure III-14: Suppressive effect of transitional and IgM memory B cells on 
CD4+ T cell cytokine production.  
A. Representative dot plots illustrating in vitro suppression of different CD19+ B cell 
subsets on anti-CD3/CD28 activated CD4+ T cell IFN-y and TNF-α production after 
48 hours of coculture B. Cumulative data summarizing B cell suppression of CD4+ T 
cell IFN-y and TNF-α production assayed by intracellular staining. Bars represent 
median values, and upper whisker of error bar represents the range for 4 healthy 
donors. *P < 0.05 for individual comparisons with controls (anti-CD3/anti-CD28 
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Figure III-15: The suppressive effect of transitional and IgM memory B cells on 
cytokine production by CD4+ T cells is comparable to that of T regulatory cells 
Using Luminex assay, IFN-y, TNF-α and IL-2 levels were measured in supernatants 
harvested from cocultures of sort purified transitional and IgM memory B cell subsets 
with CD4+ T cells. Bars represent median values and upper whiskers of error bars 
represent range for 4 healthy donors. *P<0.05 for individual comparisons with 
controls (anti-CD3/anti-CD28 stimulated CD4+ T cells alone) by nonparametric 















Figure III-16: Depletion of Treg cells does not influence the suppressive ability 
of transitional and IgM memory B cells  
Bars represent median values and interquartile ranges from triplicate experiments. 
*P<0.05 vs. T- cell control for individual comparisons with controls (anti-CD3/anti-
CD28 stimulated CD4+ T cells alone) by nonparametric ANOVA; ns, not significant. 
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 
chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the American Society of Hematology. 
 
 
III.2.8 The suppressive effect of transitional and IgM memory B cells is 
IL-10 dependent 	  
I next examined the potential mechanism(s) by which transitional and IgM 
memory B cells suppress CD4+ T cell proliferation and effector function. 
CD4+ T cells were cultured either alone or at a 1:1 ratio with sort purified 
transitional and IgM memory B cell subsets in the presence of IL-10 and IL-10 
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cytokine production and proliferation of CD4+ T cells co-cultured with 
transitional and IgM memory B cells, supporting previous data with transitional 
B cells (Blair et al., 2010), that the regulatory properties of transitional and IgM 
memory B cells is mediated through IL-10 (figure III-17A). However, IL-10 
blockade did not fully reverse the suppressive capacity of transitional and IgM 
memory B cells [median proliferating CD4+ T cells 78.2%; (65.6%-84.7%)]; 
and 74.6%; (66.7%-82.5%), respectively], (figure III.17B), when compared to 
the corresponding positive control  [median 92.3% (90%-94.8%)], suggesting 
that other mechanisms, most likely other soluble factors or costimulatory 
molecules, are involved in regulating Breg-mediated suppression of CD4+ T 
cells. I further illustrated that adding exogenous IL-10 to co-cultures of CD4+ 
T cells with naïve B cells or switched memory B cells induced minimal 
suppression of CD4+ T cell proliferation [median proliferating CD4+ T cells 
82%; (81%-89%)]; p=0.00649 and 81.5%; (78.8%-82.4%), p=0.0074 
respectively] (Figure III-18A), when compared with the corresponding positive 
control, [93.60% (91.6%-95%], but this effect was substantially less than that 
seen with transitional or IgM memory B cells [51% (25-63%) and 52.5% (33-
75%), respectively]. These results strengthen the hypothesis that IL-10 does 
not by itself confer suppressive capacity to B cells and further support the 
involvement of other mechanisms in Breg-mediated T cell suppression. 
Previous reports suggest that the immunoregulatory effects of B regulatory 
cells may be mediated by TGF-β (Blair et al., 2010). Therefore, I performed 
additional blocking experiments using TGF-β specific mAbs. TGF-β blockade 
had no significant impact on transitional and IgM memory B cell mediated 
suppression on CD4+ T cells (p=0.4585 and p=0.8637, respectively; n=3) 
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(figure 18B), indicating that this cytokine lacks any appreciable role in human 


























Figure III-17: The suppressive effect of transitional and IgM memory B cells on 
CD4+ T cells is partially dependent on IL-10. 
A. Anti-CD3/anti-CD28 stimulated CD4+ T cells were cultured with FACS-sorted CD19+ 
B cell subsets in the presence or absence of IL-10 blockade 96 hours. Unstimulated 
CD4+ T cells (negative control-grey shaded area) were included with each experiment. 
Flow cytometry histograms show proliferation of CD4+ T cells cultured alone (blue) or 
with naïve (green), switched memory (orange), IgM+ memory (red) or transitional B cells 
(yellow). Proliferation index values for histograms without IL-10 blockade are: CD4+T 
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Proliferation index values for cultures with IL-10 blockade are: CD4+T cells – 2.70, with 
naïve – 2.55, switched -2.68, transitional -2.05, IgM memory -2.23. Bar charts compare 
the suppressive effect of B cell subsets on proliferating CD4+ T cells with or without IL-10 
blockade. Bars indicate medians, and whiskers indicate the upper range for 3 healthy 
donors. *P < 0.05 vs positive control or IL-10R blockade by nonparametric ANOVA. B. 
Dose titration graphs for transitional and IgM memory B cells co-cultured with CFSE-
stained CD4+ T cells in the presence of varying concentrations of anti-IL-10 and anti-IL-
10 receptor blocking antibody (n=3)  
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 









Figure III-18: The suppressive effect of transitional and IgM memory B cells on 
CD4+ T cells is dependent on IL-10 but not TGF-β.  
A. Titrated effects of adding exogenous IL-10 at varying concentrations had minimal 
effect on the ability of naïve and switched memory B cells to suppress CD4+ T cell 
proliferation. B. TGF-β blocking had no significant effect on the suppressive ability of 
transitional and IgM memory B cells (n=3). Bars indicate medians, and whiskers 
indicate the range. *P <0.05 by nonparametric ANOVA. 
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., 
Chew, C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., 
Liu, E., Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., 
Molldrem, J., Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. 
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy 
donors but are deficient in chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the American 
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III.2.9 The suppressive effect of IL-10+ IgM memory and transitional 
B cells also depends on cell-cell contact, mediated through 
CD80/CD86   
 
Previous studies have postulated that the suppressive capability of murine 
Bregs is mediated both by the provision of IL-10 and direct contact with 
CD4+T cells (Blair et al., 2010, Mauri and Bosma., 2012, Khoder et al., 2014). 
However, it remains to be determined whether a similar direct cell-to-cell 
contact is involved in human Breg-mediated T cell suppression. To examine 
this, I performed transwell experiments, in which transitional and IgM memory 
B cells were either in direct contact or separated from anti-CD3/anti-CD28 
stimulated and CFSE-stained CD4+ T cells by a permeable membrane. 
Proliferation of CD4+ T cells was measured 96 hours after onset of culture. 
Direct co-culture of CFSE+CD4+ T cells with transitional or IgM memory B 
cells resulted in significant suppression of CD4+ T cell proliferation, median 
frequencies of proliferating CD4+ T cells are 48.9% (43.3%-65.1%) and 
47.4% (39.7%-64.7%), respectively n=5]. On the other hand, separation of B 
cell/T cell direct contact by a transwell membrane partially reversed the 
suppressive effect of these B cell subsets, [median frequencies of proliferating 
CD4+ T cells 74% (59.7%-85.5%) p=0.011 and median 67.7% (52.5%-
88.7%), p=0.0305, respectively; n=4] as shown in figure III-19. However, this 
reversal was not complete (compared with positive control). 
 
In order to examine whether a combination of IL-10 blockade and abrogation 
of direct cell-to-cell contact can completely reverse the suppressive effect of 
proposed regulatory B cell subsets on CD4+ T cell proliferation, I added IL-10 
and IL-10 receptor (IL-10R) mAbs to cultures of sort purified transitional and 
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memory B cells in a transwell setting. Subsequent addition of IL-10 blockade 
in a transwell setting almost completely abolished transitional B cell and IgM 
memory B cells mediated inhibition of CD4+ T cell proliferation [% of 
proliferating CD4+ T cells; median 87.7% (86.5%-88.3%) and median 90.4% 
(85.7%-91.0%), respectively; n=3] (figure III-19C).  
 
 
Figure III-19: Effect of B cell:T cell contact on the profiles of CD4+ T cell 
proliferation  
A. Representative histograms illustrating CD4+ T cells either directly added to sorted 
CD19+ B cell subsets at a ratio of 1:1 or placed in transwell chambers in the same 
well: CD4+ T cells alone (blue), with naïve B cells (orange), switched memory B cells 
(green) IgM+ memory B cells (red) and transitional B cells (yellow) at a ratio of 1:1. 
Unstimulated controls (grey) were included. Proliferation index values for histograms 
with direct contact are: CD4+T cells – 2.91, with naïve – 2.85, switched –3.00, 
transitional – 1.60, IgM memory – 1.41. Proliferation index values for cultures with 
transwell are: CD4+T cells – 2.91, with naïve – 3.94, switched-3.11, transitional -
2.07, IgM memory -2.28. B. Collective data (n=5) compare the effect of suppressive 
B cells on the proliferation of CD4+ T cells with or without direct cell to cell contact. 




























CD4+%T%cells% CD4:%Switched%B%cells% CD4:%Nave%B%cells% CD4:%IgM%Memory%B%cells% CD4:%Transi@onal%B%cells%
A"





























































	   146	  
by nonparametric ANOVA; ns, not significant.  C. The suppressive capacity of IgM+ 
memory B cell and transitional B cell suppression is dependent on IL10 and cell-to-
cell contact (n=3). The data shown are medians and upper whisker of error bars are 
range. *P < 0.05 by nonparametric ANOVA; ns, not significant.  
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 
chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the American Society of Hematology. 
 
Thus, both direct cell-to-cell contact and IL-10 production are necessary for 
Breg cells to achieve their full suppressive potential. To determine the 
mechanism by which Bregs produce IL-10 in the transwell setting, we 
measured the levels of soluble CD40L in the supernatant by ELISA assay. 
Soluble CD40L is naturally secreted by activated T cells (van Kooten et al., 
2000) and can induce IL-10 production by B cells (Iwata et al., 2011). As 
shown in figure III-20, soluble CD40L was present in co-cultures with 
CD3/CD28-activated CD4+ T cells. Hence, I propose that soluble CD40L can 
cross the membrane and induce IL-10 production by transitional and IgM 








Figure III-20: Anti-CD3/anti-CD28 stimulated CD4+ T cells release soluble 
CD40L, measured using the Human CD40 Ligand Quantikine ELISA kit 
(R&D) in the transwell supernatant (pg/mL) (n=4). Bars represent median 
values and error bars represent range. 
This research was originally published in Blood. Khoder, A*., Sarvaria, A*., Alsuliman, A., Chew, 
C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., 
Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., 
Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells 
are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in 
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I next tested the contribution of CD80 and CD86 costimulatory signalling to 
the suppressive ability of transitional and IgM memory B cells. Although the 
addition of blocking antibodies against CD80 or CD86 molecules individually 
did not impact on the suppressive activity of IgM memory and transitional B 
cells, addition of blocking antibodies against both molecules together partially 
inhibited the ability of transitional and IgM memory B cells to suppress the 
proliferation of CD4+ T cells (figure III-21). While blockade of IL-10/IL-10R 
and CD80/CD86 individually was not sufficient to completely reverse the 
ability of transitional and IgM memory B cells, a combination of mAbs Blocking 
mAbs against all three molecules completely reversed the inhibitory effect of 
these B cell subsets. (figure III-22). 
 
 
Figure III-21: CD80 and CD86 co receptor signalling and IL-10 are both 
prerequisites for the suppressive effect of Bregs.  
A. Cumulative data representing co-receptor blockade in cultures of purified CD4+ T 
cells and sorted CD19+ B cell subsets, which did not fully reverse the suppressive 
capacity of Bregs as compared to the corresponding positive control B. Bar charts 
compare between the effect of co-receptor blocking and IL-10 blocking in CD4+ T 
cell and B cell co cultures. All bars in (a) and (b) represent median values, and upper 
whiskers indicate the range from 3 independent experiments. *P < 0.05 by 
nonparametric ANOVA; ns, not significant. This research was originally published in Blood. 
Khoder, A., Sarvaria, A., Alsuliman, A., Chew, C., Sekine, T., Cooper, N., Mielke, S., de Lavallade, 
H., Muftuoglu, M., Curbelo, I F., Liu, E., Muraro, P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, 
N., Shaim, H., Yvon, E., Molldrem, J., Rouce, R., Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., 
and Rezvani, K. Regulatory B cells are enriched within the IgM memory and transitional subsets in 
healthy donors but are deficient in chronic GVHD. Blood. 2014; 124(13): 2034-2045. © the 
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Figure III-22: A combination of blocking antibodies to IL-10, IL-10R, CD80 and 
CD86 in the presence or absence of cell-to-cell contact reversed the ability of 
Breg subsets to suppress CD4+ T cell proliferation in vitro  
The bars represent median values and upper whisker of error bars indicate the range from 3 
independent experiments *P < 0.05 by nonparametric ANOVA 
This research was originally published in Blood. Khoder, A., Sarvaria, A., Alsuliman, A., Chew, C., 
Sekine, T., Cooper, N., Mielke, S., de Lavallade, H., Muftuoglu, M., Curbelo, I F., Liu, E., Muraro, 
P.A., Alousi, A., Stringaris, K., Parmar, S., Shah, N., Shaim, H., Yvon, E., Molldrem, J., Rouce, R., 
Champlin, R., McNiece, I., Mauri, C., Shpall, E.J., and Rezvani, K. Regulatory B cells are enriched 
within the IgM memory and transitional subsets in healthy donors but are deficient in chronic 
GVHD. Blood. 2014; 124(13): 2034-2045. © the American Society of Hematology. 
 
However, the suppressive effect of human transitional and IgM Memory B 
cells was independent of CD80 co-interaction with the inhibitory receptor 
CTLA-4 expressed on T cells (figure III-23). Thus, analogous to previous 
studies [Blair et al., 2010], the suppressive effect of human Breg cells is 
mediated by a number of mechanisms including the release of IL-10, cell-to-








Figure III-23: CTLA-4 blocking had no significant impact on the ability of Breg 
subsets to suppress CD4+ T cell proliferation in vitro 
The bars represent median values and upper whisker of error bars represent the range from 3 
independent experiments 
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III.3 Discussion 
The delicate balance between effector T-cell function and immunoregulatory 
networks in tolerance to self- and environmental antigens has been largely 
ascribed to regulatory T cells (Rezvani et al., 2006, Mielke., 2007). Recent 
research has shed light on at least one functional group of PB-derived B cells 
in humans, CD19+CD24hiCD38hi transitional B cells, that appear to exert 
robust immune regulatory capacity (Blair et al., 2010). On the other hand, 
other studies have shown that CD40L-stimulated CD24hiCD27+ memory B 
cells can release IL-10 and exert suppression of monocyte activation and 
cytokine production in vitro; (Iwata et al., 2011, Bouaziz et al., 2010). My 
results support the immunoregulatory function of transitional B cells and 
identify IgM+ memory B cells as a new candidate Breg subset in healthy 
individuals. Both transitional and IgM memory B cells can secrete IL-10 and 
suppress both the proliferation and cytokine production of CD4+ T cells in a 
manner that was comparable with that of Tregs. This suppressive effect was 
also found to be dose dependent. Although I also found the presence of IL-10 
producing B cells within naïve and switched memory B cell subsets, albeit at 
much lower frequencies, they lacked any suppressive effect on CD4+ T cell  
function. This is in agreement with other studies that have also shown lack of 
suppressive activity in naïve B cells (CD27- IgM+) (Blair et al., 2010, Iwata et 
al., 2011). However, as we have no means of purifying exclusively those B 
cells that express IL-10 in sufficient quantities to perform functional studies, it 
is also possible that a number of distinct regulatory B cell subsets may exist. It 
is therefore important to continue looking for more specific markers of IL-10 
producing B cells, given that they might play a significant role in the 
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maintenance of the balance between tolerance and autoimmunity. 
Furthermore, this discovery broadens the proportion of PB-derived regulatory 
B cell subset within circulating total CD19+ B cells from <5% 
(CD19+CD24hiCD38hi transitional cells only) to 20%-30% (transitional plus 
CD19+CD24hiCD38-/loIgM+CD27+ memory B cells), suggesting a prominent 
role for Bregs in the maintenance of immune tolerance. 
The mechanism through which transitional and IgM memory B cell subsets 
suppressed CD4+ T cell proliferation and effector function was partially via the 
provision of IL-10. IL-10 blockade led to partial reversal of CD4+ T-cell 
proliferation in the presence of either IgM memory or transitional B cells, 
which supports the role of IL-10 in mediating the suppressive effect of Bregs. 
However, as this reversal was not complete, these findings suggest that the 
regulatory function of Breg subsets is at least partly IL-10 dependent. 
Recombinant IL-10 has been tried in some autoimmune diseases such as 
Crohn’s disease, rheumatoid arthritis and psoriasis. In the majority of clinical 
trials, systemic administration of recombinant IL-10 was not associated with 
clinical improvement with the exception of psoriasis (Sanz et al., 2008). 
Similarly in my experiments, the addition of exogenous IL-10 to co-cultures of 
naïve or switched memory B cells failed to suppress CD4+ T cells to the same 
extent as seen with transitional and IgM memory B cell subsets, suggesting 
that cellular contact may be required for IL-10 to deliver immune regulation. 
Indeed, transwell experiments and CD80/CD86 blockade confirmed that cell-
to-cell contact was needed for IgM memory and transitional B cells to exert 
their full suppressive activity on CD4+ T cell function. In addition, whereas in 
mice TGF-β has been shown to mediate Breg cell-suppressive activity in 
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experimental diabetes (Tian et al., 2001), in my study transitional and IgM 
memory suppressive capacity was not dependent on TGF-β production.  
Previously published work in murine models has highlighted an important role 
for Bregs in protection against cGVHD (Huu et al., 2013, Weber et al., 2014) 
and a role for IL-10 deficiency in cGVHD pathogenesis (Barak et al., 1995, 
Korholz et al., 1997). In keeping with previous studies, previous work 
performed by Dr. Khoder, a previous member of Dr. Rezvani’s laboratory has 
also provided evidence of a deficiency in IL-10 producing B cells in cGVHD 
patients that were also refractory to CD40 activation (Khoder et al., 2014). 
These findings are in keeping with reports in SLE where Bregs were refractory 
to CD40 engagement, associated with reduced phosphorylation of STAT3 
downstream of CD40 (Blair et al., 2010). Additionally, as a result of the 
impaired IL-10 production, Dr. Khoder in our group (2014) observed a 
significantly lower ratio of IL-10+ B cells to IFN-γ+CD4+ T cells in cGVHD 
patients compared with the control group, which implies an imbalance 
between the regulatory B-cell and effector T-cell compartments, analogous to 
that recognized with Tregs during the development of cGVHD (Yamashita et 
al., 2004). My findings in this chapter may provide support for future 
investigations of regulatory B cell–based therapy to tip the scales in favor of 
immune regulation. It also highlights the need for more specific markers to 
define IL-10 producing B cells, given that they might play a significant role in 
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Chapter IV IL-10 producing regulatory B cells are enriched in cord and 





IV.1  Introduction 
Allogeneic hematopoietic SCT (HSCT) is a potentially curative option for 
many patients with high-risk hematological malignancies (Daikeler et al, 2009, 
Barrett and Battiwala, 2010). However, approximately 70% of patients who 
require an allograft will lack an HLA-identical sibling donor, and many in this 
group will lack a suitably matched unrelated donor (Koh and Chao, 2008). 
 
Human cord blood (CB) is widely used as a source of hematopoietic stem 
cells (HSC) for many patients who lack a fully matched related or unrelated 
donor due to their less stringent requirement for human leukocyte antigen 
(HLA) matching (Beaudette-Zlatanova et al., 2013, Komanduri et al., 2007, 
Stanevsky et al, 2009). Most adult and larger adolescent patients receive two 
CB units matched at ≥4/6 HLA alleles in order to overcome the limited cell 
dose in a single CB graft and to accelerate engraftment (Komanduri et al, 
2007, Stanevsky et al., 2009, Newell et al., 2013). Although an increased 
incidence of acute GVHD after double-unit CBT (DUCBT) compared with 
single CBT has been described (Cutler et al., 2011, Ballen et al, 2013) a lower 
incidence of extensive chronic GVHD has been reported after both single and 
double CBT compared with other stem cell sources, despite broader HLA 
disparity (Beaudette-Zlatanova et al., 2013, Komanduri et al., 2007, 
Stanevsky et al., 2009). 
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Alloreactive reactions between donor-derived CD4+ and CD8+ T lymphocytes 
have typically been considered to be the chief effector cells arbitrating the 
pathogenesis of acute and chronic GVHD (Shimabukuro-Vornhagen et al., 
2009, Rezvani et al., 2006). Several independent lines of evidence clearly 
demonstrate a critical breakdown in peripheral B-cell tolerance and insufficient 
immune regulation after allogeneic HSCT (Kapur et al., 2008, Khoder et al, 
2014). Indeed, evidence of typically activated B cells by increased signaling 
networks through ERK and AKT pathways have been reported in B cells 
isolated from patients with cGVHD (Allen et al., 2012, Sarantopoulos et al., 
2015). IL-10 producing B cells (B10 cells) with regulatory capacity, commonly 
known as regulatory B cells (Bregs) are a newly identified subset of 
suppressor B cells, shown to exhibit inhibitory function on the immune system. 
Mizoguchi and collaborators, first introduced the term “regulatory B cells” in 
2002 (Mizoguchi and Bhan., 2006). Since these seminal observations, a 
considerable body of evidence has conclusively demonstrated the 
significance of IL-10-producing regulatory B cells in divergent models of 
autoimmunity, infection, and cancer (DiLillo et al., 2010, Yang et al., 2013, 
Tedder et al., 2015, He et al., 2014), and more recently cGVHD 
(Sarantopoulos et al., 2015, Khoder et al., 2014., de Masson et al., 2015). To 
date, discrepancies in the cell surface antigens studied and a lack of 
consensual definitions of the Breg subset phenotypes limit the direct 
comparison of human B cell subsets with regulatory function. In murine 
studies, B cells with regulatory function were found within B10 cells, MLN B 
cells, marginal-zone B cells, T2-MZP cells, and Tim-1+ Bregs (Mauri and Blair 
et al., 2014, Blair et al., 2010, He et al., 2014). The phenotype of Breg cells in 
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humans has yet to be fully elucidated. Blair and coworkers (2010) have 
described human Bregs as CD19+CD24hiCD38hi, a phenotype that is usually 
used to define a population of human transitional B cells. Furthermore, recent 
evidence showed human Bregs, identified through IL-10 intracellular staining, 
to be contained within the CD24hiCD27+ B cell subset (de Masson et al., 2015, 
Iwata et al., 2011). 
 
I previously illustrated in Chapter III, that Bregs are enriched within both the 
transitional and IgM memory B cell subsets and mediate T cell suppression in 
an IL-10 dependent, as well as contact-dependent manner (mainly through 
CD80/CD86). Moreover, Khoder et al (2014) showed that Bregs are deficient 
in recipients of HLA-matched sibling or matched unrelated donor HSCT with 
chronic GVHD.  
 
Cord blood is a rich source of transitional B cells. Whereas 
CD19+CD24hiCD38hi transitional B cells represent approximately 4% of 
peripheral blood B cells in healthy adults, they are abundant in cord blood 
(near 50% of B cells), with their frequency progressively decreasing during 
infancy (Sims et al., 2005, Marie-Cardine et al., 2008, Cuss et al., 2006, Ha et 
al., 2008). In contrast to PB, CD24hiCD38− CD27+ memory B-cells are absent 
in CB and only become detectable in the first year of life (Cuss et al., 2006, 
Ha et al., 2008). Thus, I hypothesized that the higher frequencies of B cells 
with regulatory phenotype in CB may contribute to the lower rates of chronic 
GVHD post-CBT. 
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Here, I show that IL-10-producing B cells with Treg-independent 
immunosuppressive properties are enriched in CB. They suppress T cells 
through production of IL-10, as well as by cell-cell contact-mediated 
mechanisms involving CTLA-4. Moreover, we found a robust recovery of IL-
10-producing B cells by 6 months post CBT, with significantly greater 
frequencies than seen in the peripheral of healthy donors or in patients prior 
to CBT. Furthermore, Breg reconstitution in patients with GVHD was 
significantly impaired in comparison to patients without GVHD.  Taken 
together, these studies suggest a protective role for CB-derived B cells in the 
development of cGVHD in CBT recipients and support the development of 
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IV.2  Results 
IV.2.1  Cord Blood B cell Phenotype and subset frequencies 
Phenotypic characterization of CB revealed the presence of two distinct B cell 
populations: CD19+CD38hiCD24hi transitional B cells (a population that 
includes immature B cells) and CD19+CD38intCD24int naïve B cells (primarily 
mature B cells) (figure IV-1). In contrast to the phenotypic analysis described 
for peripheral blood B cells in chapter III, CD24hiCD38− CD27+ memory B-cells 
are almost absent in CB. In keeping with previously published studies, further 
phenotypic characterization confirmed that the majority of 
CD19+CD38hiCD24hi transitional B cells are also IgMhiIgDhiCD10+CD27−, 
whereas CD19+CD38intCD24int naive B cells are IgMintIgD+CD10−CD27− (Sims 
et al., 2005, Marie-Cardine., 2008, Ha et al., 2008, Palanichamy et al., 2009).  
Figure IV-1: Phenotypic characterization of cord blood B cell subsets 
Representative FACS plots illustrating gating strategy on lymphocyte population, total 
CD19+ B cells and CD19+CD38hiCD24hi transitional B cells and CD19+CD38intCD24int 
naive B cells 
 
 
The frequency of CD19+ B cells in healthy cord blood mononuclear cells 
(CBMCs) was 6.0% (3.21%-13.1%); 22.2%(11.42%-28.0%) of total CD19+ B 
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CD38+ naïve and 2.14%(1.38%-3.64%) of CD24hi CD38lo CD27+ memory B 








Figure IV-2: Frequency of B cell subsets in healthy control CBMCs  
Frequency of B cell subsets (n=10) out of total CD19+ B cells in healthy controls was 
determined through flow cytometric analysis of B cells subsets with respect to the 
CD24 and CD38 parameters. The line on the scatter dot plot represents median and 
error bars represent range 
 
I next validated the effect of freezing on the signal intensity and the frequency 
of CD19+ B cell populations against the CD24 and CD38 axis in paired fresh 
and frozen samples (stored at -80°c for a minimum of 8 days) from 10 CB 
units. No significant differences were found in the signal intensities or B cell 
subsets in paired fresh and frozen CBMC CD19+ B cell populations (figure 
IV-3), which validates my panel to study frozen patient samples that have 
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Figure IV-3: Effect of cryopreservation on B cell phenotype for each subset is 
illustrated as bivariate plots representing data acquired from 10 paired fresh 
and frozen samples 
Data was analyzed using a paired t-test for total CD19+ B cells (p=0.9064), transitional B cells 
(p=0.9225) and naïve B cells (p=0.9104) 
 
IV.2.2  Human cord blood is enriched in IL10-producing CD19+ B cells  
IL-10 production has long been considered a defining trait of Breg cells 
(Tedder., 2015, Mauri and Blair., 2014, Iwata et al., 2011). I first determined 
whether freshly isolated CB-derived CD19+ B cells produced IL-10 by 
magnetically purifying CD19+ B cells from CBMCs and co-culturing them with 
either irradiated fibroblasts transfected with CD154 (CD40L cells), CpG or 
BCR ligation for 24, 48 or 72 hours to study the kinetics of IL-10 production as 
described in section II.7.3. Resting B cells were also cultured alone as 
negative control. I found that that CB-derived CD19+ B cells had the capacity 
to produce IL-10 in response to stimulation by BCR ligation, CD40L or CpG in 
a time-dependent manner [figure IV-4A]. Human IL-10+ B cells from 
peripheral blood have been previously shown to be enriched within the 
CD19+CD24hiCD38hi transitional and CD24hiCD27+ and CD19+CD27+IgM+ 
memory cells (Khoder et al., 2014, Blair et al., 2010, Iwata et al., 2011). To 
discover the source of IL-10-producing B cells in CB, I magnetically isolated 
total CD19+ B cells and also sort-purified naïve and transitional B cells from 
healthy CB units and stimulated them with either CD40L, CpG, BCR ligation 
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IL-10 in the culture supernatants measured by ELISA.  Based on the previous 
ELISA results, I chose to stimulate CB-derived B cell subsets for 48 hours, 
which allowed sufficient production of IL-10 detection by ELISA without 
compromising CB B cell viability staining with trypan blue (data not shown). 
Interestingly, stimulation of transitional and naive B cells with a combination of 
CD40 ligation, CpG and BCR engagement resulted in significantly more IL-10 




Figure IV-4: IL-10 production in CB-derived B cells after stimulation with 
CD40L, CpG or BCR ligation  
A. Bar graphs showing cumulative data of IL-10 production from CB-derived CD19+ 
B cells in response to stimulation with CD40L, CpG and BCR ligation in a time 
dependent manner (n=10) B. Cumulative data illustrating IL-10 production from CB 
total CD19+ B cells, and sort purified naïve and transitional B cell subsets after 
stimulation with CD40L, CpG, BCR ligation or a combination of all. Resting B cells 
(un-stimulated) were used in each experiment as a negative control.  
The bars in A and B represent mean and the error bars represent range 
 
I next determined the effect of cryopreservation on IL-10 production by B 
cells. Paired CBMC from the same cord blood units were frozen at -80° C as 
described in II.2.3 for a minimum of 3 weeks. Cryovials were thawed as 
described in II.2.4 and rested for a minimum of 4 hours at 37° C before B cell 
selection was performed (II.4.1). Cells were activated as described previously 
for 48 hours and supernatant was assayed for IL-10 by ELISA. Minimal 
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samples and overall no significant differences were found (figure IV-5). The 









Figure IV-5: Effect of cryopreservation on IL-10 production by total CD19+ B 
cells and sort-purified transitional and naïve B cell subsets activated with 
CD40L, CpG and BCR ligation.  
Data was acquired from 10 paired fresh and frozen samples and analyzed using a 
paired t-test; ns, no significant difference. 
 
These results are in agreement with previous studies that have also described 
transitional B cells as IL-10 producing suppressor cells (Khoder et al., 2014, 
Mauri and Blair., 2014, Blair et al., 2010). However, I also propose a novel 
and previously undescribed attribute of naïve CB B cells as an IL-10 
producing B cell subset. These findings are in contrast to Breg studies in PB, 
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al., 2014). However, my results underscore the regulatory capacity of 
immature transitional B cells (CD19+CD24hiCD38hi), as previously shown by 
our group and others (Khoder et al., 2014, Mauri and Bosma., 2012, Blair et 




IV.2.3  Sort purified naïve and transitional B cells from CB inhibit 
proliferation and pro-inflammatory cytokine production by 
peripheral CD4+ T cells in a dose-dependent manner 
 
To gain further insight into the suppressive capacity of CB-derived IL-10-
producing transitional and naive CB B cells on CD4+ T cell function, I sort-
purified transitional (CD19+CD24hiCD38hi) and naïve (CD19+CD24+CD38+) B 
cell subsets as well as total CD19+ B cells from CB units (n=10) and 
evaluated their suppressive effects on PB CD4+ T cell proliferation and 
cytokine production by flow cytometry as detailed in section II.8.1 and II.8.3 
respectively. The gating strategies and post-sort purity checks are outlined in 
figure IV-6. Results illustrated that following 96-hour of co-culture with 
peripheral CFSE-stained CD4+ T cells (stimulated with anti-CD3/anti-CD28 
beads) at a B cell: T cell ratio of 1:1, total CD19+ B cells as well as both naive 
and transitional B cells significantly suppressed CD4+ T cell proliferation 
[median percent proliferating CD4+ T cells 71.8%; (64.9%-78.9%) and 68.0% 
(63.4%-77.9%) and 64.1% (58.7%-69.2%), respectively], when compared with 
anti-CD3/anti-CD28 stimulated CD4+ T cell alone (positive control) [94.6% 
(86.7%-97.5%] (figure IV-7). These effects were cell dose-dependent, with 
the highest suppression observed at a Breg: CD4+ T cell ratios of 5:1 and 
10:1 for CD19+ total B cells as well as transitional and naïve B cell subsets 
(figure IV-8).  In order to assess the suppressive effect of CB-derived B cells 
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on CD4+ T cell effector function, total CD19+ B cells and sort-purified 
transitional and naïve B cell subsets were co-cultured with anti-CD3/anti-
CD28 stimulated magnetic-bead purified CD4+ T cells. Similarly, I also found 
that CD19+ total B cells and both transitional and naïve B cell subsets 
suppressed IFN-γ, TNF-α and IL-2 production by ex vivo stimulated PB CD4+ 
T-cells in supernatants harvested from B cell/T cell cultures through ELISA 















Figure IV-­‐‑6: Gating strategy and purity checks of CB B cell sorting  
Multi-parametric flow cytometric gating strategy for sorting B cell subsets on BD 
FACS ARIA IIIu. Following lymphocyte gate and cell doublet discrimination, CD19+ B 
cells are then sort-purified based on CD24 and CD38 expression into 2 subsets, 
CD19+CD38hiCD24hi transitional B cells and CD19+CD38intCD24int naïve B cells. 
FACS plots illustrating the high purity of sorted B cell subsets are shown within the 
CD19+ gate 
 








Figure IV-­‐‑7: Cord Blood derived B cell subsets suppress allogeneic CD4+ T cell 
proliferation  
A. Representative dot plots showing the gating strategy of CD4+CFSE+ T cells. 
Gates were made on the lymphocyte population, CD4+ T cells followed by dot plots 
of CD4+CFSE+ T cells. Gate was determined based on CFSE intensity of 
unstimulated CD4+ T cells. B. Magnetically selected and CD3/CD28 activated PB-
CD4+ T cells were labeled with CFSE (eBioscience) and plated either alone (positive 
control – Blue) or at a 1:1 ratio with total CD19+ B cells (green), transitional (yellow) 
or naïve (orange). CFSE-stained T cells cultured with no stimulation (negative 
control –grey) were included in each experiment. Proliferation index values for 
histograms are: CD4+T cells – 2.87, with total CD19+ B cells- 1.94, naïve – 2.23, and 
transitional – 1.79 C. Suppressive effects of CB derived CD19+ B-cell subsets (1:1 
ratio) on CD4+ T cell proliferation index in vitro (n=14).  
In (C) and (D), bars represent median values and upper whiskers indicate the range. 




Figure IV-8: The suppressive effect of CB derived CD19+ B cells and 
transitional and naïve B cell subsets on CD4+ T cell proliferation is dose 
dependent as indicated at the B cell: T cell ratios (n=4) 
Error bars represent mean with standard deviation. 
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Figure IV-9: CB-derived CD19+ B cells and both transitional and naïve B cell 
subsets suppressed IFN-γ, TNF-a and IL-2 production by ex vivo stimulated PB 
CD4+ T-cells in supernatants harvested from cultures of CB-derived B cells or 
Tregs cocultured with CD4+ T cells 
Bars represent median values and upper whisker of error bars represent range from 
6 independent experiments. *P < 0.05 by nonparametric ANOVA. 
 
 
I further compared the suppressive capacity of naive and transitional B cells 
with that of cord blood derived Tregs, defined as CD4+CD25hiCD127- T cells. 
In experiments in which magnetically purified cord blood derived Tregs were 
cocultured with peripheral CD4+ T cells at a 1:1 ratio, and the cultured cells 
stimulated with anti-CD3/anti-CD28 beads, the inhibition of T-cell proliferation 
and IFN-γ, TNF-α and IL-2 production by CB-Bregs was comparable to that 
achieved by Tregs (figure IV-7 and IV-9). Collectively, these results suggest 
that the suppressive capacity of total CD19+ B cells and transitional and naive 
CB-derived B cell subsets on CD4+ T cell proliferation and cytokine 
production is comparable to that of T regulatory cells.  
I next determined whether pre-treatment of CB CD19+ B cells with CpG, 
CD40 and BCR ligation to induce IL-10 production could potentiate their 
suppressive capacity. These results indicate that ‘pre-activated’ CB-derived 
total CD19+ B cells as well as pre-activated sort-purified transitional and naïve 
B cell subsets suppress CD4+ T cell proliferation and cytokine production 




























































Figure IV-­‐‑10: Pre-treatment of CB CD19+ B cells with CpG, CD40 and BCR 
ligation potentiated the suppressive capacity of CB-derived B cells  
A. CD4+ T cell proliferation and B. Effector function, when compared to their non-
induced counterparts. In (A) and (B), bars represent mean and upper whiskers 





IV.2.4  IL-10 contributes to the suppressor function of cord blood derived 
transitional and naïve B cells 
 
To clarify the mechanism(s) by which CB derived naive and transitional B 
cells suppress CD4+ T cell proliferation and effector cytokine function, I 
cultured PB CD4+ T cells alone or at a 1:1 or 5:1 B : T cell ratio with total 
CD19+ B cells or with naïve or transitional B cell subsets purified from CB 
units in the presence or absence of mAbs against IL-10 and IL-10 receptor 
(IL-10R) in 4 independent experiments. IL-10 blockade partially restored the 
proliferation of CD4+ T cells cocultured with the CB-derived total CD19+ B 
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: T cell ratios (figure IV-12). These results indicate that the regulatory 
property of CB-derived Bregs is at least partially IL-10-mediated. Our finding 
that IL-10 blockade could not fully suppress CB-B cell-mediated T cell 
suppression suggests that other mechanisms may be involved in mediating 
the suppressive function of CB-derived regulatory B cells. Consistent with 
these data, I also found that IL-10 blockade did not fully reverse the 
suppressive capacity of either transitional or naïve CB B cell on CD4+ T cell 
cytokine production (figure IV-13), These data further support the 
























Figure IV-­‐‑11: IL-10 blockade partially reversed the suppressive effect of CB 
derived B cells on T cell proliferation and effector function.  
Representative histograms show CFSE-stained anti-CD3/anti-CD28 stimulated 
proliferating CD4+ T cells when cultured alone (positive control) or at a 1:1 ratio with 
CB derived total B cells or sort purified naïve and transitional B cell subsets with and 
without IL-10 blockade. Proliferation index values for histograms without IL-10 
blockade are: CD4+ T cells alone-3.09, with total CD19+ B cells-2.24, naïve-2.10, 
transitional-1.90. Proliferation index values for histograms with IL-10 blockade are: 
CD4+ T cells alone-3.09, with total CD19+B cells-2.55, naïve-2.33, transitional 2.27. 
Data are representative of 4 independent experiments. Bars represent median values 





















































































Figure IV-­‐‑12: IL-10 blockade partially reversed the suppressive effect of CB 
derived B cells at a 5:1 (B cell: T cell) ratio  
Representative histograms show CFSE-stained anti-CD3/anti-CD28 stimulated 
proliferating CD4+ T cells when cultured alone (positive control) or at a 5:1 ratio with 
CB derived total B cells or sort purified naïve and transitional B cell subsets with and 
without IL-10 blockade. Data are representative of 4 independent experiments. Bars 
represent median values and upper whisker of error bar represent range. *P < 0.05 ** 












































































Figure IV-­‐‑13: IL-10 blockade partially reversed the suppressive effect of CB 
derived B cells on CD4+ T cell cytokine production at a 1:1 and 5:1 (B cell: T 
cell) ratio  
Bar graphs represent the suppressive activity of CB-derived total B cells, transitional 
and naïve subsets on anti-CD3/anti-CD28 stimulated CD4+ T cell cytokine 
production when cultured at a 1:1 or 5:1 B cell to T cell ratio in the presence or 
absence of IL-10 blockade. Supernatants were harvested from B cell/T cell co-
cultures and assayed for the presence of IL-2, IFN-y and TNF-a production by 
ELISA. Data is representative of 4 independent experiments. Bars represent median 




Previous reports suggest that the immunoregulatory effects of B regulatory 
cells may be mediated by TGF-β (Blair et al., 2010). To pursue the notion that 
TGF-β might at least partly mediate  the immunoregulatory capacity of CB 
regulatory B cells, I performed additional blocking experiments using TGF-β-
specific mAbs. The failure of TGF-β blockade to alter the suppression of 
CD4+ T cells by either CD19+ total B cells, transitional or naive B cells (figure 
IV-14), indicates that this cytokine lacks any appreciable role in human CB 
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Figure IV-­‐‑14: TGF-β blockade has no significant effect on the suppressive 
function of CB derived Bregs  
Cumulative bar graphs histograms show CFSE-stained anti-CD3/anti-CD28 
stimulated proliferating CD4+ T cells when cultured alone (positive control) or at a 1:1 
or 5:1 ratio with CB derived total B cells or sort purified naïve and transitional B cell 
subsets with and without TGF-β blockade. Data are representative of 4 independent 
experiments. Bars represent median values and whiskers indicate the upper ranges. 
No significant differences were found between B cell subsets with or without TGF-β 
blockade by nonparametric ANOVA. 
 
 
IV.2.5  The suppressive activity of CB Bregs is partially dependent on 
cell-to-cell contact, mediated through CD80/86 and CTLA-4  
 
The suppressive capability of Bregs has previously been shown to be 
mediated by both the secretion of IL-10 and direct contact with CD4+ T cells 
in both murine and human studies (DiLillo et al, 2010, Khoder et al., 2014, 
Mauri and Blair., 2014, Blair et al., 2010). It is unclear, however, whether 
direct cell-cell contact contributes to human CB-derived Breg-mediated T-cell 
suppression. To examine this mechanism, I performed transwell experiments, 
in which CB-derived total CD19+ B cells or sort-purified transitional and naive 
B cell subsets were either in direct contact or separated from anti-CD3/anti-
CD28-stimulated and CFSE-stained PB CD4+ T cells by a permeable 
membrane. The proliferation of CD4+ T cells was measured at 96 hours after 
the culture was initiated. Separation of CB-derived B cells from anti-CD3/anti-
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suppressive effect of these CB-Bregs at a B cell: T cell ratio of 1:1 (figure IV-
15). This suppressive effect was also evident at higher B cell to T cell ratios of 
























Figure IV-­‐‑15: Effect of direct B cell: T cell contact on CD4+ T cell proliferation 
(cocultured at at a 1:1 ratio)  
Representative histograms show CFSE-stained anti-CD3/anti-CD28 stimulated 
proliferating CD4+ T cells when cultured alone (positive control) or in direct cell-cell 
contact or separated using transwells at a ratio of 1 B cell :1 T cell;  we studied CB 
derived total B cells or sort purified naïve and transitional B cell subsets. Bar graphs 
illustrate collective data representative of 4 independent experiments, which compare 
the suppressive activity of CB-derived B cells on T cell proliferation in the presence 
or absence of direct cellular contact. Bars represent median values and upper 




















































































Figure IV-­‐‑16: Effect of direct B cell: T cell contact on CD4+ T cell proliferation 
(cultured at 5:1 ratio) 
Representative histograms show CFSE-stained anti-CD3/anti-CD28 stimulated 
proliferating CD4+ T cells when cultured alone (positive control) or cultured in direct 
cell-cell contact or separated using transwell chambers (transwell) at a ratio of 5 B 
cells :1 T cell; we studied CB derived total B cells or sort purified naïve and 
transitional B cell subsets. Bar graphs illustrate collective data representative of 4 
independent experiments, which compare the suppressive activity of CB-derived B 
cells on T cell proliferation in the presence or absence of direct cellular contact. Bars 
represent median values and upper whisker of error bars represent the range. *P < 
0.05 by nonparametric ANOVA 
 
Similarly, separation of CB-derived total CD19+ B cells and sort-purified 
transitional and naïve subsets from CD4+ T cells by transwell only partially 
reversed their ability to suppress IFN-γ, TNF-α and IL-2 production by ex vivo 
activated PB CD4+ T-cells at both a 1:1 and 5:1 B cell to T cell ratios (figure 
IV-17). Thus, I next asked whether a combination of IL-10 blockade and 
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effect of CB candidate regulatory B cells on CD4+ T-cell proliferation and 
cytokine production. The addition of IL-10/IL-10R blocking mAbs to either 
purified total CB CD19+ B cells or transitional or naive B cells in the transwell 
setting completely abolished the suppressive effect of CB B cells on CD4+ T-








Figure IV-­‐‑17: Effect of cell-to-cell contact on CB B cell-mediated suppression of 
CD4+ T cell cytokine production  
I compared the suppressive activity of CB-derived B cells on T cell cytokine 
production in the presence or absence of direct cellular contact. Anti-CD3/anti-CD28 
stimulated CD4+ T cells were cultured either alone (positive control) or at a 1:1 or 5:1 
cell ratio with CB derived total B cells or sort purified naïve or transitional B cell 
subsets. The B and T cells were either in direct cell contact or separated by transwell 
membrane. Bars represent median values and upper whisker of error bars represent 
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Figure IV-­‐‑18: The suppressive capacity of CB-derived B cells is dependent on 
IL10 and cell-to-cell contact 
Bars represent median values and upper whiskers indicate the range from 3 
independent experiments. No significant differences were found between a 
combination of transwell and IL-10 blockade in B cell:T cell co-cultures vs. positive 
control (anti-CD3/anti-CD28 stimulated CD4+ T cells alone) by nonparametric 





I next examined whether soluble CD40L is the trigger for IL-10 production in 
the transwell setting. I measured the levels of soluble CD40L that is naturally 
secreted by activated T cells (van Kooten and Banchereau., 2000) in the 
supernatant harvested from the transwell cultures by ELISA, to determine 
whether soluble CD40L can induce IL-10 production by B cells (Iwata et al., 
2011). As is shown in figure IV-19, soluble CD40L was present in the 
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that soluble CD40L can cross the membrane and induce IL-10 production by 







Figure IV-19: Anti-CD3/anti-CD28 stimulated CD4+ T cells release soluble 
CD40L, measured using the Human CD40 Ligand Quantikine ELISA kit (R&D) in 
the transwell supernatant (pg/mL). 





Prompted by evidence from both murine and human B-cell experimental 
systems (Chapter III, Khoder et al., 2014., Blair et al., 2010, Mauri et al., 
2010), I next tested the contribution of CD80 and CD86 costimulatory 
signaling to the suppressive capacity of sort-purified CB derived transitional or 
naïve B cell subsets. Although the addition of blocking antibodies against 
CD80 or CD86 molecules individually was not sufficient to reverse the 
suppressive activity of total CD19+ B cells or naïve and transitional B cell 
subsets (figure IV-22), addition of blocking antibodies against both molecules 
partially inhibited the ability of CB B cell subsets to suppress the effector 
function and proliferation of PB CD4+ T cells at both T cell: B cell ratios of 1:1 
and 5:1 (figure IV-20). Thus, the suppressive effect of CB-Breg cells is at 
least partially mediated by CD80/CD86 costimulatory signaling, consistent 
with findings in human and murine experimental models (Khoder et al., 2014, 
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Figure IV-20: CD80 and CD86 co receptor signalling is a prerequisite for the 
suppressive effect of Bregs.  
A. Cumulative data representing CD80 and CD86 co-receptor blockade in cultures of 
purified CFSE-stained proliferating CD4+ T cells and sorted CB-derived CD19+ B cell 
subsets, which partially reversed the suppressive capacity of Bregs on CD4+ T cell 
proliferation as compared to the corresponding positive control at a 1:1 and 5:1 B cell 
to T cell ratios (n=4) B. Bar charts compare the effect of CD80 and CD86 co-receptor 
blocking on CD4+ T cell IFN-γ, TNF-α and IL-2 production at a 1:1 and 5:1 B cell to T 
cell ratios (n=4). Bars represent median values and upper whisker of error bars 
represent the range. *P < 0.05 by nonparametric ANOVA 
 
 
Previous evidence has illustrated that CD80/CD86 molecules co-interact with 
the CTLA-4 inhibitory receptor on T cells. (Minguela et al., 2000, Jago et al., 
2004). I next determined whether the suppressive effect of CB derived 
regulatory B cells was dependent on CD80 and CD86 co-interaction with 
CTLA-4. Addition of blocking antibody against CTLA-4 significantly inhibited 
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proliferation of peripheral CD4+ T cells at both T cell: B cell ratios of 1:1 and 
5:1  (figure IV-21). However, this reversal was not complete when compared 
to CD4+ T cell alone (positive control). Consequently, the reversal of CB-
derived regulatory B cell suppression by CTLA-4 blockade was further 
enhanced when combined with CD80/CD86 blockade (figure IV-22). These 
results provide evidence for an important interaction between CD80/CD86 on 
CB-derived Bregs and CTLA-4 on CD4+ T cells in Breg mediated T cell 
suppression. While the blockade of IL-10, CD80/CD86 and CTLA-4 
individually was not sufficient to completely reverse the suppressive capacity 
of CB-derived transitional and naïve B cells, this endpoint was achieved with a 

















































Figure IV-21: CTLA-4 blockade significantly inhibited the ability of CB B cell 
subsets to suppress the effector function and proliferation of peripheral CD4+ 
T cells at both 1:1 and 5:1 ratios  
A. Cumulative data representing CTLA-4 blockade in cultures of purified CFSE-
stained proliferating CD4+ T cells and sorted CB-derived CD19+ B cell subsets, 
which partially reversed the suppressive capacity of Bregs on CD4+ T cell 
proliferation as compared to the corresponding positive control at a 1:1 and 5:1 B cell 
to T cell ratio (n=4) B. Bar charts compare the effect of CTLA-4 blocking on CD4+ T 
cell IFN-γ, TNF-α and IL-2 production at a 1:1 and 5:1 B cell to T cell ratio. Bars 
represent median and whiskers indicate the range from 4 independent experiments. 
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Figure IV-22: A combination of blocking antibodies to IL-10, CTLA-4, CD80 and 
CD86 fully reversed the ability of CB-Breg subsets to suppress CD4+ T cell 
proliferation in vitro 
Bars represent median values and upper whiskers of error bars represent the range 
from 3 independent experiments. 
 
 
IV.2.6  Depletion of Treg cells does not influence the suppressive ability 
of transitional and naïve CB B cells  
 
To test whether the in vitro suppressive effects of IL-10 producing CB derived 
transitional and naive B cells are partly mediated by Treg cells, I depleted 
CD4+ T cells of CD127- CD25hi Tregs by using magnetic bead cell purification 
as described in section II.4.2.2. CB-derived total CD19+ B cells and naive and 
transitional CB B cell subsets were cultured with anti-CD3/ anti-CD28-
stimulated and CFSE-stained Treg-depleted CD4+ T cells at a T cell: B cell 
ratio of 1:1 and 5:1. Both subsets and total CD19+ B cells significantly 
suppressed the proliferation of Treg-depleted CD4+ T cells when compared 
















































































































































Figure IV-23: Depletion of Treg cells does not influence the suppressive ability 
of transitional and naïve CB B cells 
Bars represent median values and upper whisker of error bars represent the range 
from 3 independent experiments. *P < 0.05 by nonparametric ANOVA 
 
 
IV.2.7  Regulatory B cells in cord blood may account for lower rates of 
GVHD after CBT 
 
Rapid B-cell recovery following allo-HSCT has been reported to correlate with 
lower rates in cGVHD (Beaudette-Zlantanova et al, 2013, Shimabukuro-
Vornhagen et al., 2009, Sarantopoulos et al., 2015). Thus, given the ability of 
CB derived CD19+ B cell subsets to control CD4+ T cell function, and the low 
incidence of severe cGVHD in CB recipients (Beaudette-Zlantanova et al, 
2013, Komanduri et al., 2007, Stanevsky et al., 2009), I hypothesized that the 
higher frequencies of B cells with regulatory properties in CB grafts may 
contribute to the lower rate of GVHD post-CBT. 
To test this hypothesis, I first determined the frequency and proportion of total 
CD19+ B cells in sequential blood samples collected   pre-transplant and at 
intervals of 90 days for up to 1 - 2 years post-CBT (Table IV-1). Total CD19+ 
B cells from healthy cord blood units were also analyzed as the control group. 
CD19+ B cells could be detected at low frequencies as early as 1-month post-
CBT, and increased in frequencies and absolute numbers per µL of CD19+ B 
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which the B cell population progressively decreased. By 1-year post-CBT 
there were no significant differences in the frequency and numbers of 
circulating B cells in CBT recipients, CB units and healthy donor PB.  
 
To further determine the kinetics of IL-10 producing Breg recovery after CBT, I 
next determined the relative frequencies of IL-10+CD19+ B cells in PB 
samples collected from 17 post CBT recipients before and at intervals of 90 
days for up to 1 year post CBT and at 2 years. In the first 1-3 months post 
CBT  B cells activated through CD40L followed by PMA+ionomycin 
stimulation had low IL-10 production; however, by 3-9 months post CBT there 
was a significant increase in the ability of B cells to produce IL-10, with high 
frequencies and absolute numbers of CD19+IL-10+ B cells (figure IV-25). 
During these months, the frequency of CD19+IL-10+ B cells was significantly 
higher than the frequency of IL-10 producing B cells found in the PB of 
healthy individuals or fresh cord blood (figure IV-26), but progressively 
reduced after 9 months post transplant, to levels comparable to that of healthy 
individuals. The early and robust reconstitution of both CD19+ B cells and the 
IL-10+ B cell pool post CBT supports an important role for donor CB-B cells in 
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   N=17	  Age	  in	  years	  Median	  (range)	   42	  (21-­‐64)	  	  
Sex	   	  Females,	  n	  (%)	  Males,	  n	  (%)	   12	  (70.6)	  5	  (29.4)	  
Race,	  n	  (%)	   	  White	   11	  (64.7)	  Black	   2	  (11.8)	  Hispanic	   3	  (17.6)	  Asian	   1	  (5.9)	  
HLA	  matching,	  n	  (%)	   	  4+4	   11	  (64.7)	  4+5	   2	  (11.8)	  5+5	   2	  (11.8)	  
Conditioning	   	  Flu/Cy/TBI	   5	  	  (29.4)	  Flu/Mel/Thio	   9	  (52.9)	  Flu/Mel140	   2	  (11.8)	  Bu/Flu/Clo/TBI	   1	  (5.9)	  
Diagnosis,	  n	  (%)	   	  Primary	  AML	   9	  (52.9)	  Secondary	  AML	   3	  (17.6)	  CML	   2	  (11.8)	  CLL/NHL	   3	  (17.6)	  
Cytogenetics,	  n	  (%)	  	   	  Favorable	   	  1(5.9)	  Intermediate	   8	  (47.1)	  Unfavorable	   8	  (47.1)	  
Disease	  Status	  at	  transplant,	  n	  
(%)	  
	  CR1	   8	  (47.1)	  CR2/CR3	   4	  (35.3)	  Active	  Disease	   3	  (17.6)	  
ALC	  (k/µL)	  Median,	  range	  
Day	  30	  ALC,(x	  106/L)	  Median(range)	   0.87	  (0.20	  –	  5.28)	  406	  (70-­‐931)	  Acute	  GVHD,	  n	  (%)	   8	  (47.1)	  Chronic	  GVHD,	  n	  (%)	   7	  (41.2)	  Relapse,	  n	  (%)	   5	  (29.4)	  
PFS,	  days	  Mean,	  (95%	  CI)	   1578.3	  (1139.4-­‐2017.3)	  
Overall	  Survival,	  days	  Mean,	  (95%	  CI)	   1606	  (1131.7-­‐2080.4)	  
Follow-­‐up,	  median	  (range),	  days	   1219	  (165-­‐2283)	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Figure IV-24: B cells from CBT recipients exhibit an early and robust 
reconstitution of CD19+ B cells  
Total CD19+ B cell counts and frequencies were analyzed in sequential blood 
samples collected from CBT recipients and were significantly elevated in CB 
recipients at 3-9 months post transplant. The figures represent mean values and 
















Figure IV-25: B cells from Cord Blood transplant recipients exhibit an early and 
robust reconstitution of IL-10 B cell pool  
Thawed CBMC were used to isolate total CD19+ B cells and cultured with CD40L for 
48 hours. A. The relative frequencies and secretion (pg/ml) of IL10+CD19+ B cells in 
17 post CBT patients were significantly elevated B. The absolute counts of 
IL10+CD19+ B cells in CBT recipients were elevated at 3-9 months post transplant. 
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Figure IV-26: Bar graph compares IL-10 secretion in supernatants of activated 
total CD19+ B cells in healthy PB, healthy cord blood units and patients 6 
month post CBT assayed by IL-10 ELISA.  





I next examined the frequencies and absolute numbers of recovering CD19+ 
B cells and CD19+IL-10+ B cells at multiple time-points post CBT in patients 
who developed GVHD [acute (n=8) and chronic (n=7)] (n=9) compared to 
patients without GVHD (n=8) to further elucidate the protective role for CB- 
derived donor Breg in GVHD after CBT.  
Patients with GVHD had significantly lower frequencies and absolute counts 
(per µl) of CD19+ B cells in the first 3-9 months post CBT compared to 
patients without GVHD (figure IV-27).  Similarly, CBT recipients with GVHD 
had lower frequencies and absolute numbers of IL-10 producing-CD19+ B 
cells compared to those without cGVHD (figure IV-28). Our results are in line 
with previous studies that have also reported lower IL-10 producing Bregs in 
patients with GVHD than in healthy donors after allo-HSCT (Rowe et al., 
2006, Khoder et al., 2014, Weber et al., 2014). No significant differences were 
observed in the transitional and naïve B cell compartments in patient with or 
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Our data support our hypothesis that the robust recovery of B cells with 
regulatory properties in CB grafts observed during the first 3-9 months post 
CBT may contribute to the low incidence of GVHD post-CBT. Collectively, 
these data suggest a novel and protective role for IL-10 producing Bregs in 
the regulation of human cGVHD after CBT. 
 
Figure IV-27: CD19+ B cell frequencies and absolute counts per µl in patients 
with GVHD. Patients with cGVHD (n=9) had significantly decreased CD19+ B 
cell reconstitution when compared to patients who did not develop cGVHD 
(n=8)  
The figures represent mean values and errors bars represent range. *P < 0.05 and ** 




Figure IV-28: CD19+IL-10+ B cell frequencies and absolute numbers in patients 
with GVHD. Patients with cGVHD (n=9) had significantly decreased CD19+IL-
10+ Breg cell reconstitution when compared to patients who not develop 
cGVHD (n=8)  
The figures represent mean values and errors bars represent range. *P < 0.05 and ** 
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To further confirm that the recovering B cells after CBT have regulatory 
capacity, CD19+ B cells were magnetically isolated from sequential PB 
samples collected and cryopreserved from post CBT recipients (as described 
above) and cultured with anti-CD3/anti-CD28-activated allogeneic 
CFSE+CD4+ T cells from healthy individuals for 96 hours. B cells from 
patients at 6 and 9 months had a significantly greater suppressive capacity on 
CD4+ T cell proliferation when compared to fresh cord blood B cells (figure 
IV-29). My result indicate the presence of an expanded population of IL-10 
producing regulatory CD19+ B cells at 6-9 months, which posses greater 
suppressive function on T cell proliferation, supporting an important role for 

















Figure IV-29: Expanded population of IL-10 producing regulatory CD19+ B cells 
posses greater suppressive function on T cells as compared to healthy cord 
blood B cells.  
Magnetically isolated CD19+ B cells from post CBT patients collected at varying time 
points after CBT were cultured with anti-CD3/anti-CD28-activated CFSE+CD4+ T 
cells from healthy individuals for 96 hours at a 1:1 B cell: T cell ratio. Cells were 
harvested and stained for CD4+ CFSE+ proliferating T cells. The bars represent 
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IV.3  Discussion 
Regulation of the delicate balance between effector T cell activities against 
invading pathogens and the tolerance of self- and environmental antigens has 
been largely ascribed to regulatory T (Treg) cells (Rezvani et al., 2006).  The 
pathophysiology of GVHD involves impaired regulatory mechanisms of 
tolerance between recipient tissues and donor-derived immunity (Blazar et al., 
2012). Our understanding of the function of Bregs in this disease is limited. 
Recent research has described a functional group of IL-10 producing 
CD19+CD24hiCD38hi transitional B cells in human PB that possess immune 
regulatory capacity (Blair et al., 2010, Khoder et al., 2014). Conversely, other 
studies have identified human IL-10 producing B cells to be contained mainly 
within the CD24hiCD27+ memory B cell compartment (de Masson et al., 2015, 
Iwata et al., 2011). In addition to these studies, Khoder et al reconciled the 
results of previous studies and demonstrated that regulatory subsets of IL-10-
secreting CD19+IgM+CD27+ memory B cells coexist with IL-
10+CD24hiCD38hi transitional B cells in healthy human donors and play a role 
in protection against cGVHD after HSCT (Khoder et al., 2014).  
 
Recently published work has also established the presence of 
CD19+CD38hiCD24hi immature transitional B cells that are abundant in human 
cord blood (Ha et al,. 2008, Cuss et al., 2006). Here, we underscore the 
regulatory capacity of CB-derived immature transitional B cells, and identify 
naïve B cells as new candidate Breg subset that can be identified in CB. I 
propose that within the CB-CD19+ B cell pool there exist 2 distinct subsets; 
CD19+CD38hiCD24hi transitional B cells and CD19+CD38intCD24int naïve B 
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cells, both of which are functionally regulatory. My results signify the 
suppressive capacity of CB-derived Bregs on peripheral CD4+ T cell 
proliferation and effector function.  
 
Despite several phenotypic and functional similarities between human PB- 
and CB-derived Bregs, (Cuss et al., 2006, Marie-Cardine et al., 2008),  our 
study revealed a number of key differences. In contrast to previous studies 
that ascribed regulatory capacity to PB-derived CD24hiCD27+ or CD27+IgM+ 
memory cells (Khoder et al., 2014, Iwata et al., 2011), memory B-cells are 
absent in CB (Ha et al., 2008). Further, unlike PB-naïve B cells that failed to 
suppress CD4+ T cells (Khoder et al., 2014), our discovery presents a novel 
suppressive role for naïve B cells in CB and broadens the proportion of Bregs 
in CB, suggesting a prominent role for these functional CB-derived B cells in 
the maintenance of immune tolerance.  
 
My data further demonstrate that the suppressive capacity of CB-Breg was 
augmented in the presence of pre-activated B cells co-cultured with CD4+T 
cells, suggesting that in human PB, Breg designation may not be limited to the 
memory and transitional B cell subsets described previously and it is likely 
that discrete subsets of naïve and switched memory B cells could also be 
induced to exert regulatory function in response to CD40-ligand signaling 
provided by activated T cells, analogous to reports of inducible Tregs during 
inflammation (Feuerer et al., 2009).  
Similar to previous reports of PB-Bregs, the mechanism by which CB-derived 
total CD19+ B cells and naïve and transitional B cell subsets suppress CD4+T 
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cell function was mediated synergistically through IL-10 production and cell-
to-cell contact (Blair et al., 2010, Khoder et al., 2014). IL-10 blockade partially 
reversed CD4+ T cell proliferation and effector cytokine secretion in the 
presence of total CD19+, naïve or transitional B cells. In contrast to reports in 
murine Breg studies (Mizoguchi and Bhan., 2006, Mauri and Bosma et al., 
2012), I did not find a significant role for TGF-β in CB B cell-mediated T cell 
suppression. However, exogenous addition of IL-10 to CD4+ T cells alone 
failed to induce significant CD4+ T cell suppression, supporting the existence 
of additional mechanisms of CB-B cell-mediated T cell suppression.  
Additional mechanistic studies using transwell and CD80/86 blockade 
confirmed that CD80 and CD86 interactions between B cells and CD4+ T cells 
work synergistically with IL-10 production for Bregs to exert their full 
suppressive effect on CD4+ T cell function. Our findings are in agreement with 
previous studies with human PB Bregs that describe the involvement of CD80 
and CD86 as an important feature of their suppressive capacity (Blair et al., 
2010, Khoder et al., 2014) and with murine studies of intestinal inflammation 
where CD86 especially has been noted to facilitate B cell suppression (Mann 
et al., 2007, Mizoguchi et al., 2000). Conversely, the involvement of CD80 and 
CD86 co-interaction with CTLA-4 on T cells in CB-Breg-mediated T cell 
suppression is in contrast to findings with PB-Breg, where their suppressive 
activity was found to be independent of CTLA-4 (Khoder et al. 2014). 
However, a similar mechanism is employed by CD80 expressed on DCs, 
which acts preferentially as a ligand for CTLA-4 and mediates Treg cell 
suppression (Zheng et al., 2004). The differences in CTLA-4 mediated 
suppressive mechanisms between CB-B cells and PB-B cells found in my 
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study may be attributed to different compositions of B cells subsets, as CB 
cells are largely composed of naïve cells that may be more susceptible to 
CTLA-4 blocking than PB-B cells. 
Additionally, while the blockade of IL-10/IL-10R, CD80/CD86 and CTLA-4 
individually was not sufficient to fully reverse the suppressive activity of CB-
Bregs, this endpoint was achieved with a combination of mAbs against all 
molecules mediating the prevention of IL-10 and cell-cell contact. 
 
The role of Bregs in cord blood transplantation and GVHD has not been 
previously studied. Several studies have reported that immune reconstitution 
after CBT is characterized by an expansion in B cells during the first year post 
transplant (Komanduri et al., 2007, Nakatani et al., 2014, Beaudette-
Zlatanova et al., 2013, Saliba et al., 2015, Lucchini et al., 2015). 
 
Here, I report on B cell reconstitution in 17 CBT recipients; B cells could be 
detected at low frequencies as early as 1-month post-CBT, where the majority 
of B cells had a CD24high CD38high transitional profile. Further I observed 
expanded frequencies and absolute numbers of CD19+ B cell populations 
between 3-9 months, after which the B cell population progressively 
decreased. By 1-year post CBT there were no significant differences in the 
frequency and numbers of circulating B cells in CBT recipients and healthy 
donors.  My data further illustrate a similar pattern in the kinetics of IL-10 
producing CD19+ B cell reconstitution after CBT.  
I further demonstrated that CBT recipients that developed GVHD (acute n=8 
and chronic n=7) had a reduced CD19+ B cell recovery when compared to 
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CBT recipients that did not develop GVHD (n=8). In addition, CD19+ B cells 
isolated from CBT recipients with GVHD were refractory to stimulation and 
had significantly impaired reconstitution of CD19+IL-10+ B cells 3-9 months 
after CBT when compared to patients without GVHD. These results are in 
accord with similar studies that have also found low frequencies of IL-10 
producing B cells in cGVHD patients following AHSCT when compared to 
AHSCT recipients without cGVHD (Rowe et al., 2006, Khoder et al., 2014, 
Weber et al., 2014). Collectively, these results postulate that the early 
recovery of B cells post-CBT may define a protective role for Bregs in GVHD 
setting. However, limiting factors associated with the heterogeneous patient 
group of CBT recipients, in terms of disease background, conditioning 
regimen, cytogenetics that differ amongst the patient cohort, may affect the 
data derived and require further consideration. 
However, at present we have no means of purifying exclusively those B cells 
that express IL-10 in sufficient quantities for functional studies. Thus, given 
the potential role of Bregs in the maintenance of the balance between 
tolerance and autoimmunity, it imperative to search for a unique Breg 
signature for the identification of IL-10-producing B cells with 
immunoregulatory capacity. 
 
This study defines a novel role for CB derived donor Bregs in protection 
against cGVHD, and support the development of strategies to evaluate novel 
B-cell directed therapies for the prevention or treatment of cGVHD, 
specifically targeting B cell reconstitution and function after transplant. Hence, 
strategies to selectively target B effector cells following B-cell depletion 
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therapy whilst preferentially sparing regulatory B cells are required. Thus, to 
counterbalance immune regulation and induce protection against GVHD, so 
that GVHD is either prevented or attenuated, infusion of donor-derived Bregs 
early in the patient’s post-transplant regime may be an attractive approach. 
The potential of in-vitro expanded CB-derived IL-10 producing Bregs as an 
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Chapter V.  Control of NK functions by Human IL-10 producing 
CD19+CD24hiCD38hi Transitional and CD19+CD27+IgM+ 




In recent years, IL-10-producing B cells, a distinct newly recognized subset of 
B regulatory (Breg) cells that maintain immune tolerance and are critical in 
host suppression of autoimmune diseases have been the focus of intense 
research in immunology (Mauri et al., 2013). Breg cells have been shown to 
exert significant immunoregulatory functions both in vitro and in vivo (Qian et 
al., 2012) through the production of the immunosuppressive cytokine 
interleukin IL-10 and TGF-beta (Mauri et al., 2013), and appear to play 
important roles in autoimmunity and in cancer (DiLillo et al., 2010, Bouaziz et 
al., 2008).  
The identification of suppressor B cells that could down-regulate the immune 
response, originated in 1974 however, the term ‘regulatory B cells’, was first 
introduced by Mizoguchi and Bhan nearly 30 years later (Mizoguchi et al., 
2006, Yang et al., 2013). Despite the extensive body of evidence 
accumulating in the ensuing years since these studies were published, 
reinforcing the notion of B cells as potential regulatory cells, some controversy 
over the paucity of markers that can unequivocally identify Bregs, particularly 
in humans, still exists. Blair and colleagues (2010) have elegantly described 
human Bregs as CD19+CD24hiCD38hi, a phenotype that typically delineates 
human transitional B cells. Conversely, Iwata et al (2011) described human 
IL-10 producing B cells to be contained mainly within the CD24hiCD27+ 
memory B cell compartment.  
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In addition to these studies, recently published data from my work (Khoder et 
al., 2014), syndicates previous studies and shows that IL-10-secreting 
CD19+IgM+CD27+ memory B cells coexist with IL-10+CD24hiCD38hi 
transitional B cells in healthy human donors and significantly suppressed the 
proliferation and cytokine production of anti-CD3/anti-CD28-stimulated 
autologous CD4+ T cells through both IL-10-dependant and cell-to-cell 
contact mediated mechanisms (Chapter III).  Khoder et al (2014) further 
highlighted that IL-10 producing B cells are deficient in patients with chronic 
graft-versus-host disease (cGVHD), supporting their role in the pathogenesis 
of cGVHD. 
 
A new wave of research provides evidence that Bregs may play a role in 
cancer progression. A first indication that B cells and antibodies could be 
tumor-promoting came from studies conducted almost 60 years ago. In these 
early works, Kaliss (1958) found that transfer of tumor-specific antibodies 
augmented growth of transplanted tumor cells, whereas absence of B cells 
limited tumor formation (Brodt and Gordon, 1982). In addition, recent animal 
studies have demonstrated that Bregs support tumor growth in mouse models 
of malignancies though IL-10-mediated suppression of effective anti-tumor T 
cell responses (Visser et al, 2005., Inoue et al, 2006, Horikawa et al., 2011., 
Shao et al., 2014) . Further, Dililio et al (2013) has also highlighted IL-10-
producing B cells to be expanded in patients with chronic lymphocytic 
leukemia (CLL), suggesting that Bregs might support cancer progression in 
humans. Despite mounting evidence supporting a role for Breg cells in 
promoting tumor growth through inhibition of T cell proliferation and effector 
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function, there are currently no data on the interaction of Bregs with other 
immune effectors important in tumor-immune surveillance such as natural 
killer (NK) cells. 
 
NK cells are important components of the innate immune system and play an 
important role in tumor immune surveillance (O’Hanlon, 2004, Ljunggren and 
Malmberg, 2007, Waldhauer and Steinle, 2008). NK effector function is 
dictated by the integration of signals received through germ-line-encoded 
receptors that can recognize ligands on their cellular targets. Functionally, NK 
cell receptors are classified as activating or inhibitory (Ljunggren and 
Malmberg, 2007). In cancer patients, NK cell activation can be hampered by 
downregulation of major histocompatibility complex (MHC) class I molecules 
on target cells (missing self theory) (Smyth et al, 2002, Ljunggren and Karre, 
1990) and/or upregulation of proteins such as NKG2D ligands on ‘distressed’ 
cells (induced self theory) (Vivier et al, 2008), but Giringhelli et al (2005) 
suggested that other mechanisms may also play a role in blunting NK cell 
responses against cancer. Indeed, increased frequencies of regulatory T cells 
(Tregs) have been shown to correlate with cancer progression and hamper 
NK cell function (Ghirenghelli et al, 2005, Pedrozo-Pacheo et al, 2013).   
Recent studies have shed light on the existence of NK-B cell bidirectional 
cross-talk, through the interaction of CD48 on B cells with, 2B4, on NK cells 
(Yuan et al, 2010., Gao et al, 2006., Gao et al, 2005, Lee et al, 2006). NK 
cells can influence the ability of B cells to secrete antibodies, to present 
antigens to T cells and activate switch recombination while pre-activated B 
cells in turn upregulate IFN-y production by NK cells (Gao et al., 2006 and 
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Yuan et al, 1992).  Signaling lymphocyte activation molecule–associated 
protein (SAP) is essential for the activating function of 2B4 and signalling, and 
can bind to all 4 immuno-receptor tyrosine-based switch motifs (ITSMs) of 
2B4 (Assarsson et al, 2005., Stark and Watzl, 2006). Phosphorylated ITSM 
can also recruit the inhibitory phosphatases SHP-1, SHP-2 and SHIP 
(Assarsson et al, 2005). SAP can inhibit the interaction between 2B4 and 
these inhibitory signalling molecules and in its absence, 2B4 can bind to the 
negative signaling molecules and mediate an inhibitory signal (Eissman et al, 
2005 and Endt et al., 2007). Therefore 2B4 can also function as an inhibitory 
receptor when engaged by CD48-expressing cells or tumor targets (Lee et al., 
2006).  
 
Here I report that IgM memory (CD19+IgM+CD27+) and transitional 
(CD19+CD24hiCD38hi) regulatory B-cell subsets from human PB suppress 
NK cell effector function and proliferation. This suppressive effect was 
mediated by predominantly cell-cell contact mediated through 2B4-CD48 
signaling. Moreover, I demonstrate that the same populations of B cells are 
expanded in the PB of patients with AML and exert potent suppression of NK 
effector function and proliferation. My findings have important clinical 
implications, as they suggest that Bregs may impact effector anti-tumor NK 
cell responses in AML and other cancers and support strategies to target 
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V.2 Results 
V.2.1 Human IL-10 producing CD19+CD24hiCD38hi transitional and   
CD19+CD27+IgM+ memory cells suppress NK cell cytotoxic 
function 
 
The pathological relevance of the Treg-NK cell interaction has been shown in 
a number of tumor models (Smyth et al., 2006) and in patients with cancer 
(Pedrozo-Pacheo et al., 2013, Ralainirina et al., 2007) however the interaction 
between Bregs and NK cells is unknown. Khoder et al (2014) has recently 
reported that IL-10 producing B cells are enriched within the 
CD19+CD24+CD38+ transitional and CD19+IgM+CD27+ memory B cell 
subsets (Chapter III) and possess regulatory properties through inhibition of 
CD4+T cell proliferation and effector function. To determine if Bregs also 
suppress NK function, I sort-purified IgM memory B cells  (CD19+CD24–
CD38hiIgM+), switched memory B cells (CD19+CD24-CD38hiIgM-), naïve B 
cells (CD19+CD24+CD38+), and transitional B cells (CD19+CD24hiCD38hi) as 
described previously (section II.5) from the PB of healthy donors and co-
cultured them at a 1:1 ratio with magnetically purified autologous CD56+CD3- 
NK cells (section II.4.3) for 48 hours, in the presence of IL-15 (15ng/ml). The 
gating strategies and post-sort purity checks of B cell subsets are shown 
in figure III-10. Effector function of NK cells co-cultured with B cell subsets 
was assessed against K562 target cells by measuring the frequencies of 
degranulated (CD107a+) CD56+ NK cells as a marker of cytotoxicity and 
TNF-α and IFN-γ producing CD56+ cells by flow cytometry as described in 
section II.9.2. Transitional and IgM memory B cells suppressed CD107a 
degranulation, and expression of IFN-γ and TNF-α by NK cells in response to 
K562 targets compared to CD56+CD3-NK cells cultured alone. In contrast, 
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naïve and switched memory B cells had no significant effect on the NK 
effector function (figureV-1). The inhibitory effect of transitional and IgM 
memory B cells on NK effector function was cell dose dependent with the 
highest suppression observed at a ratio of 5:1. (figure V-2).  We further found 
that Bregs can suppress the effector function of autologous and allogeneic NK 



















































Figure V-1: Transitional and IgM memory B cells suppress NK effector function  
Sort purified B cell subsets were co-cultured with selected NK cells at a 1:1 ratio in 
the presence of K562 target cells. A. Gating strategy illustrating gated lymphocyte 
population, live cell gate and CD56+ NK cells B. Representative FACS plots 
illustrating the inhibitory effect of both transitional and IgM memory B cell subsets 
that significantly suppressed the frequencies of CD107a degranulation, TNF-α and 
IFN-γ producing CD56+ cells. Naïve and switched memory B cells had no significant 
effect on the NK effector function C. Cumulative data summarizing the suppressive 
effect of Breg subsets on NK effector function (n=14). Bars represent median values 
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Figure V-2: The suppressive effect of transitional and IgM memory B cells on 
NK effector function was cell dose dependent (n=4) 


































Figure V-3: The suppressive effect of transitional and IgM memory B cells on 
NK effector function was comparable on both autologous (Auto) and allogeneic 
(Allo) NK cells n=4 
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Granzyme B and perforin are important for the ability of NK cells to kill their 
targets (Ralainirina et al., 2007). Transitional and IgM memory B cells 
significantly suppressed perforin production by NK cells, when compared with 
NK cells alone (figure V-4A).  Interestingly, only transitional B cells could 
suppress granzyme B production by NK cells in response to K562 targets 
(figure V-4B). 
The suppressive ability of transitional and IgM memory B cells on NK 
cytotoxicity was further confirmed using chromium (51Cr) release assay, 
which measures target cell lysis (Shah et al., 2013).  The cytotoxicity of NK 
cell co-cultured with transitional and IgM memory B cell subsets against K562 
cells was significantly lower than NK cells co-incubated with naïve and 
switched subsets or NK cells cultured alone (representative from n=14 
experiments) (figure V-4C). 
We then compared the suppressive capacity of transitional and IgM memory 
B cells with that of regulatory T cells (Treg), defined as CD25hi CD127- CD4 T 
cells.  
 
Magnetically purified Treg were co-cultured with autologous NK cells at 1:1 
ratio in 4 independent experiments and cultured cells were stimulated with 
target K562 cells as described previously. The suppression of NK effector 
function and cytotoxicity by Tregs, and transitional and IgM memory B cells 
was comparable, (Figure V-5), indicating that transitional and IgM memory B 





















Figure V-4: Transitional and IgM memory B cells suppress NK cytotoxicity 
Cumulative data representing the suppressive effect of Bregs A. on NK perforin 
production (n=3). Bars represent median values and upper whisker of error bars 
represent the range B. granzyme B production (n=3). Bars represent median values 
and upper whisker of error bars represent the range and C Chromium release 
(n=14). This figure reports median values and error bars indicate interquartile ranges.  







Figure V-5: The suppressive effect of transitional and IgM memory B cells on 
NK effector function was comparable to Tregs (n=4) 
Bars represent median values and upper whisker of error bars represent the range. 
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V.2.2 Transitional and IgM memory B cells suppress proliferation of 
CD56+CD3- NK cells 
 
IL-10 producing B regulatory cells have been shown to sharply suppress T 
cell proliferation (Khoder et al., 2014). To assess whether IL-10 enriched 
transitional and IgM memory B cell subsets exert a similar inhibitory effect on 
NK cell proliferation, I cultured magnetically purified allogeneic CFSE labelled 
NK cells alone or with sort purified B cell subsets in the presence of 
exogenous IL-2 (500U/ml) for 8 days (n=12) at a ratio of 1:1 as described in 
II.9.1. Transitional and IgM memory B cells suppressed NK cell proliferation 
[median percentages of proliferating NK cells, 40.5% (31.6-62.7%) and 48.6% 
(38.5-58.5%), respectively], when compared with NK cells cultured alone 
[median percentage of proliferating NK cells, 79.2% (69.8-89.1%)], or cultured 
with naïve nor switched memory B subsets (figure V-6).  I further compared 
the suppressive capacity of IgM memory and transitional B cells on NK 
proliferation with that of Tregs. At a 1:1 ratio, the inhibition of NK-cell 
proliferation by transitional IgM memory B cells was comparable to that of 
Tregs (figure V-6). Together, these results show that transitional and IgM 
memory B cells share with Tregs a robust capacity to suppress proliferation of 
NK cells. Transitional and IgM memory B cells suppressed NK cell 
proliferation in a dose-dependent manner, with near complete abrogation of 
NK cell proliferation at a ratio of 10 B cells: 1 NK cells (figure V-7). 
 
 












Figure V-6: Transitional and IgM memory B cells suppress NK proliferation  
Sort purified B cell subsets were co-cultured with magnetically selected and CFSE 
stained NK cells at a 1:1 ratio in the presence of 500IU/mL of exogenous IL-2 for 8 
days. A. Gating strategy illustrating i. lymphocyte gated population ii. CD56+ NK cells 
iii unstimulated CFSE-stained NK cells (negative control) iv. IL-2 stimulated NK cells 
(positive control) B. Representative histograms illustrating the proliferating CD56+ 
NK cells labeled with CFSE (eBioscience) plated either alone (blue, proliferation 
index 1.85) or at a 1:1 ratio with transitional (yellow, proliferation index 1.47), IgM 
memory (red, proliferation index 1.51), Naïve (green, proliferation index 1.97) or 
Switched memory B cells (orange, proliferation index 1.84). C. Cumulative data 
summarizing the suppressive effect of Breg subsets and autologous Treg on NK 
proliferation (n=8). Bars represent median values and upper whisker of error bars 




























































Figure V-7: The suppressive effect of transitional and IgM memory B cells on 
NK proliferation is cell dose dependent (n=4) 
The figure reports mean values and error bars represent range. 
 
 
V.2.3  Human IL-10 producing transitional and IgM memory B cell 
subsets   modulate expression of NK co receptors and suppress ADCC 
 
To investigate the underlying mechanisms through which transitional and IgM 
memory B cells suppress NK cell function, I next examined whether co-culture 
with these regulatory B cell subsets modulated the phenotypic expression of 
11 inhibitory and activating receptors, as depicted in Table II-2, on the surface 
of NK cells (section II-9.3). Co-culture of healthy donor NK cells with 
transitional and IgM memory B cells, but not naïve or switched memory B 
cells, resulted in downregulation of NKG2D, CD16, DNAM-1, and NTB-A 
expression on the surface of NK cells (figure V-8). The expression of other 
activating molecules did not vary following co-culture with B cell subsets. In 
contrast, 2 inhibitory receptors, ILT and Siglec-7, were upregulated on the 
surface of NK cells co-cultured with transitional and IgM memory B cells but 
not naïve or switched memory B cell subsets. I did not find a difference in 
NKG2A or KIR expression. Taken together, these results indicate that defects 
in NK cell phenotype modulated via Bregs may contribute to the development 
and persistence of the disease in patients with AML.  
CD16 is transmembrane protein that induces a potent series of signals 
resulting in cytokine production and cytotoxic effector activity via ADCC. 
Transi'onal*:*NK* IgM*Memory:*NK*
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These results suggest that Breg subsets may suppress NK mediated ADCC. 
To determine whether transitional and IgM memory B cells suppress IFN-y, 
TNF-a and CD107a production induced by CD16 activation, magnetically 
selected CD56+CD3- human NK cells were activated with plate bound anti-
CD16 mAB for 5 hours alone or with sort purified B cell subsets at a 1:1 (B 
cell: NK cell) ratio as described in section II.9.4. Breg-NK co-culture resulted 
in significant suppression in IFN-y and TNF-a expression, and CD107a 
degranulation by NK cells following CD16 activation, when compared to the 
corresponding positive control (figure V-9).  These results highlight the role of 
transitional and IgM memory B cell subsets as potent suppressor cells of NK 
























































































































Figure V-8: Transitional and IgM memory B cells modulate NK phenotype  
A. Representative histograms were generated using FlowJo and gates for each 
marker (blue) was determined by corresponding FMO (shaded grey) with calculated 
MFI to determine the effect of NK: B co-culture B. cumulative data (n=8) illustrating 
the changes in NK phenotype when cultured alone or with B cell subsets. Bars 
represent median values and upper whisker of error bars represents the range. *P < 






























































































































































































































































Figure V-9: Transitional and IgM memory B cells suppress NK mediated ADCC. 
NK cells were activated with plate bound anti CD16 mAB either alone or with sort 
purified B cell subsets. After culture, cells were collected and stained with 
corresponding antibodies to assess the frequencies of TNFa, IFN-g and CD107a. A. 
Dot plots were generated by gating on lymphocyte population then live cells, then 
CD56+CD3- NK cells (n=3) B. Cumulative data illustrating Transitional and IgM 
Memory B cells suppress NK mediated ADCC. (n=3). Bars represent median values 




V.2.4  IL-10-producing transitional and IgM Memory B cells suppress NK 
cell function via both IL-10 dependent and cell-cell contact-
mediated mechanisms 
 
Given the reported ability of transitional and IgM memory B cells to suppress 
T cell immune effector responses through IL-10 (Blair et al., 2010, Mauri et al., 
2013, Khoder et al., 2014) I next examined whether IL-10 produced by these 
B cell subsets with regulatory capacity was responsible for the suppression of 
NK cytotoxicity and proliferation. To determine if IgM memory and transitional 
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B cells suppress NK cell proliferation and cytotoxicity though IL-10, 
magnetically isolated NK cells were cultured with sort purified IgM memory or 
transitional B cells at a 1:1 ratio in the presence or absence of mAbs against 
IL-10 and IL-10 receptor (IL-10R) as described in section II.9.5.  IL-10 
blockade only partially restored NK effector when co-cultured with transitional 
or IgM memory B cell subsets as observed through intracellular cytokine 
staining and ELISA by harvesting the supernatant after B cell and NK cell 




















































Figure V-10: The suppressive ability of B cells on NK function is partially 
reversed upon IL-10mAB blockade 
A. Dot plots of IFNγ and TNFa expression by CD56+ NK cells cultured alone 
(positive control) or in the presence of indicated B cell subsets with and without IL10 
blocking antibodies. B. Bar charts compare between frequencies of IFNγ, TNFa and 
CD107a+ CD56+ NK cells. The results were compared with paired t test analysis, ∗p 
< 0.05. (n=3) C. Bar charts compare representing IFNγ and TNFa production by NK 
cells with or without B cell co-culture and IL-10 blockade through ELISA (n=3) D.IL-
10 blocking partially reverses the inhibitory effect of Breg subsets on NK proliferation. 
(n=4). In B-D, bars represent median values and upper whisker of error bars 





































NK#Alone# Transi.onal# IgM#Memory# Naive# Switched#
NK#Alone# Transi.onal# IgM#Memory# Naive# Switched#
47.9%# 22.3%# 27.4%# 43.6%# 44.2%#
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Further, IL-10 blockade did not fully reverse the suppressive capacity of either 
transitional or IgM memory B cell subsets on NK cell proliferation [median 
percentages of proliferating NK cells, 52.7% (47.4-70.5%) and 60.4% (50.5-
66.4%), respectively; (n=4) compared with 81.9% (71.2-88.1%) for the 
positive control] (figure V-10D).  Addition of exogenous IL-10 to NK cells 
cultured alone induced marginal suppression of NK cell cytolytic function 
(figure V-11), but this effect was substantially less than that seen when NK 
cells are cultured with transitional or IgM memory B cells. Taken together, 
these data suggest that the immunoregulatory properties of transitional and 
IgM memory B cells on NK cell function are likely mediated through 








Figure V-11: Addition of exogenous IL-10 to NK cells induced marginal 
suppression of NK effector function when assessed by intracellular staining 
for of IFNγ, TNFa and CD107a+ 
Bars represent median values and upper whisker of error bars represents the range. 
*P < 0.05 by nonparametric ANOVA and comparisons were made between each 
concentration of IL-10 ng/ml. 
 
To pursue the notion that TGF-β might mediate at least part of the 
immunoregulatory effects of Bregs on NK cells, we performed additional 
blocking experiments using TGF-β-specific mAbs. TGF-β blockade had no 
significant impact on the suppression of NK effector function by either 
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indicating that TGF-β lacks any significant role in human Breg-mediated 




Figure V-12: The suppressive capacity of transitional and IgM memory 
regulatory B cell subsets is independent of TGF-β 
Bars represent median values and upper whiskers of error bars indicate the ranges 
(n=3). *P < 0.05 by nonparametric ANOVA 
 
A dynamic, bi-directional interaction exists between NK cells and CD19+ B 
cells (Yuan et al., 2010, Gao et al., 2006).  However, to date, no studies have 
assessed the interaction between Bregs and NK cells. To examine if the 
suppressive effect of Bregs on NK cells requires direct cell-to-cell interaction, I 
cultured purified CD56+CD3- NK cells either alone or at a 1:1 ratio with sorted 
IgM memory or transitional B cells either in direct contact or separated in a 
transwell by a permeable membrane as described in section II.9.6. The 
proliferation of K562-stimulated and CFSE-stained CD56+CD3- NK cells was 
measured 8 days after the culture was initiated. Separation of transitional and 
IgM memory B cells from K562-activated CD56+ NK cells by a transwell 
membrane reversed their suppressive effect on NK effector function nearly 
completely when compared with NK cells co-cultured in direct contact with 
these B cell subsets when assessed by both intracellular staining through flow 
cytometry and ELISA assay performed on supernatants harvested from NK/B 
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cell-to-cell contact by a transwell assay also significantly reversed the 
suppressive effect of transitional and IgM memory B cells on NK cell 
proliferation (figure V-13C). These results indicate that the suppressive effect 
of transitional and IgM memory B cells on NK cell proliferation and effector 
function is mediated mainly by direct cell-to-cell contact.  
 
I next determined if a combination of IL-10 blockade and abrogation of direct 
cell-cell contact could completely reverse the suppressive effect of candidate 
regulatory B cells on CD56+ NK-cell proliferation and cytolytic function. 
Whereas IL-10 blockade alone did not fully reverse the suppressive effect of 
either sort-purified transitional or IgM memory B cells on the proliferation or 
cytotoxic function of CD56+CD3- NK cells, the addition of IL-10 and IL-10R 
Abs in a transwell setting completely abolished the suppressive effect of these 
B cell subsets on NK-cell proliferation and cytotoxic function (figure V-14). 
These results suggest that both IL-10 and cell-to-cell contact are pre-
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Figure V-13: Cell to Cell contact is required for the inhibitory effect of Bregs on 
NK cell function 
A. Bar graphs illustrate the suppressive ability of B cells on NK effector function was 
reversed upon abrogation of cell-to-cell contact by a permeable membrane in a 
transwell assay. Sort purified B cell subsets were co-cultured with NK cells at a ratio 
of 1:1. Regulatory B cell subsets appeared to suppress frequencies of NK IFNy, 
TNFa and CD107a production at cell-cell contact but not in the absence of contact. 
(n=4) B. Bar graphs depicting results from supernatants that were collected from NK-
B co-cultures in a transwell setting and measured by ELISA assay for TNFa and IFNy 
(pg/ml) production after 48 hours of co-culture. Data is representative of 3 
experiments C. Negatively selected CFSE stained CD56+CD3- NK cells were co-
cultured with sort purified with B cell subsets either directly or in the presence of a 
permeable membrane in a transwell assay for 48 hours. In the absence of cellular 
contact B cell inhibitory effect on NK proliferation was reversed significantly. (n=4) In 
A-C, bars represent median values and upper whiskers of error bars indicate the 







































































































































Figure V-14: Both IL-10 and Cell to Cell contact are required for the full 
potential of Breg suppression on NK cell function  
A. Bar graphs illustrate the suppressive ability of B cells on NK effector function was 
significantly reversed upon abrogation of cell-to-cell contact and IL-10 suggesting 
that both IL-10 and cell-to-cell contact are contributors to the full potential of Breg 
suppression (n=3) B. Bar graphs depicting the absence of IL-10 and cell-to-cell 
contact inhibited the suppressive function of Breg on NK proliferation (n=3). In A and 
B, bars represent median values and upper whiskers of error bars indicate the 





V.2.5  Breg-NK cell cross-talk is mediated through the 2B4-CD48 axis 
Previous studies have shown that 2B4, a co-receptor on NK cells, interacts 
with CD48, widely expressed on hematopoietic cells, to generate bidirectional 
signals and cross-talk (Yuan et al., 2010, Gao et al., 2006, Messmer et al., 
2006, Mathew et al., 2005, Assarsson et al., 2004). Recent murine and human 
studies suggest that 2B4 can also function as an inhibitory rather than an 
activating co-stimulatory receptor when engaged by CD48-expressing tumor 
targets (Lee et al., 2006). I therefore next investigated whether CD48 on 
transitional and IgM memory B cells can act as an inhibitory receptor upon 
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To test the contribution of 2B4 and CD48 co-stimulatory signaling to the 
suppressive capacity of sort-purified transitional or IgM memory B cell 
subsets, blocking antibodies against CD48 and 2B4 molecules were added to 
co-cultures of B cell subsets and NK cells as described in section II.9.5 to 
study the interaction of Breg-NK interaction through the 2B4 and CD48 axis. 
Addition of CD48 and 2B4 molecules to co-cultures of sort purified B cell 
subsets and magnetically selected NK cells nearly completely reversed the 
suppressive effect of transitional and IgM memory B cells on NK cell 
proliferation and cytotoxic function (figure V-15). Thus, the suppressive effect 
of human Breg cells on PB-NK function is mediated primarily by 2B4/CD48 
co-stimulatory signaling. Further, whereas IL-10 blockade alone did not fully 
reverse the suppressive effect of either sort-purified transitional or IgM 
memory B cells on the proliferation or cytotoxic function of CD56+CD3- NK 
cells (V.2.4), the addition of IL-10 and IL-10R to CD48 and 2B4 blocking 
completely abolished the suppressive effect of these B cell subsets on NK-cell 
proliferation and cytotoxic function (figure V-16), which in accord with my 
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Figure V-15: The suppressive ability of B cells on NK effector function is 
mediated by 2B4 and CD48 interaction  
A. Blocking antibodies against CD48 and 2B4 were added to B cell and NK cell co-
cultures at a 1:1 ratio to prevent the interaction between 2B4 and CD48. Frequencies 
of CD107a+, TNFa+ and IFNy+ CD56+CD3- NK cells was assessed. (n=4). B. 
Supernatants were collected from NK-B co-cultures to measure the presence of 
TNFa and IFNy with the blocking of 2B4 and CD48 (n=4). C. Blocking antibodies 
against CD48 and 2B4 were added to B cell and NK cell co-cultures at a 1:1 ratio to 
prevent the interaction between 2B4 and CD48. Frequencies CFSE+ CD56+CD3- 
NK cells was assessed. (n=3). In A-C, bars represent median values and upper 
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Figure V-16: Cell-to Cell contact and IL-10 are both required for the full capacity 
of suppression by Transitional and IgM Memory B cells on NK cytotoxic 
function and proliferation 
Percentage suppression was calculated for NK+IFNy+ cells, NK+TNFa+ cells, 
NK+CD107a+ and CFSE+NK+ cells in the presence of IL-10 blocking, 2B4 blocking, 
CD48 blocking and transwell. Data shows that a combination of IL-10 blocking and 
abrogation of cell to cell contact reversed the suppressive effect of transitional and 
IgM memory B cell subsets. Bars represent median values and upper whiskers of 
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V.2.6  Reduced expression of SAP and upregulation of pSHP-1 mediates 




Triggering of 2B4 (CD244) on the surface of NK cells can induce NK–cell 
activation, co-stimulation, or even inhibition (Morandi et al., 2005, Eissman et 
al., 2005, Endt et al., 2007). The signaling lymphocyte activation molecule–
associated protein (SAP) can bind to all 4 immuno-receptor tyrosine-based 
switch motifs (ITSMs) of 2B4. The phosphorylated ITSM can additionally 
recruit the phosphatases SHP-1, SHP-2 and SHIP. SAP can also act as an 
inhibitor of interactions between 2B4 and these inhibitory molecules.  
 
To test the contribution of 2B4 and CD48 co-stimulatory signaling to the 
suppressive capacity of sort-purified transitional or IgM memory B cell 
subsets, I co-cultured NK cells with sort purified B cells subsets (naïve, 
switched memory, IgM memory and transitional) at a 1:1 ratio for 48 hours as 
described in section II.10.2, to determine the inhibitory effect of transitional 
and IgM memory B regulatory subsets on the expression of SAP+NK+ cells 
through CD48 and 2B4 signalling. Co-culture of NK cells with both transitional 
and IgM Memory B cells results in downregulation of the 2B4-activated SAP in 
NK cells [median percentages of NK+SAP+ cells, 52.7% (47.4-70.5%) and 
60.4% (50.5-66.4%), respectively; (n=4)] compared to 97.5% (94.9-98.8%)] in 
NK cells cultured alone  (figure V-17). These results highlight an important 
mechanism of Breg suppression and indicate that CD48 on the surface of 
Bregs block 2B4-mediated NK cell activation by reducing expression of the 
2B4-associated SAP molecule, which in turn contributes to inhibition of NK 
function. 















Figure V-17: Co-culture of NK cells with both transitional and IgM Memory B 
cells results in downregulation of the 2B4-activated SAP in NK cells  
A. Gating strategy illustrating CD56bright+SAP+ NK cells. Magnetically selected 
CD3-CD56+ NK cells were cultured either alone or with sort purified B cell subsets: 
naïve, switched, transitional and IgM memory for 48 hours. Following incubation, 
cells were collected and stained for CD56+SAP+ NK cells. Cells were gated on 
lymphocytes, CD56+bright NK cells and CD56bright+SAP+ NK cells. B. Transitional 
and IgM Memory B cells downregulated the expression of SAP+NK+ cells when co-
cultured with NK cells at 1:1 cell ratio. Data is representative of 3 independent 
experiments. Bars represent median values and upper whiskers of error bars indicate 




To further dissect how Bregs may be modulating the expression of NK+SAP+ 
NK cells I first determined the impact of IL-10 on SAP expression, as both 
transitional and IgM memory B cells are enriched in IL-10 producing cells. NK 
cells were cultured with IgM memory or transitional B cells at a 1:1 ratio in the 
presence or absence of mAbs against IL-10 and IL-10 receptor (IL-10R).  IL-
10 blockade had minimal effect on restoring SAP expression on NK cells 

















































98.7%! 62.9%! 55.7%! 97.0%! 94.4%!
*#
*#
	   221	  
18A). Addition of exogenous IL-10 to NK cells cultured alone induced 
marginal suppression of SAP expression on NK cells (figure V-18B). These 
data suggest that IL-10 by Bregs does not play a significant role modulating 
SAP expression in NK cells. 
 
To determine if cell-cell contact between Breg subsets and NK cells is 
required for downregulation of SAP expression by NK cells, NK-B cell 
interaction was prevented either by a transwell system through a permeable 
membrane or by the addition of blocking antibodies against CD48 and 2B4 
molecules, either separately or together, as described in section II.10.2.  
Prevention of NK-B cell interaction by a transwell membrane or by addition of 
CD48 and/or 2B4 molecules to co-cultures completely reversed NK cell SAP 
downregulation by transitional and IgM memory B cells (figure 19). My results 
highlight an important role for 2B4-CD48 interaction in inducing 
downregulation of the activating molecule SAP, thereby facilitating 
interactions of negative regulatory molecules, such as SHP-1 with 2B4. 
Hence, the suppressive effect of transitional and IgM memory B cell subsets 
may be mediated by through 2B4-CD48 interaction, which induces inhibitory 
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Figure V-18: IL-10 had minimal contribution to SAP expression on NK cells 
when co-cultured with transitional or IgM memory B cell subsets  
A cumulative data representing the effect of IL-10 blockade on restoring suppressed SAP 
expression by transitional and IgM memory B cell subsets (n=3). Bars represent median 
values and upper whiskers of error bars indicate the ranges. *P < 0.05 by 
nonparametric ANOVA B. Addition of exogenous IL-10 had minimal impact on SAP 
expression in CD56+ NK cells (n=3). The figure represents median values with range. No 






Figure V-19: Prevention of NK-B cell cell-to-cell interaction completely reversed 
NK cell SAP downregulation by transitional and IgM memory B cells  
A. Dot plots representing frequencies of NK+SAP+ expression with 2B4 and CD48 
blocking which reverses the downregulation SAP by transitional and IgM memory B cells 
when compared with NK cells cultured with naïve or switched memory B cell subsets or 
NK cells cultured alone (positive control) B Bar graphs representing negatively selected 
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hours in the presence of 2B4 and CD48 mAbs. In the absence of 2B4 and CD48 
interaction, the inhibitory activity of Bregs was reversed (n=3) C. In the absence of NK-B 
cellular contact by a transwell membrane, inhibitory effect of transitional and IgM Memory 
B cells on SAP expression on NK cells was reversed. N=4. In B and C, bars represent 




To test if 2B4-CD48 interaction induces expression of the inhibitory molecule 
pSHP-1 in NK cells, sort purified transitional and IgM memory B cell subsets 
were co-cultured with NK cells for 48 hours and expression of pSHP-1 in NK 
cells was examined using the phosphoflow assay as described in section 
II.10.3. NK cells cultured either alone or with naïve or switched memory B cell 
subsets did not express pSHP-1, however NK cells cultured with transitional 
and IgM memory B cells upregulated pSHP-1 expression [figure V-20]. These 
results support my hypothesis that Breg mediated suppression of NK cells is 
dependent on 2B4-CD48 interaction by inducing downregulation of the 
activating molecule SAP, and thereby facilitating interactions of negative 
regulatory molecules, such as SHP-1 with 2B4.  
 
To test the contribution of IL-10 by Bregs to upregulation of pSHP-1 in NK 
cells, IgM memory or transitional B cells were cultured with NK cells at a 1:1 
ratio in the presence or absence of mAbs against IL-10 and IL-10 receptor (IL-
10R).  IL-10 blockade had minimal effect on pSHP-1 expression in NK cells 
(figure V-21A). Addition of exogenous IL-10 to NK cells cultured alone 











Figure V-20: NK cells cultured with transitional and IgM memory B cells 
upregulated pSHP-1 expression  
A. Sort purified transitional and IgM Memory B cells upregulate the expression of 
pSHP-1. Magnetically selected CD56+CD3- NK cells were co-cultured with sort 
purified B cell subsets at a 1:1 ratio for 48 hours after which cells were collected and 
tested for the presence of pSHP-1 by phosflow assay kit (Beckman Coulter). Cells 
were gated on lymphocytes population and then CD56+NK cells. CD56+SHP-1+ 
cells (blue) were determined by SHP-1 Alexa fl 400 FMO (shaded grey). Transitional 
and IgM memory B cells up regulated the expression of SHP-1. B Bar graphs 
illustrate NK co-cultured with transitional or IgM memory B cells upregulated the 
expression of pSHP-1, inhibitory downstream protein of 2B4 signalling pathway 
(n=6). Bars represent median values and upper whiskers of error bars indicate the 




Next, in order to determine if CD48-2B4 interaction induces pSHP-1 
expression in NK cells, NK-B cell interaction was prevented by transwell or 
with the addition of blocking antibodies against CD48 and 2B4 molecules. 
Addition of CD48 and 2B4 molecules to co-cultures or prevention of cell-cell 
contact using a transwell device completely reversed upregulation of pSHP-1 


















































Figure V-21: IL-10 had minimal contribution to pSHP-1 expression on NK cells 
when co-cultured with transitional or IgM memory B cell subsets  
A. Bar graphs illustrate IL-10 blocking alone had minimal effect on the expression of 
pSHP-1 in NK co-cultures with transitional and IgM memory B cells (n=3) B The effect of 
varying concentrations of adding exogenous IL-10 had no significant effect on the 
expression of pSHP-1 on CD56+CD3- NK cells (n=3). Both A and B, the bars represent 
median values and upper whisker of error bars indicate the range. No significant 
differences were found by nonparametric ANOVA. 
 
 
In order to determine the relation between pSHP-1 and SAP expression I 
studied a time course and found that as regulatory B cell subsets down-
regulates SAP expression, pSHP-1 expression is augmented in a time 
dependent manner (figure V-23).  Thus, the suppressive effect of human 
Breg cells involves not only the release of IL-10 and cell-cell contact, but also 
mediation of these factors by 2B4/CD48 co-stimulatory signaling. 
 Taken together, these data support my hypothesis that Breg subsets inhibit 
NK cell activation primarily through direct cell-cell contacted mediated via 
CD48-2B4 interactions, by downregulating expression of the activating 
molecule SAP and upregulating expression of the inhibitory molecule pSHP-1. 
  
Figure V-22: In the absence of NK-B cellular contact via 2B4 and CD48 blocking 
(right) and transwell (left) assays inhibitory effect of Bregs on SHP-1 
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Data is representative of 3 independent experiments and bars represent median values 







Figure V-23: Time kinetics of SAP and pSHP-1 expression on NK cells 
highlighting the unique relationship between both the frequency (left) and mean 
fluorescence intensity (MFI) (right) of negative regulatory molecule pSHP-1 
expression and downregulation of activating 2B4-associated SAP molecule (n=4). 




V.2.7  2B4 and CD48 mediated NK-B cell interaction activates 
JAK/STAT3 pathway in transitional and IgM Memory regulatory B 
cell subsets 
 
Next I investigated the bi-directional cross-talk between NK and regulatory B 
cell subsets. I hypothesized that Breg mediated suppression of NK cells may 
be a consequence of 2B4 and CD48 mediated NK-B cell interaction, which 
activates JAK/STAT3 pathway in transitional and IgM Memory regulatory B 
cell subsets, activating the regulatory function of the B cell subsets. Greater 
production of IL-10 was observed in NK-B cell co-culture than resting B cells 
alone (figure V-24). This suggests that cell-to-cell contact between NK cells 
and B cells may perhaps activate B cells to regulate their IL-10 mediated 
suppressive function.   We next examined if this phenomenon was mediated 
through phosphorylation of the STAT3 pathway (p-STAT3) in Breg subsets.  
 































Figure V-24: B cells co-cultured with NK cells produced greater IL-10 than 
resting B cells cultured alone.  
Supernatants were harvested after cultured NK-B cell co-culture and measured for IL-10 
production through ELISA assay (n=4). Bars represent median values and upper 
whisker of error bars represents the range. *P < 0.05 by nonparametric ANOVA 
 
 
Coculture of NK cells with transitional and IgM memory B cells from healthy 
controls resulted in upregulation of p-STAT3 in transitional and IgM memory 
and to a much lesser extent in naïve and switched B cell subsets (figure V-
25A-B). These findings indicate that NK cell interaction with B cells results in 
phosphorylation of the STAT3 pathway in transitional and IgM memory B cells 
and suggest that proximal signals induced by NK cells may induce regulatory 
activity in transitional and IgM memory B cells. I next explored whether 
preventing NK-B cell interaction, either by culturing the cells the presence of a 
transwell membrane or by the addition of blocking antibodies against CD48 
and 2B4 molecules could reverse NK-induced STAT3 phosphorylation in B 
cell subsets. Inhibition of cell-cell contact completely NK cell-induced STAT3 
phosphorylation in transitional and IgM memory B cell subsets [Figure V-
25C].  
Taken together, these data indicate that 2B4 on NK cells interacts with CD48 
on transitional and IgM memory B cells to induce regulatory function by 





























Figure V-25: Activated B cells upregulate JAK/STAT3 pathway.  
A. Sort purified CD19+B cell subsets were cultured with NK cells or fibroblasts expressing 
CD40L to determine the frequency of STAT3 expression. B cells were derived from the 
lymphocyte population then CD19+ gate. CD19+JAK/STAT3+ cells (blue) were determined by 




























































IgM Memory B cells
Naive B cells
Switched B Cells









	   229	  
cell subsets after stimulation with CD40L, NK cells, NK cells with CD48/2B4 blocking 
antibodies or with H202 (positive control). CD19+STAT3+ cells (blue) were determined by PE 
FMO as indicated (shaded grey) and unstimulated B cells (orange) C. Bar graphs represent 
STAT3 expression in transitional and IgM memory B cell subsets.  Addition of CD48 and 2B4 
mAbs inhibited the upreglation of the JAK/STAT3 pathway in NK-B co-cultures. Bars 




V.2.8  Patients with AML have increased frequencies of IL-10 producing 
B cells  
 
The microenviroment of acute myelogenous leukemia (AML) is suppressive 
for immune effector cells (Stringaris et al., 2014). To determine if patients with 
AML have higher frequencies of B cell subsets with regulatory capacity, I 
measured transitional and IgM memory B cells in the PB of 13 patients with 
AML (Table V-1) at diagnosis and13 healthy controls. In comparison with 
healthy controls, AML patients had significantly higher frequencies and 








Figure V-26: Patients with AML have greater frequencies of transitional and IgM 
memory B cells than healthy controls  
Frequencies of B cell subsets: naïve, switched, transitional and IgM memory B cells 
were significantly different in AML patients than healthy controls. AML patients 
expressed expanded population of B regulatory subsets transitional and IgM memory 
B cells (n=13). Bars represent mean values and upper whisker of error bars 
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Table V-1: Clinical Characteristics of Patients with AML 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  All	  N=13	  
Age	  in	  years	  Median	  (range)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  68	  (20-­‐80)	  	  
Sex	   	  Female,	  n	  (%)	  Male,	  n	  (%)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  7	  (53.8%)	  	  	  	  	  	  	  	  	  	  	   6	  (46.2%)	  
Race	   	  White	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  8	  (63.5%)	  Black	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  (7.7%)	  Hispanic	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  (30.8%)	  
Diagnosis,	  n	  (%)	   	  Primary	  AML	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9	  (69.2%)	  Secondary	  AML	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  (30.8%)	  
Cytogenetics,	  n	  (%)	  	   	  Poor	  Risk	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  12	  (92.3%)	  
Day	  30	  ALC	  (k/µL)	   	  Median,	  range	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1.98	  (0.19	  –	  8.18)	  Mean,	  S.D.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.4	  (4.1)	  
Disease	  status	   	  Remission	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  (15.4%)	  Died	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  11	  (84.6%)	  
WBC	  (k/µL)	   	  Median,	  range	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  15.5	  (0.8-­‐65.9)	  Mean,	  S.D.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  22.97	  (21.4)	  
PB	  Blasts	  (%)	   	  Median,	  range	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  34	  (11-­‐97)	  Mean,	  S.D.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  48	  (29.4)	  
%	  CD19+	  B	  Cells	   	  Median,	  range	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  15.2	  (4.46	  -­‐	  35.4)	  Mean,	  S.D.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  17.9	  (9.4)	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To determine if the expanded B cell populations in AML had the capacity to 
produce IL-10, I measured IL-10+CD19+ B cells following stimulation with L 
cells as described in section II.6.5. AML patients had significantly higher 
frequencies and absolute numbers of IL-10-producing B cells compared to 
healthy controls [figure V-27]. I next determined whether this functional 
difference noted in the overall population of IL-10+CD19+ B cells may 
contribute to an altered ratio of regulatory-to-effector cells in AML patients. 
Patients with AML had a significantly higher IL-10+CD19+ B-cell/ CD56+CD3- 
NK-cell ratio, whether in terms of relative frequency or absolute counts, 
compared with that for healthy control group [figure V-28]. These results 
suggest that patients with AML present an expanded population of potential 
IL-10 producing B regulatory cells, which may contribute to suppressed NK 
frequencies, absolute counts and function, thus, promoting cancer 
progression through an imbalance in immunoregulatory and effector subsets. 
For this reason, I next investigated if the expanded population of IL-10 
producing candidate regulatory CD19+ B cells derived from AML patients 
could suppress NK cell function in vitro in a similar fashion to healthy PB 





















Figure V-27: Patients with AML have abnormally higher frequencies and absolute 
numbers of IL-10-producing B cells at diagnosis compared to healthy controls  
A. Magnetically selected CD19+ B cells from AML patients and healthy controls were 
incubated with L cells alone for 48 hours. PMA, Ionomycin and BFA were added for the last 6 
hours of culture and cells were surface stained for the expression of CD19 and intracellular 
staining for IL10. Representative FACS plot of IL10 IC staining in gated CD19+ B cells AML 
patients and Healthy controls. Frequencies of IL10+ CD19+ B cells were assessed relative to 
isotype controls n=13 B. B cells from AML patients had higher frequencies and absolute 
numbers of total CD19+ B cells and produced higher frequencies and absolute numbers of 
IL10+ B cells when stimulated with L cells compared with healthy controls (n=13). Figure 
represents mean value and whiskers of error bars represent the ranges. *P < 0.05 and 
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Figure V-28: Patients with AML had a significantly higher IL-10+CD19+ B-cell/ 
CD56+CD3- NK-cell ratio, whether in terms of relative frequency or absolute 
counts, compared with that for healthy control group  
The box and whiskers plot extends from the 25th to 75th percentiles and were computed by 
Graphpad Prism software from 13 independent experiments. The line in the middle of the box 




Purified CD19+ B cells from the PB of AML patients and healthy controls were 
co-cultured at a 1:1 ratio with magnetically purified healthy control NK cells for 
48 hours as described in section II.9.2. NK cell effector function was then 
assessed against K562 target cells by measuring the frequencies of 
degranulated (CD107a+) CD56+ NK cells and TNF-α and IFN-γ producing 
CD56+ cells by flow cytometry.  AML CD19+ B cells induced significant 
suppression of CD107a degranulation, and expression of IFN-γ and TNF-α by 
NK cells in response to K562 targets when compared to B cells from healthy 
controls [figure V-29A-B].  The potent suppressive effect of AML CD19+ B 
cells on NK cytotoxicity was further confirmed using chromium (51Cr) release 
assay [figure V-29C]. These results support my hypothesis and suggest that 
expanded population of IL-10 producing CD19+ B cells in AML patients may 

















































































 	  	  	  	  	  	  	  	  
Figure V-29: Total CD19+B cells from AML patients exhibited greater 
suppressive function on NK effector function than total CD19+ B cells from 
healthy control 
A. Magnetically selected total CD19+ B cells from AML patients and Health controls 
were co-cultured with selected healthy NK cells at a 1:1 ratio for 48 hours. 
Representative dot plots illustrate gated frequencies of CD56+IFN-y+ NK cells, 
CD56+TNF-a NK cells and CD56+CD107a+ NK cells cultured alone (positive 
control), with total CD19+ B cells from AML patients or total CD19+ healthy B cells B. 
Bar graph represents total CD19+B cells from AML patients exhibited greater 
suppressive function on NK effector function than total CD19+ B cells from 
healthy control (n=9). Bars represent median values and upper whiskers of 
error bars represent the range. *P < 0.05 by nonparametric ANOVA C.Total 
CD19+B cells from AML patients exhibited greater suppressive function on NK 
cytotoxicity than total CD19+ B cells from healthy control when compared with 
healthy NK cells alone (positive control) (n=6). The figure represents mean values 
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I also investigated if coculture of purified AML CD19+ B cells with healthy 
donor NK cells induced changes in the expression of activating and inhibitory 
receptors on NK cells [figure V-30]. Co-culture resulted in downregulation of 
the activating NK co-receptors NKG2D, DNAM-1, NTB-A and natural 
cytotoxicity receptors, NKp46 and NKp30 and upregulation of the inhibitory 













Figure V-30: NK cells from AML patients at diagnosis were shown to have 
dysfunctional expression of receptors when compared to health control NK 
cells 
Frequencies of NKG2D, CD16, DNAM-1, NKp46, and NKp30 was significantly lower 
in AML NK cells whereas, expression of Siglec-7, ILT and NKG2A was significantly 
elevated when compared to the expression of these receptors in healthy controls 
(n=9). No differences of receptor expression between the 2 groups was found for 
Pan KIR and NKp44. Bars represent mean values and error bars represent range. 
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Given my earlier findings that IgM memory and transitional B cells suppress 
NK cell function via 2B4-CD48 interaction, resulting in down regulation of the 
activating molecule SAP and upregulation of the inhibitory regulator pSHP-1, I 
further evaluated whether AML B cells suppressed NK cell function through a 
similar mechanism. NK cells from AML patients had significantly lower 
expression of SAP and higher expression of pSHP-1 than healthy control NK 
cells [figure V-31]. Further, AML CD19+ total B cell significantly suppressed 
the expression of SAP and consequently upregulated the expression of 
pSHP-1 in healthy PB NK cells, when compared with total CD19+ B cells from 
healthy controls [figure V-32]. 
 
Collectively, my findings demonstrate transitional and IgM memory B 
regulatory cells inhibit NK cell activity suggesting that B regulatory cells can 
directly act on NK cells, a unique phenomenon which may recognize Bregs as 
contributing factors that may be recruited and exploited by leukemic cells to 
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Figure V-31:	  Dysfunctional NK cells from AML patients had reduced expression 
of SAP and increased expression of negative regulator pSHP-1 than healthy 
controls  
Magnetically selected CD3-CD56+ NK cells from AML patients and healthy controls 
were stained for SAP and SHP-1 expression. Data representative of n=12 and 
highlight both the frequency and MFI of SAP and pSHP-1 expression. Bars represent 
mean values and errors bars represent range. *p<0.05 and **p<0.01 by a non-paired 






Figure V-32: Dysfunctional B cells from AML patients significantly reduced 
expression of SAP and increased expression of negative regulator pSHP-1 
Magnetically selected CD19+ B cells from AML patients were co-cultured with 
healthy NK cells at a 1:1 ratio for 48 hours. After the culture period NK cells were 
stained for SAP and SHP-1 expression (n=8). Bars represent mean values and 
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V.3 Discussion 
In recent years, a number of studies in mice and humans have identified a 
distinct subpopulation of B cells with significant regulatory function. Despite 
increasing evidence showing an important role for Bregs in autoimmunity 
(Mauri et al., 2013, Yang., 2013), lack of a clear phenotype or the paucity of 
specific markers have hampered their in depth characterization. In this study, I 
demonstrate the capacity of human CD19+CD24hiCD38hi transitional and 
CD19+IgM+CD27+ memory B cells to significantly inhibit the effector function 
and proliferation of NK cells in a contact-dependent manner. 
 
Previous studies in mice and humans have shown that the Breg-mediated 
suppression of cell proliferation and effector function is mediated through both 
IL-10 and cell-cell contact-mediated mechanisms (Yang et al., 2013, Blair et 
al., 2010, Iwata et al., 2011, Khoder et al.,2014). In addition, TGF-β has also 
been shown to be an important mediator of Breg suppression in experimental 
models of diabetes (Tian et al., 2001). In contrast, I show here that IL-10 
secretion is not a major mechanism for regulatory B cell-mediated 
suppression of NK cell proliferation and function. Instead, transitional and IgM 
memory B cells require direct cell-cell contact to suppress NK cells. 
 
There is evidence for bi-directional crosstalk between NK cells and B cells, 
mediated through interactions involving CD48-2B4 and CD40-CD40L (Yuan et 
al., 2010, Gao et al., 2006, Blanca et al., 2001, Sinha et al., 2010). I did not 
detect any soluble CD40L in my NK-B cell co-culture experiments (data not 
shown) and thus did not pursue this interaction further. Instead, I found an 
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important role for CD48-2B4 in mediating suppression of NK cells by Breg 
subsets. CD48 is expressed widely on hematopoietic cells including B, T and 
NK cells and binds to the 2B4 co-receptor on the surface of NK cells (Yuan et 
al., 2010, Gao et al., 2006,	  Sinha et al., 2010, Assarsson et al., 2005, Lee et 
al., 2006). B cells can activate NK cells (Gao et al., 2006, Sinha et al., 2010). 
However, in my study I show an important role for CD48-2B4 interaction in 
mediating the suppressive effect of Breg subsets on NK cell proliferation and 
effector function. Blocking either CD48 or 2B4 resulted in near complete 
abrogation of the suppressive effect of CD19+CD24hiCD38hi transitional and 
CD19+IgM+CD27+ memory Breg subsets on NK cells and resulted in 
restoration of NK cell proliferation and effector function. My findings are 
supported by murine studies reporting that CD48 on tumor cells can interact 
with 2B4 on NK cells and inhibit their function (Lee et al, 2006), supporting the 
notion that CD48-2B4 interaction can induce both positive and negative 
signals.	  
 
To understand this phenomenon more mechanistically, I studied the 2B4 
signaling pathway in NK cells. In humans, NK cell activation through 2B4 is 
accompanied by the phosphorylation of immunoreceptor tyrosine-based 
switch motifs (ITSMs) in its cytoplasmic tail and the recruitment of SLAM-
associated protein (SAP), a signaling adaptor protein (Stark et al., 
2006,Eissman et al., 2005). SAP is crucial for 2B4 to deliver activating signals 
to NK cells. In the absence of SAP, the phosphorylated ITSM of the 2B4 
receptor recruits inhibitory signaling molecules such as SHP-2, SHP-1, SHIP 
(Assarsson et al., 2005, Eissmann et al., 2005), resulting in dephosphorylation 
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of downstream molecules involved in NK cell activation (Hallet et al., 2006, 
Moretto et al 2003). The importance of SAP in immune regulation was first 
highlighted by SAP mutation found in cases of X-linked lymphoproliferative 
(XLP) disease, an immunodeficiency disorder characterized by 
lymphoproliferation and abnormal responses to Epstein-Barr virus (EBV) 
infection. Patients with XLP have also been found to exhibit impaired NK cell 
cytotoxicity (Eissmann et al., 2005, Hallet et al., 2006, Lanier et al., 2008). 
 
Here, I showed that the interaction between CD48, on transitional and IgM 
memory Breg subsets, but not naïve or switched memory B cells, and 2B4 on 
NK cells results in downregulation of, SAP and recruitment of pSHP-1. The 
effect of Breg subsets on SAP and SHP was completely reversed upon 
disrupting the interaction between 2B4 and CD48 using blocking antibodies, 
suggesting a crucial role for this axis in the mechanism of Breg-mediating NK 
cell suppression.  It is quite possible that additional signaling pathways also 
play a role in Breg-mediated suppression of NK function. Indeed, Assarsson 
et al (2005) have noted that 2B4 and CD48 both reside within glycolipid-rich 
microdomains, which contain many other molecules that may be involved in 
signaling, and additional studies of 2B4-CD48 signaling pathways involved in 
Breg-mediated suppression of NK cells are underway.  
 
Blair et al (2010) highlighted that CD19+CD24hICD38hI transitional B cells 
require the activation of the CD40/STAT3 signaling pathway to exert their 
immunoregulatory function on CD4+ T cells. Here I show that following 
coculture with B cells subsets, NK cells trigger phosphorylation of STAT3 in 
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both IgM memory as well as transitional B cell subsets (but to a much lesser 
extent in naïve and switched memory B cells). Taken together, these data 
support the existence of bidirectional 2B4-CD48-mediated cross-talk between 
NK cells and B cells and suggest that NK cells can deliver signals to 
regulatory B cell subsets, and the latter in turn deliver inhibitory signals to NK 
cells by inducing downregulation of SAP and recruitment of pSHP. 
 
Recent reports in murine models indicate that Bregs can potently inhibit 
antitumor immune responses (Balkwill et al., 2013, He et al., 2014) and 
clinically, IL-10-producing B cells have been shown to play an important role 
in resistance to anti-CD20 mAb therapy in patients with B-cell lymphoma 
(Horikawa, et al., 2011). My report provides for the first time functional 
evidence for a significant increase in Bregs with potent suppressive activity 
against NK cells in the peripheral blood of patients with AML.  
Coculture of AML CD19+ B cells with healthy donor NK cells resulted in 
significant suppression of SAP, recruitment of pSHP-1, and significant 
suppression of healthy donor NK cell proliferation and function. It is 
noteworthy that ex vivo-purified NK cells from AML patients expressed 
significantly less SAP and, higher pSHP-1 than their normal counterpart, 
further supporting the notion that in AML, engagement of 2B4 on NK cells by 
CD48 on B cells will deliver inhibitory signals to NK cells, resulting in 
suppression of their effector function. Although earlier studies have 
demonstrated that CD48 on hematopoietic cells interacts with 2B4 on NK cells 
to generate bidirectional activating signals and cross-talk (Gao et al., 2005, 
Yuan et al., 2010, Messmer et al., 2006, Mathew et al., 2005, Assarsson et 
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al., 2004), this is the first study to provide mechanistic insights into inhibitory 
cross-talk between NK cells and Breg subsets and to demonstrate the 
relevance of this inhibitory axis in acute myeloid leukemia. However, The AML 
patients were derived from a very heterogeneous group and factors such as 
immunosuppressive AML blast cells may also have affected NK properties in 
AML samples and require further consideration. 
 
The immune microenvironment in AML displays a spectrum of abnormalities, 
including aberrant expression of immunomodulatory cytokines (Stringaris et 
al., 2014, Ferrara and Schiffer., 2013, Lion et al., 2012) and numerical and 
functional alterations in immunoregulatory subsets such as Tregs and 
myeloid-derive suppressor cells (Ustan et al., 2011, Szczepanski et al, 2009). 
Our findings point to the existence of a broader network of immunoregulatory 
cells, also involving Bregs, that can be recruited and exploited by leukemic 
cells to evade immunesurveillance. Breg-mediated suppression of NK cell 
function may have important implications not only on cancer immune 
surveillance and defense against pathogens but also in determining response 
to therapy.  For instance, Bregs may negatively impact the effectiveness of 
immunotherapies in AML, such as antibody-dependent cellular cytotoxicity 
(ADCC) of tumor-targeted monoclonal antibodies (e.g., anti-CD33 mAbs). 
This data will have implications for other cancers and studies to explore the 
role of Bregs in other types of cancer and the consequences of their depletion 
on NK cell antitumor activity in vivo are currently under way. Finally, I propose 
that depletion of Breg subsets may be a novel strategy to enhance cancer 
immunity in humans.  
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Chapter V1.  General Discussion and Future plans 
VI.1 General Discussion 
In recent years, a distinct newly described subpopulation of IL-10-producing B 
regulatory (Breg) cells, that have been shown to exert significant 
immunoregulatory functions both in vitro and in vivo, has been the focus of 
intense immunological research (Mauri and Bosma., 2012). Breg cells have 
been shown to exert suppressive functions through the production of IL-10 in 
various diseases, including inflammation, cancer, autoimmunity and more 
recently cGVHD (DiLillo et al., 2010, Sarantopoulos et al., 2015, Khoder et al., 
2014). Bregs suppress a variety of immune cells through differing 
mechanisms (Rosser et al., 2014). Further, the understanding of human Breg 
suppressive function and interaction with other effector cells may facilitate the 
understanding of imbalance between regulatory and effector subsets that 
leads to loss of tolerance and induction of allo-reactivity in GVHD.  
Despite the extensive body of evidence reinforcing the notion that B cells can 
exert immunoregulatory function, controversy over the paucity of markers that 
can unequivocally identify Bregs particularly in humans still exists. Blair and 
colleagues have elegantly described human Bregs as CD19+CD24hiCD38hi, a 
phenotype that typically delineates human transitional B cells (Blair et al., 
2010). Conversely, Iwata et al (2011) described human IL-10 producing B 
cells to be contained mainly within the CD24hiCD27+ memory B cell 
compartment (de Masson et al., 2015, Iwata et al., 2011). In addition to these 
studies, Khoder et al syndicates previous studies and demonstrates that IL-
10-secreting CD19+IgM+CD27+ memory B cells coexist with 
IL10+CD24hiCD38hi transitional B cells in healthy human donors and 
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significantly suppresses the proliferation and cytokine production of 
autologous CD4+ T cells through both IL-10-dependant and cell-to-cell 
contact mediated mechanisms. Further, considerable evidence from murine 
studies supports the presence of more than one Breg phenotype. Thus, 
discrepancies in the cell surface antigens studied and a lack of consensual 
definitions of the Breg subset phenotypes hampers their in depth 
characterization.  
 
In my PhD thesis, I studied the phenotypic and functional characterization of 
Breg subsets in peripheral blood and cord blood and their potential interaction 
with other immune effector cells (CD4+ T cells and CD56+ NK cells). This 
understanding may aid the development of Breg cells as novel therapeutics 
for the treatment of immune-mediated diseases including GVHD and cancer. 
 
For the phenotypic characterization of B cells, I designed an extended panel 
of surface antibodies, using a constellation of markers reported in a number of 
B-cell classification schemes. The panel was validated using freshly isolated 
healthy control samples and their frozen counterparts. I correlated the 
different B cell subsets namely, transitional, naïve, IgM+ memory and non-
switched memory B cells according to different B cell classifying schemes, 
each of which had limitations as a result of limited surface markers used. I 
therefore, extensively phenotyped CD19+ B cell subsets based on CD24 and 
CD38 axis, with use of additional markers including IgM, CD27, CD21 and 
CD10 to characterize B cell subsets and demonstrated that CD38/24 
combination with IgM could be used as a sorting panel.  
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The intracellular detection of IL-10 combined with flow cytometric phenotyping 
demonstrated the presence of IL-10–producing B cells that were enriched 
within the CD19+CD24hiCD38hiIgMhiCD27- transitional and CD19+CD38-/lo 
CD24hi CD27+IgM+ memory B cell population and relatively fewer in the 
CD19+CD38+CD24+CD27- naïve and CD19+CD24hiCD38-/loCD27+IgM- 
switched memory B cell subsets. The functional assessment of sort purified 
transitional and IgM memory B cells supports the immunoregulatory functions 
of transitional B cells and identify IgM+ memory B cells as a new candidate 
Breg subset in healthy individuals. This discovery broadens the proportion of 
PB-derived regulatory B cell subset within circulating total CD19+ B cells, 
suggesting a prominent role for Bregs in the maintenance of immune 
tolerance. Both IL-10 enriched transitional and IgM memory B cells exerted 
suppressive function on proliferation and cytokine production of CD4+ T cells 
in a manner that was comparable with that of Tregs. Although I also found the 
presence of IL-10 producing B cells within naïve and switched memory B cell 
subsets, albeit at much lower frequencies, they lacked any suppressive effect 
on CD4+ T cell function. This is in agreement with other studies that have also 
shown lack of suppressive activity in naïve B cells (CD27‐ IgM+) (Blair et al., 
2010, Iwata et al., 2011). Moreover, the regulatory capacity of these human 
Bregs on CD4+ T cell proliferation and cytokine production was dependent on 
both cell-cell contact and IL-10 production. These finding are consistent with 
Blair et al’s report where the suppressive effect of CD19+CD24hiCD38hi 
transitional B cells was also partially mediated by IL-10 (Blair et al., 2010). On 
the other hand, although Tedder et al’s study also demonstrated a subset of 
IL-10 producing CD24hiCD27+CD148+ memory B cells, this subset failed to 
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suppress CD4+T cells and instead was shown to suppress both IFNγ and 
TNFα production of CD14+ monocytes (Iwata et al., 2011). Thus contrary to 
these results, in this study, IL-10+ B cells were defined as CD27+IgM+ CD38-/lo 
CD24hi memory B cells and were found to suppress CD4+ T cells. 
Conclusively, for clinical purposes, sort‐purification based on a phenotype of 
transitional and IgM memory B cells is likely to yield an enriched population of 
IL-10+Breg. Further, in the majority of clinical trials, systemic administration of 
recombinant IL-10 was not associated with clinical improvement with the 
exception of psoriasis (Sanz et al., 2008). Similarly in my experiments, the 
addition of exogenous IL-10 to co-cultures of naïve or switched memory B 
cells failed to suppress CD4+ T cells to the same extent as seen with 
transitional and IgM memory B cell subsets, suggesting that cellular contact 
may be required for IL-10 to deliver immune regulation. Indeed, transwell 
experiments and CD80/CD86 blockade confirmed that cell-to-cell contact was 
needed for IgM memory and transitional B cells to exert their full suppressive 
activity on CD4+ T cell function. These findings may provide support for future 
investigations of regulatory B cell–based therapy to tip the scales in favor of 
immune regulation for the treatment of GVHD.  
 
As I found that human Bregs are enriched within both the transitional and IgM 
memory B cell subsets and since CD19+CD24hiCD38hi transitional B cells 
are abundant in cord blood (CB) (near 50% of B cells), I next studied Bregs in 
CB and their potential regulatory function. My findings support the notion that 
CB may offer an invaluable source of off-the-shelf regulatory B cells for the 
treatment of GVHD and other autoimmune conditions. 
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Allogeneic hematopoietic SCT (HSCT) is a potentially curative option for 
many patients with high-risk hematological malignancies, however the high 
onset rate of acute and chronic graft-versus-host disease (GVHD) remains a 
major obstacle its success (Daikeler et al, 2009, Barrett and Battiwalla, 2010). 
Human CB is widely used as a source of HSC for many patients and a lower 
incidence of chronic extensive GVHD has been reported after CBT compared 
with other stem cell sources, despite broader HLA disparity (Beaudette-
Zlatanova et al., 2013, Komanduri et al., 2007). Alloreactive reactions 
between donor-derived CD4+ and CD8+ T lymphocytes have typically been 
considered to be the chief effector cells arbitrating GVHD pathogenesis 
(Shimabukuro-Vornhagen et al., 2009, Rezvani et al., 2006). Our 
understanding of the function of Bregs in this disease is limited. However, 
recent evidence has postulated a role for B cell dysregulation in the 
development of GVHD (Shimabukuro‐Vornhagen et al., 2009, Sarantopoulos 
et al., 2015). In keeping with these studies, previous research has also 
highlighted protective role for IL-10 producing regulatory B cells in the 
regulation of GVHD (Rowe et al., 2006, Lee et al., 2012, Huu et al., 2013, 
Weber et al., 2014, Khoder et al., 2014, de Masson et al., 2015). 
However, further insights into the mechanistic role of B cells in this debilitating 
disease is required to highlight the therapeutic benefits of targeting B cells in 
GVHD. 
 
I therefore next determined whether cord blood-derived B cells possess 
regulatory function as seen with peripheral blood-derived Bregs, which may 
contribute to the lower rates of chronic GVHD seen in CBT recipients.  
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Extensive phenotypic characterization of CB-derived B cells revealed the 
presence of two distinct B cell populations: CD19+CD38hiCD24hi transitional B 
cells (a population that includes immature B cells) and CD19+CD38intCD24int 
naïve B cells (primarily mature B cells). In contrast to peripheral blood B cells, 
CD24hiCD38− CD27+ memory B-cells are almost absent in CB and only 
become detectable in the first year of life (Cuss et al., 2006, Ha et al., 2008). 
The phenotype panel was validated on both freshly isolated CB-derived B 
cells and their frozen counterparts before applying it to frozen samples from 
post-CBT patients.  
I next demonstrated that IL-10+CD19+ B cells are enriched within both CB-
derived transitional and naïve subsets and exert suppressive function on 
allogeneic CD4+ T cell function. I propose that within the CB-CD19+ B cell 
pool there exist 2 distinct subsets; CD19+CD38hiCD24hi transitional B cells 
and CD19+CD38intCD24int naïve B cells, both of which are functionally 
regulatory. 
Despite several phenotypic and functional similarities to PB-B cells, this study 
revealed a number of key differences between human PB- and CB-derived 
Bregs. In contrast to PB-derived CD24hiCD27+ and CD27+IgM+ memory 
cells that have been ascribed with regulatory capacity by previous studies, 
memory B-cells were absent in CB (Iwata t al., 2011, Khoder et al., 2014). 
Further, unlike PB-naïve B cells that failed to exert suppressive activity on 
CD4+ T cells, our discovery presents a novel suppressive role for naïve B 
cells in CB and broadens the proportion of Breg in CB, suggesting a 
prominent role for these functional CB-derived B cells in the maintenance of 
immune tolerance.  
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Functional assessment of CB-derived total CD19+B cells as well as sort 
purified transitional and naïve B cell subsets revealed that these populations 
suppressed both the proliferation and effector cytokine production of 
allogeneic peripheral blood-derived CD4+T cells in a manner that was 
comparable to CB-derived Tregs. This suppressive capacity was further 
augmented in the presence of pre-activated B cells co-cultured with CD4+T 
cells suggesting that in human PB, Breg designation may not be limited to the 
IgM memory and transitional B cell subsets described previously and it is 
likely that discrete subsets of naïve and switched memory B cells could also 
be induced to exert regulatory function in response to CD40 ligand signaling 
provided by activated T cells, analogous to reports of inducible Tregs during 
inflammation (Feuerer et al., 2009). Similar to previous reports of PB-Bregs, 
the mechanism by which CB-derived naïve and transitional B cells suppress 
CD4+T cell function was mediated synergistically through IL-10 production 
and cell-to-cell contact involving CD80/CD86 and CTLA-4 (Blair et al., 2010, 
Khoder et al., 2014). These findings are in agreement with previous studies 
with human PB Bregs that describe the involvement of CD80 and CD86 as an 
important feature of their suppressive capacity (Blair et al., 2010, Khoder et 
al., 2014) and with murine studies of intestinal inflammation where CD86 was 
noted to facilitate B cell suppression (Mann et al., 2007, Mizoguchi et al., 
2000). Interestingly, I found involvement of CTLA-4 in the suppressive 
mechanism of CB-Bregs; this is in contrast to data with PB Bregs where 
CTLA-4 was not found to play a major role in their suppressive function 
(Khoder et al. 2014). However, a similar mechanism is employed by CD80 
expressed on DCs, which acts preferentially as a ligand for CTLA-4 and 
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mediates Treg cell suppression (Zheng et al., 2004). This study provides 
support that CD80 and CD86 on Bregs may also function as ligands for 
CTLA-4 and could play a role in Breg suppressive function. 
 
The role of Bregs in cord blood transplantation and GVHD has not been 
previously studied. I next investigated whether CB-Bregs account for lower 
rates of GVHD after CBT. Several studies have reported that immune 
reconstitution after CBT is characterized by an expansion in B cells during the 
first year post transplant (Komanduri et al., 2007, Nakatani et al., 2014, 
Beaudette-Zlatanova et al., 2013, Saliba et al., 2015, Lucchini et al., 2015). 
In accord with these published work, I found a robust expansion in both the 
frequencies and absolute numbers of CD19+ B cells and IL-10 producing 
CD19+B cells during the first 3-9 months post CBT, after which the B cell 
population progressively decreased and by 1-year post CBT there were no 
significant differences in the frequencies and numbers of circulating B cells 
and IL-10+B cells in CBT recipients and healthy donors. The recovering B 
cells at 6-9 months post-CBT were found to be more suppressive on a cell per 
cell basis when compared to B cells derived from cord blood. These results 
suggest a role for the expanded population of IL-10 producing B-cell 
population in CBT patients in mediating T-cell suppression and thus reducing 
the severity of GVHD. A previous study by Stiff et al also postulated that 
robust B cell recovery might attenuate T cells responses post CBT 
(Beaudette-Zlatanova et al., 2013). I further demonstrated that CD19+IL-10+ 
B cell recovery was impaired in patients with GVHD compared to those 
without GVHD after CBT, and that B cells isolated from CBT recipients with 
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GVHD were refractory to stimulation and were unable to produce IL-10. These 
results are in accord with similar studies that have also found low frequencies 
of IL-10 producing B cells in cGVHD patients following AHSCT than in AHSCT 
recipients without cGVHD (Rowe et al., 2006, Khoder et al., 2014, Weber et 
al., 2014), suggesting that the early recovery of B cells post CBT may define a 
protective role for Bregs in GVHD setting.  
This study defines a novel potential role of CB derived donor Bregs in 
reducing the risk of GVHD, emphasizing the potential of novel B-cell directed 
therapies for the prevention or treatment of GVHD.  
Further, although there is no unique marker to purify exclusively suppressor B 
cells that express IL-10, my studies illustrate that at IL-10+B cells are enriched 
in selected B cell compartments in both peripheral and cord blood. This 
serves as an advantage in using Breg based therapies compared to Treg for 
use in the treatment of GVHD, since there is currently no defined Treg 
phenotype to accurately identify human Treg as a result of discrepancies 
between surface markers and cell plasticity. Additionally, recent in vitro 
human data, indicating that activated B cells directly suppress allogeneic 
CD4+ T-cell proliferation through inducing the expansion of alloantigen-
specific suppressor Tregs further supports a significant advantage in the 
development of Breg cell based immunotherapy and suggests the use of 
inducing B-cell expanded Treg cells for treatment of GVHD (Chen et al., 
2009). 
 
 Moreover, the use of anti-CD20 B-cell depleting agent, Rituximab in cases 
where B cells are considered the main arbitrators for disease pathology may 
	   252	  
need to be avoided as all described regulatory B cells express CD20. Hence, 
strategies to selectively target B effector cells whilst preferentially sparing 
regulatory B cells are required. Thus, to tip the scales in favor of immune 
regulation and induce protection against GVHD, so that GVHD is either 
prevented or attenuated, infusion of donor-derived Bregs early in the patient’s 
post-transplant regime may be essential. Therefore, the potential of in-vitro 
expanded CB-derived IL-10 producing Bregs as an invaluable source of off-
the-shelf treatment of human GVHD also merits further investigation. 
 
To date, recent evidence has firmly identified the suppressive capacity of 
Bregs on T cell function in murine models and humans, which maintains 
immune tolerance and is critical in host suppression of autoimmune diseases 
(Iwata et al., 2011, Mauri and Bosma., 2012, Rosser and Mauri., 2015). 
However, recent studies have also highlighted a role for Bregs in cancer 
progression (Inoue et al., 2006, DiLillo et al., 2013, Horikawa et al., 2011, 
Shao et al. 2014). Despite mounting evidence supporting a role for Breg cells 
in autoimmunity and promoting tumor growth through inhibition of T cell 
proliferation and effector function, there is limited data on the interaction of 
Bregs with other immune effectors important in tumor-immune surveillance 
such as natural killer (NK) cells. NK cells are important components of the 
innate immune system and play an important role in tumor immune 
surveillance (O’Hanlon, 2004, Ljunggren and Malmberg, 2007, Waldhauer 
and Steinle, 2008). In cancer patients, NK cell activation can be hampered by 
downregulation of major histocompatibility complex (MHC) class I molecules 
on target cells (missing self theory) (Smyth et al, 2002, Ljunggren and Karre, 
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1990) and/or upregulation of proteins such as NKG2D ligands on ‘distressed’ 
cells (induced self theory) (Vivier et al, 2008), but Giringhelli et al suggested 
that other mechanisms may also play a role in blunting NK cell responses 
against cancer. Indeed, increased frequencies of regulatory T cells (Tregs) 
have been shown to correlate with cancer progression and hamper NK cell 
function (Ghirenghelli et al, 2005, Pedrozo-Pacheo et al, 2013).  Although 
recent studies have shed light on the existence of NK-B cell bidirectional 
cross-talk, through the interaction of CD48 on B cells with, 2B4, on NK cells 
(Yuan et al, 2010., Gao et al, 2006., Gao et al, 2005, Lee et al, 2006), no 
studies to date have explored the role of Breg and NK interaction.  
I therefore next determined the effect of Breg mediated suppression of NK 
function. Both PB-derived and IL-10 enriched transitional and IgM memory B 
cells suppressed the proliferation, effector function and cytotoxicity of 
CD56+CD3-NK cells in a manner that was comparable with that of PB-Tregs. 
Previous studies in mice and humans have shown that Breg-mediated 
suppression of T cells is mediated through both IL-10 and cell-cell contact-
mediated mechanisms (Yang et al., 2013, Blair et al., 2010, Iwata et al., 2011, 
Khoder et al.,2014). In contrast, I found that IL-10 secretion is not a major 
mechanism for regulatory B cell-mediated suppression of NK cell proliferation 
and function. Instead, transitional and IgM memory B cells require direct cell-
cell contact to suppress NK cells. Although, there is evidence for bi-directional 
crosstalk between NK cells and B cells, mediated through interactions 
involving both CD48-2B4 and CD40-CD40L (Yuan et al., 2010, Gao et al., 
2006, Blanca et al., 2001, Sinha et al., 2010), I did not detect any soluble 
CD40L in my NK-B cell co-culture experiments and thus did not pursue this 
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interaction further. Instead, I found an important role for CD48-2B4 interaction 
in mediating suppression of NK cells by Breg subsets. Although, previously 
published work has shown that B cells can activate NK cells through B cell-NK 
cell cross-talk (Gao et al., 2006, Sinha et al., 2010), in my study I show an 
important role for CD48-2B4 signalling pathway in mediating suppression of 
NK function through induction of inhibitory signalling via 2B4 by Bregs. 
Although 2B4 is commonly associated with delivering activating signals to NK 
cells through SAP (a signalling adapter molecule), my findings are in accord 
with murine studies reporting that CD48 on tumor cells can interact with 2B4 
on NK cells and inhibit their function (Stark and Watzl., 2006, Lee et al, 2006). 
The mechanistic suppression of NK cells by Breg through CD48-2B4 
signalling was mediated through downregulation of SAP, which is crucial for 
2B4 to deliver activating signals to NK cells and recruitment of pSHP-1, an 
inhibitory signalling molecule recruited in the absence of SAP. These findings 
are supported by cases of X-linked lymphoproliferative (XLP) disease, where 
patients have also been found to exhibit impaired NK cell cytotoxicity through 
2B4/SAP dysfunction (Eissmann et al., 2005, Hallet and Murphy., 2006, 
Lanier., 2008). Furthermore, it is quite possible that additional signaling 
pathways also play a role in Breg-mediated suppression of NK function. 
Indeed, Assarsson et al have noted that 2B4 and CD48 both reside within 
glycolipid-rich microdomains, which contain many other molecules that may 
be involved in signaling, and additional studies of 2B4-CD48 signaling 
pathways involved in Breg-mediated suppression of NK cells are underway 
(Assarsson et al., 2005). 
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Since the interaction between CD48, on transitional and IgM memory Breg 
subsets, but not naïve or switched memory B cells induces an inhibitory effect 
on NK function via 2B4, I studied the effect of NK cells on Breg subsets. Blair 
et al highlighted that CD19+CD24hICD38hI transitional B cells require the 
activation of the CD40/STAT3 signaling pathway to exert their 
immunoregulatory function on CD4+ T cells (Blair et al., 2010). In keeping with 
these findings, I found that NK cells trigger phosphorylation of STAT3 in both 
IgM memory as well as transitional B cell subsets (but to a much lesser extent 
in naïve and switched memory B cells). Collectively, these data support the 
existence of bidirectional 2B4-CD48-mediated cross-talk between NK cells 
and B cells and suggest that NK cells can deliver signals to regulatory B cell 
subsets, and the latter in turn deliver inhibitory signals to NK cells by inducing 
downregulation of SAP and recruitment of pSHP. To further unravel whether 
Bregs may exert potent suppressive activity promoting cancer progression 
and NK effector dysfunction, I functionally characterized CD19+ B cells in the 
peripheral blood of patients with AML.  The immune microenvironment in AML 
displays a spectrum of abnormalities, including aberrant expression of 
immunomodulatory cytokines (Stringaris et al., 2014, Ferrara and Schiffer., 
2013) and numerical and functional alterations in immunoregulatory subsets 
such as Tregs and myeloid-derive suppressor cells (Ustan et al., 2011, 
Szczepanski et al, 2009). 
AML patients had increased frequencies and absolute numbers of both 
CD19+ B cells and IL-10-producing B cells in comparison to healthy controls. 
Further, patients with AML had a significantly higher IL-10+CD19+ B-cell/ 
CD56+CD3- NK-cell ratio, compared with that for healthy control group 
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suggesting that an altered ratio of regulatory-to-effector cells in AML may 
suppress NK cell number and function, thus, promoting cancer progression. 
Coculture of AML CD19+ B cells with healthy donor NK cells resulted in 
significant suppression of SAP, recruitment of pSHP-1, and significant 
suppression of healthy donor NK cell function. It is noteworthy that ex vivo-
purified NK cells from AML patients expressed significantly less SAP and, 
higher pSHP-1 than their normal counterpart, further supporting the notion 
that in AML, engagement of 2B4 on NK cells by CD48 on B cells will deliver 
inhibitory signals to NK cells, resulting in suppression of their effector function.  
Conclusively, this is the first study to provide mechanistic insights into 
inhibitory cross-talk between NK cells and Breg subsets and to demonstrate 
the relevance of this inhibitory axis in acute myeloid leukemia. 
These findings point to the existence of a broader network of 
immunoregulatory cells, also involving Bregs that can be recruited and 
exploited by leukemic cells to evade immunesurveillance. Breg-mediated 
suppression of NK cell function may have important implications not only on 
cancer immune surveillance and defense against pathogens but also in 
determining response to therapy.  For instance, Bregs may negatively impact 
the effectiveness of immunotherapies in AML, such as antibody-dependent 
cellular cytotoxicity (ADCC) of tumor-targeted monoclonal antibodies (e.g., 
anti-CD33 mAbs). These data may have implications for other cancers and 
studies to explore the role of Bregs in other types of cancer and the 
consequences of their depletion on NK cell antitumor activity in vivo are 
currently under way. Finally, I propose that depletion of Breg subsets may be 
a novel strategy to enhance cancer immunity in humans.  
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VI.2  Conclusion 
Based on these data, I propose that an imbalance between regulatory B cells 
and immune effector subsets leads to loss of tolerance and perpetuation of an 
inflammatory process that may induce allo-reactivity in GVHD or suppress 
anti-tumor activity through inhibition of immune effector responses. These 
findings have important clinical implications and suggest that Bregs may be 
exploited to treat immune-mediated diseases. Adoptive transfer of donor-
derived Bregs early in the patient’s post-transplant course may tip the scales 
in favor of immune regulation, so that GVHD is either prevented or attenuated, 
an may offer a potentially effective immunomodulatory therapy for the 
treatment of GVHD. Conversely, strategies to deplete Bregs for optimal anti-
cancer immunotherapy may benefit antitumor activity in AML and other 
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VI.3  Future Plans 
In my thesis, I have proposed that an imbalance between regulatory and 
proinflammatory networks leads to loss of tolerance and induction of GVHD. I 
have shown a robust expansion in both frequencies and absolute numbers of 
CD19+ B cells and IL-10 producing CD19+B cells in the first 3-9 months after 
CBT, which were also found to exert greater suppressive function on healthy 
PB-CD4+T cells when compared to CD19+ B cells from cord blood units. 
These results postulate that attenuated T cell responses (Komanduri et al., 
2007, Beaudette-Zlatanova et al., 2013) and the lower risk of cGVHD after 
CBT may be a result of robust regulatory B cell recovery. To further assess 
whether robust expansion of B cells attenuates T cell responses post CBT 
leading to protection against GVHD, I propose to phenotypically and 
functionally characterize T cells subsets and determine effector T 
cell/regulatory B cell ratio in terms of frequency and absolute counts in CBT 
recipients with and without GVHD development post transplant. These results 
will highlight whether a reduced regulatory network may cause an increased 
proinflammatory effector function leading to inflammation and GVHD 
pathology post CBT.  
 
I have further shown that AML patients had increased frequencies and 
absolute numbers of both CD19+ B cells and IL-10-producing B cells in 
comparison to healthy controls. Further, patients with AML had a significantly 
higher IL-10+CD19+ B-cell/ CD56+CD3- NK-cell ratio, compared with that for 
healthy control group suggesting that an altered ratio of regulatory-to-effector 
cells in AML may suppress NK cell number and function, thus, promoting 
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cancer progression. I further plan to determine if this phenomena is still 
present in AML patients after remission to better understand whether NK 
dysfunction in relation to effector function and expression of SAP and an 
altered Breg/NK ratio may be a prognostic marker for survival outcome in 
patients with cancer. 
 
I have demonstrated that IL-10-producing regulatory B cells are enriched 
within PB-derived transitional and IgM memory B cell subsets and within CB-
derived transitional and naïve subsets. Both CB-derived and PB-derived Breg 
have been shown to exert suppressive capacity on CD4+ T cell effector 
function, which has implications in a cGVHD setting post transplant as 
described previously. Subsequently, as CD8+T cells possess a pathogenic 
role in aGVHD, I propose to explore the suppressive function of Breg on this 
effector subset, that may facilitate a broader understanding of the therapeutic 
benefits of Breg therapy in GVHD and their potential in aGVHD setting.  
 
In my study, I found that PB-derived Breg subsets, transitional and IgM 
memory B cells share functional similarities. I propose to study the gene 
expression profiling of these subsets with the aim of identifying a unique 
signature for this population of regulatory cells, by using IL-10 cytokine 
capture beads to purify IL-10+B cells. The identification of a specific marker 
for regulatory B cell subsets may aid strategies to target the selected 
depletion of these cells for treatment of AML and other cancers. Finally to 
confirm that Bregs can attenuate or suppress cGVHD, I propose to infuse 
these CB-derived and PB-derived regulatory B cells in minor and major 
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mismatched mouse models of cGVHD to evaluate the effect of Breg infusion 
as a potential therapy.  
 
In particular, murine studies of B-cell depletion have reported a preferential 
expansion of the Breg cell subset in the reconstituting B-cell population has 
(Palanichamy et al, 2009, Blair et al., 2010, Yang et al., 2013). Hence, it will 
be noteworthy to evaluate the effect of adoptive transfer of PB-Bregs and CB-
Bregs either alone or with in vivo B-cell depletion as a treatment option for 
GVHD and other autoimmune conditions.  
Further, whereas the direct administration of IL-10 has had limited beneficial 
effect due its short half life, the adoptive transfer of Bregs is likely to be more 
effective as they are able to continually secrete IL-10 (Yang et al., 2013). 
I therefore, propose to develop strategies to trigger the expansion of Breg 
population to maintain or induce immune tolerance. To study this, I will 
stimulate B cells with appropriate stimulations including CD40, BCR ligation 
and/or CpG with growth factors and other cytokines in vitro for the generation 
of Bregs for adoptive transfer, which could play a pivotal role in 
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